Document:

EX-10.1

 Exhibit 10.1 

[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	Fujifilm – Synageva Agreement		EXECUTION COPY

 COMMERCIAL SUPPLY AGREEMENT 

This Commercial Supply Agreement (this “Agreement”) dated January 28, 2015 (the “Effective Date”) between Synageva
BioPharma Corp., a Delaware corporation (“Sponsor”), having its principal place of business at 33 Hayden Avenue, Lexington, Massachusetts 02421 and FUJIFILM Diosynth Biotechnologies U.S.A., Inc., a Delaware corporation
(“Fujifilm”), having its principal place of business at 101 J. Morris Commons Lane, Morrisville, NC 27560, (each a “Party”, and together, the “Parties”). 

WHEREAS, Sponsor and Fujifilm entered into a Bioprocessing Services Agreement dated January 22, 2013 that was subsequently amended with change orders
(“BSA”), pursuant to which Fujifilm agreed to perform certain process development services including process validation and Conformance Campaign (as defined below) with respect to sebelipase alfa on behalf of Sponsor; 

WHEREAS, Sponsor wants Fujifilm to Manufacture (as defined below) in accordance with the terms of this Agreement the Product (as defined below) for the
anticipated initial commercial launch and, after receiving Market Authorization (as defined below), for routine commercial supply of the Drug Product (as “Drug Product” is defined below); and 

WHEREAS, Fujifilm wants to Manufacture the Product. 
 NOW
THEREFORE, in consideration of the above statements, which form part of this Agreement, and other good and valuable consideration, the sufficiency and receipt of which are hereby acknowledged, the Parties hereto agree as follows: 

Definitions: 
 “2015
Lack of Approval Event” shall have the meaning set forth in Section 2(c)(ii). 
 “Actual Batch Yield” shall mean the quantity
of Product resulting from Manufacturing for a Batch, without reduction for sampling performed by Fujifilm pursuant to this Agreement or the Quality Agreement. Quantity of Product shall be determined by the following calculation: [**]. 

“Adverse Event” shall mean any untoward medical occurrence in a patient or clinical trial subject administered a human medicinal product
irrespective of whether there is a causal relationship with the Product or the Drug Product or not. An Adverse Event can therefore be any unfavorable and unintended sign (e.g., abnormal laboratory finding), symptom, or disease temporally
associated with the use of the Product or the Drug Product in humans, whether or not considered related to the Product or the Drug Product. 

“Affiliate” shall mean any corporation or other business entity directly or indirectly controlled by, controlling, or under common control
with a Party or its parent corporation. The term “control” (including, with correlative meaning, the terms “controlled by,” “controlling” and “under common control with”) shall mean the legal power to direct
or cause the direction of the general management and policies of such entity whether through the ownership of at least 50% of voting securities or capital stock of such business entity or any other comparable equity or ownership interest with
respect to a business entity other than a corporation. 
 “Agreement” shall have the meaning set forth in the preamble. 

  

							
			CONFIDENTIAL		 	1	  

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

 “Annual Program Fee” shall have the meaning set forth in Section 6(b). 

“Anti-Bribery Laws” shall have the meaning set forth in Section 33. 

“Applicable Law” shall mean all laws, statutes, directives, ordinances, codes, regulations, rules, by-laws, judgments, decrees or orders of
any governmental or regulatory authority (including any Regulatory Authority, as defined below), department, body or agency or any court, tribunal, bureau, commission or other similar body, whether foreign, federal, state, provincial, county or
municipal, applicable to the manufacture and production (including the Manufacture, as defined below), processing, testing, packaging, use, storage, sale, and distribution (including transport, import and export) of the Product and/or the Drug
Product, including, without limitation all applicable cGMPs. 
 “Batch” shall collectively refer to [**] Batches and [**] Batches. 

“Batch Packet” shall mean a compilation of records identified in the Quality Agreement for a Batch, including but not limited to, [**]. 

“Batch Price” shall have the meaning set forth in Section 6(a)(i). 

“Binding Order” shall mean a non-cancellable order of specified number of Batches in the [**] to be delivered to Sponsor by Fujifilm in
accordance with Section 2(f), which order shall be submitted to Fujifilm according to the process specified in Section 2 and which shall be binding on Fujifilm to fulfill. 

“Binding Period” shall mean the forecast for [**] of each Rolling Forecast and shall be the [**] starting with the first day of the [**]
ending on the last day of the [**]. For clarity, if Sponsor submits a Rolling Forecast on [**] the Binding Period for such Rolling Forecast would be from [**]. 

“BSA” shall have the meaning set forth in the preamble. 

“Bulk Fill” shall mean, with respect to a Batch, the point in time when Product comprising that Batch is filled into bags and stored in cold
temperature storage. 
 “Campaign” shall mean the Manufacture of a Batch or a series of Batches operated in succession for the production
of Product, including in each case, set-up of the GMP Facility, inter-Batch cleaning and a final clean-out of the GMP Facility. 
 “cGMP”
shall have the meaning set forth in Section 4(a). 
 “Change Order” shall have the meaning set forth in Section 10(b). 

“Claim” shall have the meaning set forth in Section 19(a). 

“COA” shall mean certificate of analysis, as described in the Quality Agreement. 

“[**] Batch” shall mean a specific quantity of Product that is Manufactured by Fujifilm during the same cycle of Manufacture and that is
intended to have uniform character and quality within specified limits, with an [**] according to the Specifications. 

  

					
			CONFIDENTIAL		2

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

 “Confidential Information” shall have the meaning set forth in Section 11(c). 

“Conformance Campaign” shall mean the [**] manufacturing campaign at Fujifilm under the [**]. 

“Consumable Price” shall have the meaning set forth in the Section 6(a). 

“Delivery Date” shall have the meaning set forth in Section 2(f)(iii). 

“Disposition Date” shall mean the date of Batch disposition by Fujifilm in accordance with and as contemplated by the Quality Agreement. 

“Disposition of Product Statement” shall have the meaning set forth in the Quality Agreement. 

“Drug Product” shall mean the filled and finished final dosage form of the Product in association with other active or inactive ingredients
intended for commercial or clinical use. 
 “Drug Product Complaint” shall mean any verbal, written, or electronic communication received
that suggests dissatisfaction with the identity, quality, stability, reliability, safety, efficacy, performance, or usage of the Drug Product after it is released for distribution to the clinic or to the market. 

“Effective Date” shall have the meaning set forth in the preamble. 

“EMA” shall mean the European Medicines Agency, or any successor agency or authority thereto. 

“Facilities” shall mean the GMP Facility, Fujifilm’s process development laboratories located at 3000 Weston Parkway, Cary, NC 27513,
and Fujifilm’s administrative building located at 101 J. Morris Commons Lane, Morrisville, NC 27560. 
 “Facility Assessment Memo”
shall have the meaning set forth in the Quality Agreement. 
 “FDA” shall mean the United States Food and Drug Administration, or any
successor agency or authority thereto. 
 “First Shipment” shall have the meaning set forth in Section 2(d)(i). 

“Frustration of Purpose Event” shall have the meaning set forth in Section 2(c)(iii). 

“Fujifilm” shall have the meaning set forth in the preamble. 

“Fujifilm Confidential Information” shall have the meaning set forth in Section 11(b). 

“Fujifilm Indemnitees” shall have the meaning set forth in Section 19(b). 

“GMP Facility” shall mean Fujifilm’s manufacturing plant located at 6051 George Watts Hill Drive, Durham, NC 27709 that is operated in
compliance with cGMP. 
 [**] 

  

					
			CONFIDENTIAL		3

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

 “Indemnified Party” shall have the meaning set forth in Section 19(c). 

“Indemnifying Party” shall have the meaning set forth in Section 19(c). 

“Indemnity Claim” shall have the meaning set forth in Section 19(c). 

“Index Figure” shall mean [**] index [**]. 

“Initial Binding Order” shall have the meaning set forth in Section 2(d). 

“Initial Term” shall have the meaning set forth in Section 23(a). 

“Joint Steering Committee” shall have the meaning set forth in Section 24(a). 

“Key Manufacturing Assumption” shall have the meaning set forth in Section 10(a). 

“Late Delivery Credit” shall have the meaning set forth in Section 9(b). 

“Loss” shall have the meaning set forth in Section 19(a). 

“Manufacture”, “Manufactured” or “Manufacturing” shall mean the manufacture of Product by Fujifilm and all related
activities, including but not limited to quality assurance, quality control, testing, storage and packaging for shipment, in accordance with this Agreement and the Quality Agreement. 

“Manufacturing Price” shall have the meaning set forth in Section 6(a)(i). 

“Manufacture Start Date” shall mean the thaw date of the Starting Material. 

“Market Authorization” shall mean approval by one or more Regulatory Authorities to market, sell and distribute the Drug Product in any part
of the world. 
 “Maximum Annual Order” shall mean the maximum number of Batches that Fujifilm shall be obligated to Manufacture and
Sponsor shall be obligated to purchase within a twelve (12) month period, as further defined in Section 2(c)(v). 
 “Maximum Binding
Order” shall mean the maximum number of Batches that Fujifilm shall be obligated to Manufacture and Sponsor shall be obligated to purchase pursuant to a Binding Order, as determined according to Section 2(c)(iv). 

“Minimum Binding Order” shall mean the minimum number of Batches that Sponsor shall be obligated to purchase and Fujifilm shall be obligated
to Manufacture pursuant to a Binding Order, as determined according to Section 2(c)(i). 
 “Modifications” shall have the meaning set
forth in Section 10(b). 
 “[**] Batch” shall mean a Batch which [**] Manufactured in accordance with or [**] the requirements
of: cGMPs, this Agreement or the Quality Agreement (including the Specifications). 

  

					
			CONFIDENTIAL		4

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

 “Order Expansion” shall have the meaning set forth in Section 2(e). 

“[**] Batch” shall mean a specific quantity of Product that is Manufactured by Fujifilm during the same cycle of Manufacture and that is
intended to have uniform character and quality within specified limits, [**], provided that it is releasable according to the Specifications. 

“Party” or “Parties” shall have the meaning set forth in the preamble. 

“PIP” shall have the meaning set forth in Section 5. 

“Process” shall mean the process for Manufacture of the Product, as initially determined during the Conformance Campaign and as subsequently
updated by the process detailed in the Quality Agreement and changes thereto implemented pursuant to Section 10. 
 “Process
Consumables” shall mean materials required to Manufacture Product (excluding [**]). For the purpose of this Agreement, this definition includes [**]. 

“Process Consumables LOA” shall have the meaning set forth in Section 6(e). 

“Process Inventions” shall have the meaning set forth in Section 13(b). 

“Product” shall mean the product described in the Specifications that is Manufactured by Fujifilm under this Agreement. 

“Product Inventions” shall have the meaning set forth in Section 13(b). 

“Program” shall mean the Manufacturing services to be performed under this Agreement. 

“Program Inventions” shall have the meaning set forth in Section 13(a). 

“Program Manager” shall have the meaning set forth in Section 24(b). 

“Quality Agreement” shall mean the quality agreement executed by the Parties dated as of January 28, 2015, as may be amended from time
to time. 
 “[**] Deviation Reports” shall have the meaning set forth in the Quality Agreement. 

“Recall” shall have the meaning set forth in Section 8(a). 

“Receiving Date” shall mean the date indicated in the Receiving Schedule as the date by when Fujifilm will receive a shipment of Starting
Material from Sponsor, provided that, unless the Parties agree otherwise in writing (which may be via email) such date shall be no more than [**] before the target Manufacture Start Date for the applicable Batches identified by Fujifilm pursuant to
Section 2(f) and provided further that the Receiving Date shall be [**] after Sponsor’s receipt of the Receiving Schedule. 
 “Receiving
Schedule” shall mean a schedule issued by Fujifilm in accordance with Section 2(g) for receiving Starting Material at GMP Facility for a specific Binding Order, which schedule must include the receiving quantity of the Starting
Material and Receiving Dates, subject to Section 2(g). 

  

					
			CONFIDENTIAL		5

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

 “Regulatory Authority” shall mean foreign, national, regional, state or local regulatory
agency, department, bureau, commission, council or other governmental entity in any country or region listed in Attachment 1 hereto with authority over the manufacture and production (including the Manufacture, as defined above), processing,
testing, packaging, use, storage, sale, pricing, and distribution (including transport, import and export) of the Product, including, without limitation, the FDA and the EMA and any successor entities thereto. The definition may be expanded to other
regulatory authorities upon mutual written agreement. 
 “Reservation Fee” shall have the meaning set forth in Section 6(a)(i). 

“Resin Cost” shall have the meaning set forth in Section 6(a)(ii). 

“Restriction Summary” shall have the meaning set forth in the Quality Agreement. 

“Rolling Forecast” shall have the meaning set forth in Section 2(b). 

“Safety Information” shall mean all information relating to known or potential risk to humans, obtained or otherwise received from any
source, including information derived from clinical investigations, commercial marketing experience, post-authorization, post-authorization epidemiological/surveillance studies, reports in the scientific literature, unpublished scientific papers,
animal or in vitro studies, electronic communications and reports. Safety Information may include Adverse Events/experiences, lack of efficacy, suspected transmission of infectious agents, overdose, abuse, misuse, medication errors,
pregnancy/breastfeeding exposure, and off-label use. 
 “Safety Stock” shall have the meaning set forth in Section 6(e). 

“Second Shipment” shall have the meaning set forth in Section 2(d)(ii). 

“Specifications” shall mean the specifications for the Product, as set forth in and/or attached to the Quality Agreement. 

“Sponsor” shall have the meaning set forth in the preamble. 

“Sponsor Confidential Information” shall have the meaning set forth in Section 11(a). 

“Sponsor Deliverables” shall have the meaning set forth in Section 3(a). 

“Sponsor Indemnitees” shall have the meaning set forth in Section 19(a). 

“Starting Material” shall mean [**] provided from Sponsor to Fujifilm as the starting material for Manufacturing. 

“Starting Material Failure” shall have the meaning set forth in Section 7(b)(vii)(A). 

“Term” shall have the meaning set forth in Section 23(a). 

“Third Shipment” shall have the meaning set forth in Section 2(d)(iii). 

“Work Output” shall have the meaning set forth in Section 12(a). 

  

					
			CONFIDENTIAL		6

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

 Section 1. Manufacture of Product 

 

	 	a)	Manufacture of Product. Fujifilm will Manufacture the Product for Sponsor at the GMP Facility, based on Binding Orders submitted by Sponsor, in accordance with the terms and conditions of this Agreement, the
Quality Agreement and Applicable Law (including cGMPs). Terms defined in this Agreement shall have the same meaning when used in Quality Agreement. In the event of any conflict between this Agreement and the Quality Agreement, the terms of this
Agreement shall have the precedence except with respect to matters of quality, in which case the terms of the Quality Agreement shall govern. Fujifilm may change the site of Manufacture for the Product only with the prior written consent of Sponsor
and any such change will be at Fujifilm’s sole cost and expense, unless the Parties agree otherwise in writing. 

  

	 	b)	Process Surveillance. Fujifilm will perform process surveillance on all Batches Manufactured under this Agreement, which will include the surveillance listed below, in addition to any surveillance detailed in the
Quality Agreement: 

  

	 	i.	Trending process yield and release testing data in accordance with the mutually agreed process surveillance plan, including per [**] and Step Yields will also be trended; 

 

	 	ii.	Statistical analysis of surveillance parameters at the end of [**] once a minimum of [**] are available; and 

  

	 	iii.	Preparation of surveillance parameter data report after [**] after the Disposition Date of the last Batch of the Binding Order), not to exceed [**]. 

 

	 	c)	Regulatory Support. Fujifilm will provide routine regulatory support to Sponsor for the Program at Sponsor’s request that will include: 

[**] 
 Any additional regulatory
support, which in Fujifilm’s reasonable opinion, exceeds reasonable expectations of the Parties established upon Agreement execution will be provided by Fujifilm based on a Change Order or separate agreement. 

 

	 	d)	Sponsor Obligations. Sponsor shall: 

  

	 	i.	Perform its obligations as set forth in this Agreement and the Quality Agreement; and 

  

	 	ii.	Support and cooperate with the execution of each Binding Order. 

  

	 	e)	[**] 

  

	 	f)	 Purchasing Commitment. Sponsor shall order at least [**] supply from Fujifilm [**] during the Term. Within [**], Sponsor shall send Fujifilm a
written, signed certification of [**] ordered from Fujifilm [**]. In the event Sponsor ordered [**] from Fujifilm [**], it shall add the difference between the actual amount ordered and the minimum required order (i.e., [**]) to the Binding Orders
for [**]. If such additional Batches result in Batches in excess of 

  

					
			CONFIDENTIAL		7

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

	 	
[**] obligation to order and purchase such additional Batches shall apply only to the extent [**]. In addition to the foregoing, in the event [**] willfully misrepresents the amount ordered on an
[**]. The obligations set forth in this Section 1(f) shall not apply in the event of a Frustration of Purpose Event described in Section 2(c)(iii)(C), in the event of [**], until such time as such [**], but in no event longer than[**]
after such events have ended, at which time the purchasing commitment described in this Section 1(f) shall recommence. [**] compliance with the commitment [**] shall be calculated based on the [**] effect and, for clarity, not [**]. In the
event of (i) [**] pursuant Section 7(b)(vii)(B) [**] (by way of clarification, [**] for purposes of this Section 1(f)(ii)), or (iii) [**], the purchasing commitment described in this Section 1(f) shall not apply to the [**]
nor until such time as [**], but in no event later than [**]. 

  

	 	g)	Subcontractors. With respect to this Agreement and the Quality Agreement, Fujifilm shall not delegate its responsibilities to, or perform any of its obligations through, any third party unless (i) such third
party is not involved in processing, testing or handling Product, or (ii) expressly permitted hereunder or thereunder or approved in writing in advance by Sponsor, such approval not to be unreasonably withheld or delayed. Fujifilm’s
delegation of any such responsibility to, or performance of any of such obligation through, any third party shall not in any way relieve Fujifilm of its duties and responsibilities under this Agreement and the Quality Agreement and Fujifilm shall
remain primarily obligated and liable for the performance thereof. 

  

	 	h)	Process Improvements. Parties agree that during the course of the Agreement, the Parties may identify and implement Process improvements that can benefit both Parties. In the case one of the Parties identifies an
opportunity for improvements related to raw materials, such Party will notify the other Party and the Parties will [**] to these opportunities. Any cost-related improvements resulting from these projects will be [**]. Such improvements must be
within the validated parameters of the Process and shall not be effective unless mutually agreed in writing by the Parties pursuant to Section 10. 

  

	 	i)	Periodic Inventory Reporting. Fujifilm shall furnish the following information to Sponsor at the end of each Binding Period: Product, Starting Material and [**] quantities remaining, lot numbers and sub lots, and
expiry dates as applicable. 

 Section 2. Rolling Forecast and Binding Orders; Scheduling; Starting Material and
[**] 
  

	 	a)	General. The Initial Binding Order meeting the Sponsor’s Product requirements for year 2015 is described in Section 2(d). Future orders for the year 2016 and the following years will be based on a
Rolling Forecast (as defined below) according to the mechanism described below. 

  

	 	b)	Rolling Forecast. No later than August 31, 2015, Sponsor shall provide Fujifilm with a good-faith rolling forecast, and every [**] months thereafter (by the following [**], respectively), that projects the
number of Batches needed for the following [**] beginning on [**] (the “Rolling Forecast”). Fujifilm shall use the Rolling Forecast to plan capacity and resources. The Rolling Forecast shall indicate the number of Batches to be
provided during [**] period and shall cover the Binding Period, the semi-binding period and the non-binding periods, as follows: 

  

	 	i.	Period 1 (months [**]) – notice period; 

  

					
			CONFIDENTIAL		8

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

	 	ii.	Period 2 (months [**] ordered); 

  

	 	iii.	Period 3 (months [**] 

  

	 	iv.	Periods 4-7 [**]. 

 When applying the percentages set forth in this Section 2(b), the
Parties will [**], as applicable. 
  

	 	c)	Binding Orders. The forecast for Period 2 of each Rolling Forecast (i.e., the Binding Period) shall constitute a Binding Order and shall be subject to the following limitations: 

 

	 	i.	“Minimum Binding Order” shall be for [**] Batches. 

  

	 	ii.	If Sponsor has not received [**] (“2015 Lack of Approval Event”), Sponsor (i) will purchase all [**] and (ii) all [**] will no longer be in effect as of such date. The Parties will use [**].

  

	 	iii.	Each of the following events constitute a “Frustration of Purpose Event”: 

  

	 	(A)	[**] 

  

	 	(B)	[**] 

  

	 	(C)	[**] 

 If a Frustration of Purpose Event occurs, Sponsor shall purchase [**]. Otherwise, all
current and future [**], provided, however that such requirements shall [**]. In addition, with respect to a Frustration of Purpose Event described in Section 2(c)(iii)(A) or (B), the Parties will [**] the system of forecasting and ordering
(including any applicable [**] unless otherwise agreed by the Parties. 
  

	 	iv.	“Maximum Binding Order” shall be for [**]. 

  

	 	v.	Total number of Batches ordered within [**] (“[**]”). 

  

	 	d)	Initial Binding Order for 2015. During calendar year 2015, Fujifilm shall Manufacture and Sponsor shall [**] Batches of Product (“Initial Binding Order”) according to the following schedule:

  

	 	i.	The first Batch of the initial [**] shall have a Manufacturing Start Date no later than [**], with the remaining [**] in the Campaign having a targeted [**] than [**] (“First Shipment”);

  

	 	ii.	The first Batch of the [**] shall have a Manufacturing Start Date no later than [**], with the remaining [**] in the Campaign having a targeted [**] than [**] (“Second Shipment”); and 

 

	 	iii.	The first Batch of the [**] shall have a Manufacturing Start Date no later than [**], with the remaining [**]in the Campaign having a targeted [**] than [**] (“Third Shipment”). 

Notwithstanding anything in Section 2(f) to the contrary, Fujifilm will perform [**]. Fujifilm shall provide Sponsor at least [**] prior
written notice of the [**]. The Delivery Date for such Batches shall follow the requirements of Section 2(f)(iii). 

  

					
			CONFIDENTIAL		9

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

	 	
Sponsor shall have the right to order additional Batches for delivery in calendar year 2015 by notifying Fujifilm not later than [**] for the Second Shipment and not later than [**] for the Third
Shipment, and Fujifilm shall [**]. Such additional Batches shall be purchased by Sponsor [**] as the Batches of the original Binding Order and Sponsor shall [**]. For the Initial Binding Order, Fujifilm shall provide Sponsor with Receiving Schedules
for the corresponding Campaigns [**] of the Effective Date for the First Shipment, [**] for the Second Shipment and [**] for the Third Shipment. 

  

	 	e)	Batches in excess of Maximum Binding Order. Sponsor may request shipment of additional Batches in excess of Maximum Binding Order or [**] (“Order Expansion”) and Fujifilm shall make [**] to
accommodate such request. In the event Sponsor requests an Order Expansion, Fujifilm shall notify Sponsor in writing within [**] of receipt of such request whether Fujifilm will be able to accommodate such request. In the event Fujifilm confirms its
ability to accommodate Sponsor’s Order Expansion request, the quantity of additional Batches in excess of the Maximum Binding Order or [**] indicated in the Order Expansion shall become a Binding Order. Such additional Batches shall be
purchased by Sponsor [**] and Sponsor acknowledges and agrees that Sponsor [**]. 

  

	 	f)	Manufacturing Scheduling and Product Shipment Schedule. Once Fujifilm receives a Binding Order from Sponsor ([**] after receiving a Binding Order), Fujifilm will provide Sponsor with a written confirmation of the
[**] for the Batches ordered pursuant to such Binding Order. Fujifilm shall [**], provided that, unless mutually agreed to in writing, which may be via email: 

  

	 	i.	The actual Manufacture Start Date [**] by Fujifilm for such Binding Order; 

  

	 	ii.	Fujifilm will use commercially reasonable efforts to ensure the actual Disposition Date [**] from the completion of Bulk Fill for the Batch, as reflected in the Batch Records for that Batch; and 

 

	 	iii.	Fujifilm shall provide Sponsor with good-faith estimated date on which Fujifilm anticipates providing possession of a Batch to Sponsor [**] before such estimated date. The actual date of transfer of possession of a
Batch from Fujifilm to Sponsor shall ultimately be subject to the Parties’ mutual agreement and shall [**] after the Disposition Date unless otherwise requested by Sponsor and agreed by Fujifilm in writing, which may be via email (such
agreement not to be unreasonably withheld or delayed) (the “Delivery Date”). 

  

	 	g)	Starting Material Receiving Schedule. Within [**] of receiving a Binding Order, Fujifilm shall prepare and deliver to Sponsor a Receiving Schedule. 

 

	 	i.	Based on the Receiving Schedule, Sponsor shall use commercially reasonable efforts to deliver the Starting Materials to the GMP Facility in the quantity listed on the Receiving Schedule (i) no later than on the
[**], but (ii) no earlier than [**]. Parties shall agree in writing, which may be via email, on specific shipment dates for Starting Material. Sponsor acknowledges that the failure by Sponsor to provide Starting Material within the timeframe
agreed by the Parties may result in postponed Manufacture Start Date or Delivery Date equal to Sponsor delay. 

  

	 	ii.	Sponsor shall ship Starting Material so that [**] batches of such Starting Material are received [**]. 

  

					
			CONFIDENTIAL		10

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

	 	iii.	In the Receiving Schedule, Fujifilm shall not request a quantity of Starting Material greater than the quantity of Starting Material required (based on the Specifications) for the number of Batches indicated in Binding
Order, [**] in the amount sufficient for [**] unless Fujifilm already has [**]. 

  

	 	iv.	Starting Material received by Fujifilm shall have [**] for each batch of Starting Material received. 

  

	 	v.	Starting Material delivered by Sponsor to Fujifilm shall meet quality requirements specified in the Specifications. Upon receipt of a batch of Starting Material, Fujifilm shall review the accompanying documentation and
examine such shipment to confirm the quantity received is consistent with the quantity specified in the Receiving Schedule. Fujifilm shall also perform identification testing and any other testing required by the Quality Agreement to confirm that
the Starting Material meets the quality requirements specified in the Specifications. In the event Fujifilm notifies Sponsor of non-conformity of any Starting Material received by Fujifilm, Sponsor shall promptly investigate Fujifilm’s claim of
non-conformity in the Starting Material and shall provide Fujifilm with instructions on how to handle such Starting Material and any return of such Starting Material shall at Sponsor’s sole cost and expense if Sponsor elects for the return of
such Starting Material in lieu of destruction. Notwithstanding the results of Sponsor investigation, Fujifilm shall [**]. 

  

	 	vi.	Fujifilm shall use commercially reasonable effort to apply the “first-expired-first-out” principles to processing of Starting Material. 

 

	 	h)	[**]. During the Term, [**]. Concurrently with providing [**] shall provide [**] of its requirements for [**]. Based on the feedback from [**] with lead-time required by the [**] required to Manufacture a Batch as
specified in the Specifications, including appropriate [**] agreed by the Parties. Sponsor’s [**]. The Parties acknowledge and agree that [**] in accordance with this Section shall be made under the [**]. Fujifilm will be responsible for [**]
and agrees to comply with the [**] shall review the accompanying documentation and perform incoming identification testing and perform any other tests required in the Quality Agreement to confirm the [**] conforms with the Specifications and was
received in the quantity indicated in the shipment-related documentation, including confirmation that the [**]. In the event the [**] shall be responsible for the [**]. 

Section 3. Sponsor Deliverables 
  

	 	a)	Sponsor will use commercially reasonable efforts to timely provide Fujifilm with Sponsor Deliverables (as defined below). Sponsor acknowledges that the failure by Sponsor to provide Sponsor Deliverables within the
timeframe set forth below or otherwise agreed by Parties may result in postponed Manufacture Start Date or Delivery Date equal to Sponsor delay. “Sponsor Deliverables” means the following: 

 

	 	i.	For each Binding Order, Sponsor shall deliver the quantity of Starting Material as specified in the Receiving Schedule. 

  

	 	ii.	Sponsor shall provide documentation review and approval within timeframes specified in Quality Agreement, provided that Sponsor received such documentation on a timely basis from Fujifilm. 

  

					
			CONFIDENTIAL		11

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

	 	iii.	Sponsor shall review the Batch Packet within the period specified in the Quality Agreement to determine, to the extent ascertainable from such documentation, whether or not the Batch covered by such Batch Packet
conforms to the Specifications and shall issue a Certificate of Compliance. For clarity, Sponsor’s issuance of a Certificate of Compliance shall [**].  

 

	 	b)	Title to Sponsor Deliverables shall remain with Sponsor. Fujifilm shall not sell, pledge, hypothecate, dispose of, or otherwise transfer any interest in Sponsor Deliverables and shall use Sponsor Deliverables solely for
purposes of performing the Program. Fujifilm shall provide safe and secure storage conditions at the GMP Facility for Sponsor Deliverables while they are at the GMP Facility and shall store the Sponsor Deliverables [**] at the GMP Facility, unless
otherwise agreed with Sponsor in writing, in accordance with all Applicable Law and any storage guidelines provided by Sponsor and agreed upon with Fujifilm. 

Section 4. Compliance with Government Regulations 
  

	 	a)	Fujifilm shall operate the GMP Facility in compliance with Applicable Law and any requirements provided for in the Quality Agreement for all aspects of Manufacturing (including but not limited to testing, holding,
packaging, labeling and delivery of the Product and/or intermediates produced for Sponsor). For clarity, this shall include the obligation for Fujifilm to operate the GMP Facility as compliant with (i) the U.S. Federal Food, Drug and Cosmetics
Act, as amended (21 U.S.C. et seq.), (ii) U.S. regulations found at 21 CFR Parts 11, 210, 211, 600, & 610, (iii) ICH Q7 GMP Guidance for Active Pharmaceutical Ingredients, (iv) EC Directive 2003/94/EC, (v) the EC Guide
to Good Manufacturing Practice for Medicinal Products and Division 2 of the Food and Drug Regulations (Canada), (vi) the latest Health Canada, FDA and EMA guidance documents all pertaining to manufacturing and quality control practice and
(vii) the good manufacturing practices required by any other Regulatory Authority to the extent such required practices do not contradict or negate the requirements or guidance documents issued by FDA or EMA, all as updated, amended and revised
from time to time (collectively, “cGMP”). Fujifilm shall not permit debarred persons to participate in the Program or persons for whom debarment is pending or threatened. Fujifilm shall undertake commercially reasonable steps to
prevent such participation. 	 

  

	 	b)	Sponsor shall have the sole right and responsibility for determining regulatory strategy, decision and actions relating to the Program and the Product. Subject to each Party’s contractual obligations under this
Agreement, Fujifilm shall have the sole right and responsibility for determining regulatory strategy, decision and actions to the extent relating to (i) the Facilities; (ii) Fujifilm’s quality systems; or (iii) any requirement
imposed directly on Fujifilm by a Regulatory Authority, provided that a Regulatory Authority requirement shall not be considered to be “a requirement imposed directly on Fujifilm by a Regulatory Authority” if it is applicable to or imposed
on Sponsor regarding the services provided by Fujifilm with respect to the Product, but is not applicable to other Fujifilm’s client in respect to Fujifilm’s services provided to them. Fujifilm hereby [**], as of the Effective Date, [**]
Sponsor with commercial supply of Product or otherwise complying with its obligations hereunder. Notwithstanding the foregoing, [**] Sponsor will consult with Fujifilm in respect to and prior to any action that may be reasonably expected to impact
Fujifilm’s obligations with respect to the Product. 

  

					
			CONFIDENTIAL		12

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

	 	c)	Should such applicable requirements of Regulatory Authorities change or should the mutually agreed upon expansion of the definition of Regulatory Authorities impact Fujifilm’s regulatory obligations hereunder,
Fujifilm will promptly notify the other Party of such change and the effect on the Program, and Fujifilm will use reasonable efforts to satisfy the new requirements. In the event that compliance with such new applicable regulatory requirements
necessitates performing additional studies or other work not reasonably expected and anticipated as part of routine commercial manufacturing, Fujifilm will submit to Sponsor a Change Order in accordance with Section 10 of this Agreement.

  

	 	d)	Subject to this Section 4, in the event of a conflict in government regulations applicable to the performance of the Program, Sponsor and Fujifilm will [**] in its performance of the Program; provided, however,
that Fujifilm shall not be required to [**]. 

  

	 	e)	If Fujifilm receives any contact or communication from any Regulatory Authority governing commercial licensing of the Product, Fujifilm will (i) notify Sponsor and provide Sponsor with copies of any such
communication (to the extent the communication relates to the Program) within [**] of Fujifilm’s determination that such communication relates to the Program (but not to exceed [**] of Fujifilm’s receipt of such communication) and
(ii) comply with all reasonable requests by Sponsor with respect to any actions to be taken or responses to be made to any such Regulatory Authority. Fujifilm will promptly inform Sponsor in the event that any such Regulatory Authority takes
any action against Fujifilm for any reason that could be reasonably expected to have an effect on Fujifilm’s performance of the Program. Unless required by Applicable Law, Fujifilm will have no contact or communication with any such Regulatory
Authority regarding the Product without the prior written consent of Sponsor, which consent will not be unreasonably withheld. If Fujifilm is required by Applicable Law to contact or communicate with any Regulatory Authority regarding the Product,
Fujifilm shall provide Sponsor with reasonable prior notice to allow Sponsor the opportunity to participate in any such contact or communication, to the maximum extent permitted by law. In the event of an inspection of Fujifilm by a Regulatory
Authority that pertains to Product, Fujifilm shall allow Sponsor and its representatives to attend and participate in such inspection. The Quality Agreement shall govern with respect to obligations related to the Parties’ notifications and
submissions to a Regulatory Authority governing the commercial license of the Product. 

  

	 	f)	Fujifilm shall secure and maintain in good order, at its sole cost and expense, such current governmental registrations, permits and licenses as are required by any Regulatory Authority or otherwise required by any
Applicable Law in order for Fujifilm to perform its obligations under this Agreement. 

  

	 	g)	If Fujifilm receives notice of action or threat of action with respect to its debarment or debarment of any individual involved in the performance of Fujifilm’s obligations hereunder during the Term of this
Agreement: (i) Fujifilm shall so notify Sponsor immediately and (ii) Sponsor shall have the right to terminate this Agreement immediately upon written notice. 

 

	 	h)	 If Sponsor receives notice of action or threat of action with respect to its debarment or debarment of any individual involved in the performance of
Sponsor’s obligations hereunder during the Term of this Agreement (i) Sponsor shall so notify Fujifilm immediately and (ii) in the event of Sponsor’s actual debarment, Fujifilm shall have the

  

					
			CONFIDENTIAL		13

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

	 	
right to terminate this Agreement immediately upon written notice. In the event of actual debarment of any Sponsor employee involved in the performance of Sponsor’s obligations hereunder,
provided Sponsor has not terminated the employment of such individual within [**] after debarment, Fujifilm shall have the right to terminate this Agreement immediately upon written notice. 

 

	 	i)	In the event that Fujifilm receives notification of an Adverse Event or other Safety Information pertaining to the Product as Manufactured by Fujifilm under this Agreement, Fujifilm shall notify Sponsor within one
(1) business day by sending all relevant information to pharmacogivilance@synageva.com. In the event that Fujifilm receives a Drug Product Complaint, Fujifilm shall notify Sponsor within one (1) business day by sending all relevant
information to QA@synageva.com. 

  

	 	j)	In the event that Sponsor receives a Drug Product Complaint, Adverse Event or other Safety Information pertaining to the Product as Manufactured by Fujifilm under this Agreement, Sponsor shall notify Fujifilm within one
(1) business day by sending all relevant information to the Quality Assurance contact specified in the Quality Agreement. 

Section 5. Facility Visits 
 The terms and
conditions of Sponsor audit rights and rights to inspect the GMP Facility are provided in the Quality Agreement. Sponsor’s person-in-the-plant (“PIP”) shall have the right to access [**]. The PIP shall follow Fujifilm policies
and operating procedures while in the GMP Facility. The PIP [**]. 
 Section 6. Compensation 

 

	 	a)	Reservation Fee and Batch Price; Resins.  

  

	 	i.	Upon placement of a Binding Order, Fujifilm shall invoice Sponsor a reservation fee in the amount of [**] of the aggregate Batch Price (as defined below) for all the Batches ordered under such Binding Order
(“Reservation Fee”). [**] of the aggregate Batch Price for all the Batches ordered under such Binding Order shall be invoiced to Sponsor upon Manufacture Start Date of the First Batch under the Binding Order and [**] of the
aggregate Batch Price for the all the Batches ordered under such Binding Order shall be invoiced [**] upon shipment of each of the Batches under the Binding Order. The “Batch Price” shall mean the price for [**]
(“Manufacturing Price”) together with the price for [**] allocated to Manufacturing of such Batch [**] and shall be calculated as set forth in, and in accordance with, Attachment 2. Notwithstanding the foregoing, [**].

  

	 	ii.	In addition to the Batch Price, Sponsor shall [**] purchased and used by Fujifilm in Manufacturing the Product pursuant to a Binding Order, provided the [**]. 

 

	 	b)	[**] Fee. In addition to fees for Product delivered under Binding Orders, Sponsor shall [**] (“[**] Fee”). The [**] Fee shall be subject to [**], provided that Sponsor shall receive at least [**]
written notice of any such [**]. 

  

	 	c)	 [**] Batch Price Adjustment. Batch Price specified in Attachment 2 shall be adjusted [**] according to the following mechanism, provided
that Sponsor must receive at least [**] 

  

					
			CONFIDENTIAL		14

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

	 	
prior written notice of any such adjustment before it may take effect and such notice shall include the details on any changes to the [**]: 

 

	 	i.	Manufacturing Price shall [**], in which case the [**]. Notwithstanding the foregoing, if the [**]. 

  

	 	ii.	Initial Consumable Price is specified in Attachment 2. The Consumable Price will be [**], Fujifilm will issue Sponsor [**] to Fujifilm by Sponsor for the prior [**]. 

 

	 	iii.	The adjusted Manufacturing Price and [**] Price shall together constitute the new Batch Price, which shall be included in a revised Attachment 2 to this Agreement together with new Annual Program Fee. 

 

	 	d)	[**]: 

 [**] 

[**] 
  

	 	e)	Safety Stock. Fujifilm shall carry sufficient safety stock of Process Consumables to help ensure uninterrupted Manufacturing of Product (“Safety Stock”) and timely delivery of Product according
to Binding Orders. Fujifilm and Sponsor have jointly determined the required initial level of Safety Stock before the first Campaign under this Agreement ([**]) pursuant to that certain Letter of Agreement between the Parties dated October 30,
2014 (“Process Consumables LOA”), and shall review the level of Safety Stock and adjust, as needed, at least [**] upon receiving updated Rolling Forecasts. The cost of an increase in Safety Stock shall be borne by Sponsor, except of
Process Consumables that are regularly stocked by Fujifilm, or if otherwise agreed in writing. Fujifilm shall invoice Sponsor for Process Consumables purchased for the increase in Safety Stock other than Process Consumables that are regularly
stocked by Fujifilm, including [**], after receiving the invoices from its vendors, provided that except as set forth in Section 2(h) with [**], Sponsor shall not have an obligation to pay for any Process Consumables that do not meet the
Specifications, the Bill of Materials or Fujifilm’s order placed with the third party supplier. Fujifilm shall use such Process Consumables (other than those Process Consumables that are regularly stocked by Fujifilm) solely for purposes of
performing the Program. Fujifilm shall use commercially reasonable efforts to use “first-to-expire-first-out” principles for managing the Safety Stock. If the Parties agree to reduce the Safety Stock, Fujifilm shall make a commercially
reasonable effort to use the Process Consumables from the Safety Stock in the upcoming Campaigns, until the Safety Stock is reduced to the desired level, and shall credit Sponsor for the purchase cost of used consumables. Any unused expired
materials from the Safety Stock shall be disposed as described in Section 6(g). 

  

	 	f)	Invoices. Fujifilm shall issue invoices separately for (i) each [**] and (ii) the [**] and (iii) any additional [**]. Invoices for any work performed under a Change Order shall be issued as
specified in the applicable Change Order. All invoices shall be submitted and payable in U.S. Dollars. Payments are due [**] from the date an invoice issued by Fujifilm is received by Sponsor. If Sponsor disputes an invoice, Sponsor shall pay the
undisputed amount and notify Fujifilm of the dispute within [**] of receipt of invoice and advise Fujifilm in good faith and in writing the specific basis for disputing an invoice. In addition to all other remedies available to Fujifilm, in the
event [**], Fujifilm may [**] deliveries of Product or provision of reports until [**]. 

  

					
			CONFIDENTIAL		15

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

	 	g)	Disposal of Expired or Unused Starting Materials and Process Consumables. Fujifilm shall be responsible for disposal of expired or unused Process Consumables. The cost of such Consumables and their disposal shall
be borne by Fujifilm except of Process Consumables from Safety Stock not regularly stocked by Fujifilm, disposal cost of which shall be borne by Sponsor unless such [**]. Fujifilm shall invoice Sponsor for [**], except as set forth in the preceding
sentence. Sponsor shall be responsible for an [**], Fujifilm shall provide Sponsor with remaining inventory of Starting Material including expiry dates. For any expired Starting Material, Sponsor may request Fujifilm to deliver remaining Starting
Material to Sponsor or a designated storage site in lieu of destruction by incineration. 

  

	 	h)	Sponsor-dedicated Process Equipment. In anticipation of Market Authorization for the Drug Product, Fujifilm shall perform evaluation of the equipment used in Manufacturing of Product in respect to the risk posed
to uninterrupted supply of Product under this Agreement and shall propose to Sponsor appropriate countermeasures that may include dedication of equipment to the Program. If Sponsor elects to have any equipment dedicated solely to Sponsor’s
Process, Sponsor shall carry the cost of procurement, installation and qualification of such equipment, which shall be set forth in a Change Order. 

Section 7. Non-Conforming Batches 
  

	 	a)	Fujifilm shall [**] ensure that it will only deliver Batches to Sponsor that (i) are Manufactured in accordance with, and meet the requirements of, this Agreement, the Quality Agreement (including the
Specifications) and Applicable Laws (including cGMPs) [**]. 

  

	 	b)	The following provisions shall apply if it is ascertained by either Party that a Batch is a Non-Conforming Batch during disposition of a Batch or as a result of Sponsor’s review of the applicable Batch Packet [**]:

  

	 	i.	If Fujifilm is the first to discover the non-conformity, Fujifilm shall [**] provide written notice of same, including an explanation of the non-conformity, to Sponsor within [**] from discovery, but not to exceed [**]
from discovery. If Sponsor is the first to discover the non-conformity, Sponsor shall [**] provide written notice, including an explanation of the non-conformity, to Fujifilm within [**] from discovery, but not to exceed [**] from Sponsor’s
receipt of Batch, or in the case of [**] from Sponsor’s receipt of the Batch. 

  

	 	ii.	The Non-Conforming Batch shall not be delivered to Sponsor if it is still located at the GMP Facility as of the date of Fujifilm’s issuance or receipt (as applicable) of the notice of non-conformity.

  

	 	iii.	If Sponsor has provided the notice of a Non-Conforming Batch to Fujifilm, within [**] of receiving such notice, Fujifilm shall investigate the presence and source of defect following the Fujifilm complaint procedure and
notify Sponsor in writing as to whether Fujifilm agrees or disagrees in good faith with Sponsor’s determination of the existence or cause of the non-conformity and the reasons therefor. [**]. 

  

					
			CONFIDENTIAL		16

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

	 	iv.	If Fujifilm has provided the notice of a Non-Conforming Batch to Sponsor, within [**] of receiving such notice, Sponsor shall notify Fujifilm whether Sponsor agrees or disagrees in good faith with Fujifilm’s
determination of the existence or cause of the non-conformity and the reasons therefor. If Sponsor does not provide a written notice within such period, Sponsor shall be deemed to have accepted the existence and cause of non-conformity as stated by
Fujifilm. 

  

	 	v.	In the event the Parties do not agree as to the existence or cause of a Non-Conforming Batch, then within [**] of Fujifilm’s written notice pursuant to Section 7(b)(iii) or Sponsor’s written notice
pursuant to Section 7(b)(iv), the authorized Quality Assurance representative(s) of each Party will [**] to evaluate the existence and the cause of non-conformity and [**]. This evaluation will be [**] for purposes of determining respective
financial liability pursuant to Section 7(b)(vii). The Party [**] shall bear the costs of the evaluation. 

  

	 	vi.	Fujifilm shall [**] start Manufacture of a further Batch to replace the Non-Conforming Batch [**] after it is determined that the Batch was a Non-Conforming Batch). 

 

	 	vii.	The cost of replacing a Non-Conforming Batch shall be allocated as follows: 

  

	 	(A)	If a Non-Conforming Batch results from the Starting Material’s failure to comply with the applicable Specifications as of the date of delivery to Fujifilm and such failure could not have been reasonably detected
during Fujifilm’s proper performance of its review and testing obligations of the Starting Material (a “Starting Material Failure”), Fujifilm will manufacture a conforming replacement Batch pursuant to Subsection
(vi) above and [**]. 

  

	 	(B)	Fujifilm shall Manufacture a further Batch [**] if the Non-Conforming Batch arose from any cause other than a Starting Material Failure. In addition, disposal of the Non-Conforming Batch, if applicable pursuant to
Section 7(b)(viii), shall be [**]. Notwithstanding the foregoing, Sponsor [**] unless the Non-Conforming Batch arose from [**], in which case [**] for the cost of [**], as specified in Attachment 2 and [**] needed to produce the [**].

  

	 	viii.	Unless otherwise requested by Sponsor in writing, Fujifilm shall dispose of any Non-Conforming Batch that Fujifilm is obligated to replace pursuant to Section 7(b)(vi) in accordance with Applicable Law.

  

	 	c)	In the event of [**] Non-Conforming Batches within a Campaign, the root cause of which is either not identifiable or is the same across the Non-Conforming Batches and is not the result of [**], the parties will [**] a
plan for [**]) in an effort to reduce the number of Non-Conforming Batches. Such [**] may result in Process changes or other changes, subject to Section 10 on Modifications. The reasonable [**] shall be borne by [**]. In addition, to the extent
required for compliance with cGMP, Fujifilm may [**], provided that the [**]. 

  

					
			CONFIDENTIAL		17

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

	 	d)	[**], the remedies set out in this Section 7 shall be [**] in relation to a Non-Conforming Batch. Notwithstanding the foregoing, this Section 7(d) shall not limit Fujifilm’s obligations pursuant to
Section 19 or Sponsor’s rights pursuant to Section 1(f). 

 Section 8. Recalls 

 

	 	a)	Records and Notice. Fujifilm shall maintain records necessary to permit a Recall (as defined below). Each Party will promptly notify the other by telephone (to be promptly confirmed in writing) of any information
which might affect the marketability, safety or effectiveness of the Product or Drug Product or which might result in a Recall. Upon receiving this notice or upon this discovery, Sponsor may elect by written notice for Fujifilm to stop making any
further shipments of any Product in its possession or control until a decision has been made whether a Recall or some other corrective action is necessary. The decision to initiate a Recall or to take some other corrective action, if any, will be
made and implemented by Sponsor. “Recall” will mean any action (i) by or at the request of Sponsor to recover title to or possession of quantities of the Product shipped to third parties or Drug Product sold or shipped to third
parties (including, without limitation, the voluntary withdrawal of Drug Product from the market); or (ii) by any Regulatory Authorities to seize, detain or destroy any of the Product or Drug Product. Recall will also include any action by
either Party to refrain from selling or shipping quantities of the Product or Drug Product to third parties which would have been subject to a Recall if sold or shipped. 

 

	 	b)	Recalls. If (i) any Regulatory Authority issues a directive, order or, following the issuance of a safety warning or alert about a Product or Drug Product, a written request that any Product or Drug Product
be Recalled, (ii) any Regulatory Authority threatens to prohibit the delivery or use of any Product or Drug Product or any other regulatory reportable event for the Product or Drug Product occurs, (iii) a court of competent jurisdiction
orders a Recall, or (iv) Sponsor determines that a Recall should be instituted or that a “Dear Doctor” letter or its equivalent is required relating to the restrictions on the use of any Drug Product, Fujifilm will notify Sponsor as
within the period specified in the Quality Agreement (in the event it is the Party that becomes first aware of such event) or Sponsor will notify Fujifilm within the period specified in the Quality Agreement (in the event it is the Party that
becomes first aware of such event) and, in any case, Fujifilm and Sponsor will co-operate as reasonably required by each Party, having regard to all Applicable Law. 

 

	 	c)	Responsibility for Costs of Recall. If a Recall results from the Product’s deviation from the Quality Agreement (including the Specifications), this Agreement, cGMPs or other Applicable Law, to the extent
such deviation arose from the items for which [**] responsible thereunder(other than [**]), [**] will be responsible for the cost of the replacement Product [**] provided, that [**] the expenses related to such Recall and provided that if the [**].
For clarity, the foregoing limit on Fujifilm’s liability for Recall expenses [**] responsibility for the cost of any replacement Product or, to the extent such Recall results from [**] responsibility for [**] of the [**] and the Starting
Material needed to produce any replacement Batches. [**] Products involved in the Recall with new Products, contingent upon the receipt from [**]. 

  

					
			CONFIDENTIAL		18

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

 Section 9. Late Delivery 

 

	 	a)	Late Delivery of Starting Material. If Sponsor delivers the required amount of Starting Material more than [**] after the Receiving Date, Fujifilm [**] and Sponsor shall [**] if, despite [**] Fujifilm is [**]
provided however that if Fujifilm is [**] Sponsor’s Binding Order [**]. 

  

	 	b)	[**] Manufacture Start Date. [**] The amount of the [**] will vary based on the [**] and will equal the following [**]: 

  

			
	[**]		[**]

 Section 10. Change Orders 
  

	 	a)	Key Manufacturing Assumption. The Parties have agreed upon certain analytical methods for Product release being transferred by Sponsor to Fujifilm and the Parties intend for such release testing to be performed
by Fujifilm, provided the requisite Regulatory Authority approval is received (“Key Manufacturing Assumption”). 

  

	 	b)	Sponsor Change Orders. Sponsor shall inform Fujifilm in writing of any proposed modifications to the Key Manufacturing Assumption, equipment, systems, GMP Facility, Process, Process Consumables, Starting
Materials, Specifications or other changes relating to the Manufacture (collectively, “Modifications”). Once a Modification has been requested by Sponsor, and agreed with by Fujifilm (to the extent Fujifilm’s agreement is
explicitly required per this Section 10), Fujifilm shall provide Sponsor with a change order containing an estimate of the increase or decrease, as applicable, in Batch Price or any other costs to Sponsor as well as the activities,
deliverables, estimated duration, and payment schedule (“Change Order”) within [**] of receiving such notice from Sponsor. Sponsor shall be deemed to have not approved the Change Order if Fujifilm does not receive a written approval
of the Change Order from Sponsor within [**] of Sponsor’s receipt of the Change Order. If Sponsor does not approve such Change Order, then Sponsor and Fujifilm shall negotiate in good faith to agree on a Change Order that is mutually
acceptable. Any Modification proposed by Sponsor that would [**].

  

	 	c)	Fujifilm Change Orders. Fujifilm may not make any Modifications without the prior written consent of Sponsor, other than a Modification required by a Regulatory Authority that would not affect the Product’s
Biologic License Application (or foreign equivalent) or Product validation. If such a Modification required by a Regulatory Authority would affect the Product’s Biologic License Application or Product validation, the Parties shall discuss such
proposed Modification in good faith and such Modification shall require Sponsor’s prior written consent, which consent shall not be unreasonably withheld or delayed. Fujifilm shall promptly notify Sponsor in writing of any Modification after
becoming aware of the need for such Modification. If a Modification is expected to have an impact on Process or Fujifilm obligations under this Agreement, Parties shall discuss the feasibility of such Modification in good faith. [**]. Fujifilm shall
request Modifications in writing from Sponsor by issuing a Change Order to Sponsor for review and approval. Sponsor shall be deemed to have not approved the Change Order if Fujifilm does not receive a written approval of the Change Order from
Sponsor within [**] of Sponsor’s receipt of the Change Order. If Sponsor does not approve such Change Order, then Sponsor and Fujifilm shall negotiate in good faith to agree on a Change Order that is mutually acceptable. 

  

					
			CONFIDENTIAL		19

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

	 	d)	Cost of Change Orders. If Modifications are requested by or from Fujifilm as a result of [**] then Sponsor and Fujifilm will review such requirements and use good faith efforts to agree on the reasonable costs
associated therewith, [**]. If Modifications are requested by or from Fujifilm as a result of requirements set forth by a Regulatory Authority and such Modifications apply generally to the Product as well as other products produced by Fujifilm (for
itself or for third parties) or the general operation of the Facilities, then Fujifilm shall bear the reasonable costs associated therewith. Except as set forth above, the reasonable costs associated with Modifications requested by Fujifilm which
exclusively benefit Fujifilm and/or its other customers shall be borne by Fujifilm, and the reasonable costs associated with Modifications requested by Sponsor shall be borne by Sponsor, if such costs have been accepted by Sponsor pursuant to
Section 10(b) above. When Fujifilm provides a proposed Change Order to Sponsor for any reason, Fujifilm shall provide reasonable detailed explanation of activities to be performed to enable Sponsor to understand and evaluate the source of such
changes in price. 

  

	 	e)	Regulatory Authority Approval of Modifications. Sponsor shall have sole responsibility for obtaining any and all necessary approvals from any Regulatory Authority for implemented Modifications and for reporting
any implemented Modifications to any Regulatory Authority as appropriate, except if Modifications are requested by or from Fujifilm as a result of requirements set forth by a Regulatory Authority and such Modifications apply generally to the Product
as well as other products produced by Fujifilm (for itself or for third parties) or the general operation of the Facilities, in which case Fujifilm shall have the responsibility for the aforementioned actions. Upon request by a Party, the other
Party [**]. 

 Section 11. Confidential Information/Legal Proceedings 

 

	 	a)	 During the Term of this Agreement and for five (5) years following the expiration or earlier termination of this Agreement, Fujifilm will hold in
confidence and will not disclose, without Sponsor’s prior written permission, any Confidential Information pertaining to the Drug Product, the Product, the Program or otherwise disclosed by Sponsor to Fujifilm in connection with the Program
(“Sponsor Confidential Information”) unless: (i) such disclosure is to an Affiliate of Fujifilm that is under an obligation to keep such information confidential comparable in scope to Fujifilm’s obligation under this
Section 11; (ii) such information is or becomes publicly available through no fault of Fujifilm; (iii) such information became known to Fujifilm through disclosure by sources other than Sponsor, having no duty of confidentiality with
respect to such information, whether to Sponsor or another party, and having the legal right to disclose such information; (iv) such information is already known to Fujifilm, without restriction, at the time of disclosure, as shown by its prior
written records; or (v) such information was independently developed by Fujifilm without reference to or reliance upon Sponsor Confidential Information. In the event Sponsor Confidential Information rises to the level of a trade secret under
law, the obligations of this Section 11 shall continue with respect to such Sponsor Confidential Information for so long as such Sponsor Confidential Information retains its status as a trade secret. Notwithstanding the obligations of
confidentiality specified in this Section 11, disclosure of Sponsor Confidential Information shall not be prohibited to the extent required to be disclosed by any law, rule, regulation, order decision, decree, subpoena or other legal process,
provided that, to the extent possible, Fujifilm provides prior written notification to Sponsor of such disclosure promptly prior to any disclosure to permit Sponsor to oppose and/or minimize the extent of such disclosure by appropriate legal

  

					
			CONFIDENTIAL		20

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

	 	
action. Fujifilm shall use reasonable precautions to protect the confidentiality of Sponsor Confidential Information comparable to precautions taken to protect its own proprietary information but
in no event shall Fujifilm use less than a reasonable degree of care. 

  

	 	b)	During the Term of this Agreement and for five (5) years following the expiration or earlier termination of this Agreement, Sponsor will hold in confidence and will not disclose, without Fujifilm’s prior
written permission, any Confidential Information pertaining to Fujifilm’s performance of the Program disclosed by Fujifilm to Sponsor (“Fujifilm Confidential Information”) unless: (i) such disclosure is to an Affiliate of
Sponsor that is under an obligation to keep such information confidential comparable in scope to Sponsor’s obligation under this Section 11; (ii) such information is or becomes publicly available through no fault of Sponsor;
(iii) such information became known to Sponsor through disclosure by sources other than Fujifilm, having no duty of confidentiality with respect to such information, whether to Fujifilm or another party, and having the legal right to disclose
such information; (iv) such information is already known to Sponsor, without restriction, at the time of disclosure, as shown by its prior written records; or (v) such information was independently developed by Sponsor without reference to
or reliance upon Fujifilm Confidential Information. In the event Fujifilm Confidential Information rises to the level of a trade secret under law, the obligations of this Section 11 shall continue with respect to such Fujifilm Confidential
Information for so long as such Fujifilm Confidential Information retains its status as a trade secret. Notwithstanding the obligations of confidentiality specified in this Section 11, disclosure of Fujifilm Confidential Information shall not
be prohibited to the extent required to be disclosed by any law, rule, regulation, order decision, decree, subpoena or other legal process, provided that, to the extent possible, Sponsor provides prior written notification to Fujifilm of such
disclosure promptly prior to any disclosure to permit Fujifilm to oppose and/or minimize the extent of such disclosure by appropriate legal action. Sponsor shall use reasonable precautions to protect the confidentiality of Fujifilm Confidential
Information comparable to precautions taken to protect its own proprietary information but in no event shall Sponsor use less than a reasonable degree of care. Notwithstanding anything to the contrary in this Agreement, no provision of this
Agreement shall be construed so as to preclude Sponsor’s disclosure of Confidential Information, including Fujifilm Confidential Information, as may be reasonably necessary to secure from any Regulatory Authority or other governmental agency
necessary approvals or licenses, or, in the case of Sponsor’s Confidential Information, in a patent application with respect to the Product or Drug Product. Disclosure of Fujifilm’s Confidential Information in a patent application with
respect to the Product or Drug Product shall require written approval from Fujifilm. 

  

	 	c)	For both Parties, “Confidential Information” shall mean and include without limitation inventions, methods, plans, processes, specifications, characteristics, raw data, analyses, equipment design, trade
secrets, costs, marketing, sales, and performance information, including patents and patent applications, grant applications, notes, and memoranda, whether in writing or presented, stored or maintained electronically, magnetically or by other means,
which are disclosed by the disclosing Party to the recipient Party in writing or in other tangible form and whether or not marked “confidential”; provided, that, if disclosed orally (or in some other non-tangible form), the disclosing
Party shall use reasonable efforts to identify such information as confidential to the recipient Party in writing within sixty (60) days of such oral disclosure but the failure to so mark information shall not affect its treatment as
Confidential Information if it is reasonably clear that the information is commercially sensitive. 

  

					
			CONFIDENTIAL		21

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

	 	d)	Upon the expiration or termination of this Agreement, to the extent requested by the disclosing Party, each recipient Party shall use all commercially reasonable efforts to collect and return to the disclosing Party any
and all data, notes, records, reports, and other electronic or written information, including any and all copies that may have been made thereof, that contain Confidential Information received from the disclosing Party; provided, that, each
recipient Party shall be entitled to keep one archival copy of Confidential Information provided by the disclosing Party in its confidential files, subject to ongoing obligations of confidentiality hereunder. 

Section 12. Work Output 
  

	 	a)	All information, data, documentation and reports produced by Fujifilm in the conduct of the Program and/or all other cGMP documentation (“Work Output”) will be prepared by Fujifilm using Fujifilm’s
standard format(s). 

  

	 	b)	Sponsor will be supplied with copies of Work Output as part of Batch Packet and Campaign summary reports. Fujifilm shall not be obliged to supply all data generated but instead will supply relevant data to Sponsor and
Sponsor will have access to all data generated in relation to the Program for on-site review either (i) during any audits or (ii) upon Sponsor’s written request. All Work Output and Product samples will be archived by Fujifilm as
required by the Quality Agreement or for a period of five (5) years, whichever is longer. Sponsor may elect to have the Work Output retained in the Fujifilm archives for an additional period of time at additional cost to Sponsor. If Sponsor
chooses to have Fujifilm dispose of Work Output and Product samples, a reasonable disposal fee will be charged. Notwithstanding the foregoing, Fujifilm will continue to retain such Work Output and Product samples as required by Applicable Law
pertaining to such activities as well as for archival purposes. In the absence of such notice, at the end of the applicable period, Fujifilm shall notify Sponsor of the expiration of such period and, upon notice from Sponsor, Fujifilm shall send the
Work Output to Sponsor at Sponsor’s cost and expense. 

 Section 13. Inventions and Patents 

 

	 	a)	Fujifilm shall promptly and fully disclose to Sponsor any and all inventions, improvements, developments, original works of authorship or other intellectual property conceived, developed and/or reduced to practice,
whether in whole or in part, by Fujifilm in the course of the performance of the Program (collectively, “Program Inventions”). 

  

	 	b)	 All Program Inventions that relate to Fujifilm’s general manufacturing and analytical methods and that are not specific to the Product or Sponsor
Deliverables shall be Confidential Information of and shall be solely owned by Fujifilm (collectively, “Process Inventions”). All other Program Inventions, including without limitation, any Program Inventions that are specific to
the Product or the Sponsor Deliverables (collectively, “Product Inventions”) shall be Confidential Information of, and shall be solely owned by, Sponsor. Fujifilm hereby agrees to assign, and does hereby assign, to Sponsor and its
successors and assigns, without further consideration, its entire right, title and interest in any Product Inventions, whether or not patentable. If Sponsor requests and at Sponsor’s expense, Fujifilm will execute any and all applications,
assignments or other instruments and give testimony which shall be necessary to apply for and obtain Letters of Patent of the US or of any foreign country with respect to any Product Inventions and Sponsor shall

  

					
			CONFIDENTIAL		22

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

	 	
reimburse it for actual out-of-pocket expenses incurred. For Product Inventions assigned pursuant to this section, Sponsor shall provide Fujifilm a royalty-free license necessary to perform the
Program for the Term of this Agreement.  

  

	 	c)	Fujifilm agrees to grant and hereby grants to Sponsor a perpetual, world-wide, fully paid-up, royalty-free, sublicensable, exclusive license under all Process Inventions for use in connection with the Product. If
Fujifilm requests and at Fujifilm’s expense, Sponsor will execute any and all applications, assignments or other instruments and give testimony which shall be necessary to apply for and obtain Letters of Patent of the US or of any foreign
country with respect to any Process Inventions and Fujifilm shall reimburse it for actual out-of-pocket expenses incurred. 

  

	 	d)	Fujifilm reserves the right to use data during the course of the Program to support applications, assignments or other instruments necessary to apply for and obtain Letters of Patent of the U.S. or any foreign country
with respect to Process Inventions so long as no information which Fujifilm is required to keep confidential under this Agreement is disclosed in any such application, assignment, or other instrument. Fujifilm shall notify Sponsor ninety
(90) days in advance of intent to file such application, assignment or other instrument and Sponsor shall have the right to require that any Sponsor Confidential Information contained in any such application, assignment or other instrument be
deleted therefrom. 

  

	 	e)	Sponsor shall retain all right, title and interest arising under applicable laws, rules and regulations in and to all Sponsor Deliverables, Product, and other intellectual property belonging to Sponsor (including ideas,
concepts, discoveries, inventions, developments, know-how, trade secrets, techniques, methodologies, modifications, innovations, improvements, writings, documentation, data and rights, whether or not protectable under state, federal or foreign
patent, trademark, copyright or similar laws or the like and whether or not written or otherwise fixed in any form or medium). Neither Fujifilm nor any third party shall acquire any right, title or interest in such intellectual property of Sponsor
by virtue of this Agreement. For the avoidance of doubt and without limitation, Fujifilm shall have no right to use any of Sponsor’s intellectual property or Confidential Information to produce or manufacture any product(s) for or on behalf of
itself or a third party. 

 Section 14. Independent Contractor 

Fujifilm shall perform the Program as an independent contractor of Sponsor and shall have complete and exclusive control over its facilities, equipment,
employees and agents. The provisions of this Agreement shall not be construed to establish any form of partnership, agency or other joint venture of any kind between Fujifilm and Sponsor, nor to constitute either Party as the agent, employee or
legal representative of the other. All persons furnished by either Party to accomplish the intent of this Agreement shall be considered solely as the furnishing Party’s employees or agents and the furnishing Party shall be solely responsible
for compliance with all laws, rules and regulations involving, but not limited to, employment of labor, hours of labor, working conditions, workers’ compensation, payment of wages, and withholding and payment of applicable taxes, including, but
not limited to income taxes, unemployment taxes, and social security taxes. 

  

					
			CONFIDENTIAL		23

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

 Section 15. Insurance 

 

	 	a)	Fujifilm shall secure and maintain in full force and effect throughout the performance of the Program policies of insurance with companies with an AM Best Rating of at least A-, VII or its equivalent for
(a) workmen’s compensation with statutory limits, (b) general liability with combined single limits of not less than [**] per occurrence and [**] in the aggregate and (c) product liability with combined single limits of not less
than [**] per occurrence and [**] in the aggregate.  

  

	 	b)	Sponsor shall secure and maintain in full force and effect throughout the performance of the Program policies of insurance with an AM Best Rating of at least A-, VII or its equivalent for the minimum of
(a) workmen’s compensation with statutory limits, (b) general liability with combined single limits of not less than [**] per occurrence and [**] in the aggregate and (c) product liability with combined single limits of not less
than [**] per occurrence and [**] in the aggregate. Such limits may be satisfied in part through umbrella liability coverage.  

Section 16. Delivery 
 Fujifilm shall package
for shipment and deliver Product, samples or other materials in accordance with Sponsor’s full written and reasonable instructions. Freight terms shall be [**]. Sponsor shall be responsible for shipments. Title, possession, risk of loss, risk
of damage and all forward costs and expenses shall [**]. Fujifilm shall retain representative samples of Product solely for record keeping, testing obligations or testing in the event of an alleged Batch non-conformity and regulatory purposes.
Sponsor shall provide for shipping of each Batch of Product on the Delivery Date, unless otherwise agreed between the Parties. In the event of any delay by Sponsor in shipping of Product in accordance with this Section 16, the Parties shall
work together in good faith to reschedule the Delivery Date and Fujifilm shall store such Batch in accordance with the storage requirements provided by Sponsor and agreed to by Fujifilm, provided that liability and risk of loss for such Batch shall
automatically transfer to (and be assumed by) Sponsor effective upon expiration of [**] after the originally scheduled Delivery Date. 

Section 17. Default/Limitation of Warranty 
  

	 	a)	If Fujifilm is in material default of its obligations under this Agreement, Sponsor shall promptly notify Fujifilm in writing of any such default. Fujifilm shall have a period of [**] from the date of receipt of such
notice within which to cure. If Fujifilm fails to so cure such breach, then this Agreement shall, at Sponsor’s option, immediately terminate; provided, however, if a cure cannot reasonably be effected within such [**], Fujifilm shall deliver to
Sponsor a plan for curing such breach that is reasonably sufficient to effect a cure as soon as practicable thereafter,[**]. Fujifilm shall commence in good faith to cure such default in accordance with the plan within such [**] period and if
Fujifilm fails to cure such default as set forth in accordance with the plan’s deadlines, Sponsor may terminate this Agreement immediately upon written notice. Any cure involving the supply to Sponsor of a replacement shipment of Product must
be agreed in advance by Sponsor, and if such cure is agreed by Sponsor, the Parties will agree in good faith on a reasonable date by which Fujifilm shall supply such Product. 

  

					
			CONFIDENTIAL		24

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

	 	b)	If Sponsor is in material default of its obligations under this Agreement, Fujifilm shall promptly notify Sponsor in writing of any such default. Sponsor shall have a period of [**] from the date of receipt of such
notice within which to cure such default; provided, however, if a cure cannot reasonably be effected within such [**] period, Sponsor shall deliver to Fujifilm a plan for curing such breach that is reasonably sufficient to effect a cure as soon as
practicable thereafter but in no more than [**] and to commence in good faith to cure such default in accordance with the plan within such [**] period. If Sponsor fails to so cure, or commence to cure, such breach within the specified cure period,
Fujifilm may terminate this Agreement immediately upon written notice. 

  

	 	c)	Notwithstanding anything herein to the contrary, EXCEPT WITH RESPECT TO A BREACH OF SECTION 11 OR A PARTY’S OBLIGATIONS PURSUANT TO SECTION 19 OR SECTION 33: (I) UNDER NO CIRCUMSTANCES SHALL EITHER PARTY BE
ENTITLED TO INCIDENTAL, INDIRECT , CONSEQUENTIAL OR SPECIAL DAMAGES ARISING IN CONNECTION WITH THIS AGREEMENT OR THE QUALITY AGREEMENT AND (II) [**]. 

 

	 	d)	EXCEPT AS EXPRESSLY STATED HEREIN, NEITHER PARTY PROVIDES TO THE OTHER PARTY HERETO ANY WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT TO THE MATERIALS AND SERVICES PROVIDED HEREUNDER, AND ALL SUCH WARRANTIES, EXPRESS
OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE ARE WAIVED. 

Section 18. Dispute Resolution 
  

	 	a)	In the event any dispute shall arise between Sponsor and Fujifilm with respect to any of the terms and conditions of this Agreement or the Program, and such dispute has been discussed at a meeting of the Joint Steering
Committee, or such Joint Steering Committee was not able to meet within the time period specified in Section 24(e), then the senior executives of the Parties shall meet as promptly as practicable, but at least within [**] after notice of such
dispute to resolve in good faith such dispute. 

  

	 	b)	If the senior executives of the Parties fail to resolve the dispute within [**] of the initial meeting pursuant to Section 18(a) above, then such dispute shall be finally settled by an arbitrator in accordance with
this Section 18(b). The arbitration will be held in Washington, D.C., and except as noted below, shall be conducted in accordance with the rules of the American Arbitration Association by a neutral arbitrator who is experienced in arbitrating
matters related to commercial manufacturing of drugs or other health care products agreeable to both Parties. If the Parties do not agree on an arbitrator [**] of the failure of the senior executives of the Parties to resolve the dispute, the
American Arbitration Association shall appoint an arbitrator who is experienced in arbitrating matters related to commercial manufacturing of drugs or other health care products to hear the case in accordance with its rules. The arbitrator shall
have no authority to award consequential, punitive or exemplary damages or to vary from or ignore the terms of this Agreement and shall be bound by controlling law. The Parties may seek judicial intervention for emergency relief, such as restraining
orders and injunctions where appropriate. 

  

					
			CONFIDENTIAL		25

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

	 	c)	Any decision by the arbitrator shall be binding upon the Parties and may be entered as final judgment in any court having jurisdiction. The cost of any arbitration proceeding shall be borne by the Parties as the
arbitrator shall determine if the Parties have not otherwise agreed. The arbitrator shall render a final decision in writing to the Parties. 

Section 19. Indemnification 
  

	 	a)	Fujifilm shall indemnify, defend and hold harmless Sponsor and its Affiliates and their respective officers, directors and employees (“Sponsor Indemnitees”) from any loss, cost, damage or expense
(“Loss”) from any lawsuit, action, claim, demand, assessment or proceeding made or brought by a third party (“Claim”) arising from or related to (i) the breach of any representation, covenant or warranty by
Fujifilm under this Agreement; (ii) the failure of Fujifilm to perform the Manufacturing in accordance with this Agreement, the Quality Agreement (including Specifications) or cGMPs or other Applicable Law or a failure of the Product to meet
the Specifications or the requirements of this Agreement or the Quality Agreement to the extent such failure did not arise from a Starting Material Failure [**] (unless such failure could have been reasonably discovered by Fujifilm through its
review or [**] required by this Agreement or the Quality Agreement); (iii) the material breach by Fujifilm of this Agreement; (iv) the infringement or alleged infringement of the intellectual property rights of a third party covering the
use of any of Fujifilm’s methods, technical information, materials, or know-how used in the Manufacturing; or (v) Fujifilm’s negligence or intentional misconduct or inaction (including violation or non-performance of this Agreement);
provided, that, if such Loss or Claim arises in whole or in part from Sponsor’s negligence or intentional misconduct or inaction, then the amount of the Loss that Fujifilm shall indemnify, defend and hold harmless Sponsor Indemnitees for
pursuant to this Section 19 shall be reduced by an amount in proportion to the percentage of Sponsor’s responsibilities for such Loss determined by a court of competent jurisdiction in a final and non-appealable decision or in a binding
settlement between the Parties. 

  

	 	b)	Sponsor shall indemnify, defend and hold harmless Fujifilm and its Affiliates and their respective officers, directors and employees (“Fujifilm Indemnitees”) from any Loss from any Claim arising from or
related to: (i) except to the extent of Fujifilm’s indemnification obligations pursuant to Section 19(a) above, Starting Materials, [**] or the Drug Product; (ii) the breach of any representation, covenant or warranty by Sponsor
under this Agreement; (iii) the infringement or alleged infringement of the intellectual property rights of a third party covering the use of any of Sponsor’s methods, technical information, materials (including the Starting Material),
[**] or know-how that, in each case, is provided by Sponsor to Fujifilm [**] and used by Fujifilm in the Manufacturing for Fujifilm’s conduct of the Program in a manner not in violation of this Agreement, except to the extent that the Claim
arises from the use of Fujifilm’s own general manufacturing and analytical methods; or (iv) the negligence or intentional misconduct or inaction of Sponsor; provided, that, if such Loss or Claim arises in whole or in part from
Fujifilm’s negligence or intentional misconduct or inaction, then the amount of such Loss that Sponsor shall indemnify the Fujifilm Indemnitees for pursuant to this Section 19 shall be reduced by an amount in proportion to the percentage
of Fujifilm’s responsibilities for such Loss as determined by a court of competent jurisdiction in a final and non-appealable decision or in a binding settlement between the Parties. 

  

					
			CONFIDENTIAL		26

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

	 	c)	Upon receipt of notice of any Claim which may give rise to a right of indemnity from the other Party hereto, the Party seeking indemnification (the “Indemnified Party”) shall give prompt written notice
thereof to the other Party (the “Indemnifying Party”) with a Claim for indemnity (“Indemnity Claim”). Any delay or failure to give notice shall not discharge the duty of the Indemnifying Party to indemnify except to
the extent it is prejudiced by such delay or failure. Such Indemnity Claim shall indicate the nature of the Indemnity Claim and the basis therefore. Promptly after notice of an Indemnity Claim is provided to the Indemnifying Party, the Indemnified
Party shall permit the Indemnifying Party, at its option and expense, to assume the complete defense of such Indemnity Claim; provided, that, (i) the Indemnified Party will have the right to participate in the defense of any such Indemnity
Claim at its own cost and expense, (ii) the Indemnifying Party will conduct the defense of any such Indemnity Claim with due regard for the business interests and potential related liabilities of the Indemnified Party and (iii) the
Indemnifying Party will, prior to making any settlement, consult with the Indemnified Party as to the terms of such settlement and receive written approval thereof, not to be unreasonably withheld. The Indemnifying Party will not, in defense of any
such Indemnity Claim, except with the written consent of the Indemnified Party, consent to the entry of any judgment or enter into any settlement which does not include as an unconditional term thereof, the giving by the claimant or plaintiff to the
Indemnified Party of a release from all liability in respect thereof. 

 Section 20. Representations and Warranties 

 

	 	a)	Each Party represents and warrants to the other that: (i) it has the full right and authority to enter into this Agreement and to perform this Agreement in accordance with the terms and conditions set forth herein;
(ii) this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, binding obligation, enforceable against such Party in accordance with its terms except as enforceability may be limited by
bankruptcy, fraudulent conveyance, insolvency, reorganization, moratorium and other laws relating to or affecting creditors’ rights generally and by general equitable principles; and (iii) the execution, delivery and performance of this
Agreement does not breach, violate, contravene or constitute a default under any contract or commitment to which such Party is a party or by which it is bound nor does the execution, delivery and performance of this Agreement by such Party violate
any order, law or regulation of any court, governmental body or administrative or other agency having authority over it. Each Party represents and warrants to the other that neither it nor any of its officers, directors, or its employees performing
services under this Agreement has been debarred, or convicted of a crime which could lead to debarment, under the Generic Drug Enforcement Act of 1992, 21 United States Code §§335(a) and (b). 

 

	 	b)	Fujifilm represents, warrants and covenants that it has obtained and will at all times during the Term, hold and comply with all licenses, permits and authorizations necessary to perform its obligations under this
Agreement as now or hereafter required under any Applicable Law. 

  

	 	c)	Sponsor hereby represents and warrants to Fujifilm that, to its knowledge, (i) it has legal title and/or a valid license to the Starting Materials, (ii) any methods, technical information, materials or
know-how provided by Sponsor and used by Fujifilm to perform the Manufacturing is Sponsor’s unencumbered property, may be lawfully used by Fujifilm and does not infringe and will not infringe the rights of any third party and (iii) the
Product does not infringe the rights of any third party. 

  

					
			CONFIDENTIAL		27

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

	 	d)	Fujifilm hereby represents, warrants and covenants to Sponsor that: (i) Fujifilm will operate and maintain the GMP Facility in compliance with cGMP in all aspects of Manufacturing; (ii) Fujifilm will perform
the Manufacturing in compliance with this Agreement, the Quality Agreement (including Specifications) and cGMPs and all other Applicable Law and packaging instructions provided by Sponsor and agreed upon by Fujifilm; (iii) to its knowledge, any
of the methods, technical information, materials or know-how used by Fujifilm to perform the Manufacturing (other than those provided by Sponsor) is Fujifilm’s unencumbered property, may be lawfully used by Fujifilm and does not infringe and
will not infringe the rights of any third party; (iv) to its knowledge, any other Manufacturing activities by Fujifilm pursuant to this Agreement that are not unique to the Product may lawfully be used by Fujifilm and do not infringe and will
not infringe the rights of any third party; (v) all Product, at the time of shipment from Fujifilm, shall not be adulterated or misbranded within the meaning of the Federal Food, Drug and Cosmetic Act, provided, however, this warranty shall not
be applicable in the event Sponsor requests shipment of Product prior to completion of testing; (vi) Fujifilm owns or lawfully controls the GMP Facility; (vii) Fujifilm has written agreements with all its employees involved in the creation
of intellectual property, which agreements shall require that all discoveries and inventions conceived or reduced to practice by such employees in the conduct of the Manufacturing shall be promptly disclosed and assigned to Fujifilm, and Fujifilm
has the right to assign to Sponsor its rights in and to all Product Inventions as provided in this Agreement and to license to Sponsor the rights in the Process Inventions as provided in this Agreement and (viii) Fujifilm is under no
contractual or other obligation or restriction that is inconsistent with Fujifilm’s performance of this Agreement. 

 Section 21.
Force Majeure 
 Either Party shall be excused from performing its respective obligations under this Agreement if its performance is delayed or
prevented by any event beyond such Party’s reasonable control, including, but not limited to, acts of God, fire, explosion, weather, disease, war, insurrection, civil strife, riots, government action, acts of terrorism or power failure;
provided, that such performance shall be excused only to the extent of and during such disability. The Party subject to such event shall promptly notify the other Party of the occurrence thereof and, if known, the expected duration and shall take
all reasonable steps to mitigate the effect of such occurrence. Any time specified or estimated for completion of performance falling due during or subsequent to the occurrence of any such events shall be automatically extended for a period of time
to recover from such disability. Fujifilm will promptly notify Sponsor if, by reason of any of the events referred to herein, Fujifilm is unable to meet any such time for performance. If any part of the Program is invalid as a result of such
disability, Fujifilm will, upon written request from Sponsor, but at Sponsor’s sole cost and expense, repeat that part of the Program affected by the disability. If, as a result of a force majeure event described in this Section, Fujifilm is
unable to Manufacture the Product ordered by Sponsor or which Sponsor would have ordered but for such circumstances, then if such circumstances continue or are reasonably likely to continue for more than one hundred eighty (180) days, Sponsor
may terminate this Agreement by providing written notice to Fujifilm in writing. 

  

					
			CONFIDENTIAL		28

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

 Section 22. Use of Names 

The Parties anticipate that there may be opportunities for joint or independent press releases or other announcements relating to the activities
contemplated hereby. Notwithstanding the foregoing, neither Party shall use the name of the other Party or the names of the employees of the other Party nor disclose the terms of this Agreement in any press releases, advertising or sales promotional
material or in any publication without prior written permission of such Party. Such consent shall not be unreasonably withheld. This provision shall not restrict a Party’s ability to use the other Party’s name and to disclose the
terms of this Agreement to the extent, in the reasonable opinion of such Party’s legal counsel, required by law or by the requirements of any nationally recognized securities exchange, quotation system or over-the-counter market on which such
Party has its securities listed or traded. In the event that such disclosure is required as aforesaid, the disclosing Party shall make reasonable efforts to provide the other Party with advance notice and to coordinate reasonably with the other
Party with respect to the wording and timing of any such disclosure, subject to the requirements of such securities laws. 
 Section 23.
Term/Termination 
  

	 	a)	This Agreement shall take effect on the Effective Date and continue in effect for five (5) years (“Initial Term”). After the initial five (5) year period the Agreement shall be automatically
extended in two (2) year installments, unless it is earlier terminated (the Initial Term and any extensions thereof being collectively referred to herein as the “Term”). 

 

	 	b)	In addition to the termination rights set forth elsewhere in this Agreement (including but not limited to Sections 4(g), 4(h), 17(a), 17(b), 21 and 23(c)), either Party may terminate this Agreement after expiration of
the Initial Term by giving two (2) years’ written notice to the other Party prior to the end of the then-current Term, without payment of any termination penalties. For clarity, termination does not void any payments due under Binding
Orders that cannot be cancelled or terminated except that in the event of termination by Sponsor pursuant to Section 4(g), Section 17(a), Section 21 or Section 23(c), Sponsor may elect to cancel any outstanding Binding Orders and
shall not be obligated to make any payment to Fujifilm for such cancelled Binding Orders. 

  

	 	c)	Either Party may immediately terminate this Agreement upon written notice to the other Party if (i) the other Party is declared insolvent or bankrupt by a court of competent jurisdiction, (ii) a voluntary
petition of bankruptcy is filed in any court of competent jurisdiction by the other Party or (iii) this Agreement is assigned by the other Party for the benefit of creditors. 

 

	 	d)	 For the avoidance of doubt, in the event of termination of this Agreement, (i) Fujifilm will terminate all services in progress other than
Manufacturing under Binding Order, provided that if this Agreement is terminated by Sponsor pursuant to Section 4(g), Section 17(a), Section 21 or Section 23(c) and Sponsor has elected to cancel any outstanding Binding Orders,
Fujifilm will terminate all services in progress including Manufacturing under any Binding Order in an orderly manner as soon as practicable and in accordance with a schedule agreed to by Sponsor, unless Sponsor specifies in the notice of
termination that such services in progress should be completed, (ii) Fujifilm will deliver to Sponsor any Sponsor Deliverables, Safety Stock, completed and in-process Product and Work Output in its possession or control and all Product
Inventions developed through the date of 

  

					
			CONFIDENTIAL		29

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

 
termination or expiration, and (iii) Sponsor will pay Fujifilm any monies due and owing Fujifilm, up to the time of termination or expiration, for services actually performed and all
expenses actually incurred for procurement and/or disposal of Process Consumables for Batches cancelled by Sponsor, including any Safety Stock. In the event of any termination by Sponsor under this Agreement for reason other than termination
pursuant to Section 23(b), Sponsor may request that the effective date of the termination be a later date (not to exceed twenty-four (24) months from the notice date), which if agreed to by Fujifilm, such agreement not to be unreasonably
withheld for the duration of then Binding Period, Fujifilm shall continue to perform the Manufacturing and Sponsor shall continue to perform all its obligations under this Agreement (other than forecasting beyond the designated termination date)
until the effective date of the termination. The respective obligations of the Parties set forth in the following sections shall survive expiration or earlier termination of this Agreement: Sections 1(e), 3(b), 4(e), 4(i), 8, 11, 12, 13, 16, 17, 18,
19, 22, 23, 26, 27, 28, 29, 30, 31 and 33. 
 Section 24. Program Management  

 

	 	a)	Joint Steering Committee. Within thirty (30) days from the Effective Date, Sponsor and Fujifilm shall establish a Joint Steering Committee (the “Joint Steering Committee”) comprised of an
equal number of representatives designated by Sponsor and Fujifilm. 

  

	 	b)	Program Managers. Each Party shall appoint one (1) person to serve as a Program Manager (each, a “Program Manager”) with responsibility for overseeing the day-to-day activities of the
Parties with respect to the Program and for being the primary point of contact between the Parties with respect to the Program. The Program Managers shall report their activities to the Joint Steering Committee. The Program Managers shall be
responsible for calling meetings, sending notices of meetings and preparing the agenda for such meetings. 

  

	 	c)	Replacement of Joint Steering Committee Representatives and Program Managers. Each Party shall be free to replace its representative members on the Joint Steering Committee or its Program Manager with employees
of such Party, upon notice to the other Party. 

  

	 	d)	Responsibilities of Joint Steering Committee. The Joint Steering Committee shall be responsible for overseeing the Parties’ interaction and performance of their respective obligations under this Agreement.
Without limiting the generality of the foregoing, its duties shall include: 

  

	 	(i)	monitoring the performance of the Program; 

  

	 	(ii)	attempting to resolve disagreements that arise under the Agreement; and 

  

	 	(iii)	assisting in the evaluation as to whether there is a need for any Change Orders. 

  

	 	e)	 Meetings. The Joint Steering Committee shall meet at such times as the Joint Steering Committee determines to resolve issues arising hereunder
and to perform its responsibilities under this Agreement; provided, that, the Joint Steering Committee shall 

  

					
			CONFIDENTIAL		30

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

	 	
meet not less than four (4) times per calendar year unless otherwise mutually agreed. Such meetings may be in person or by telephone as agreed by the Joint Steering Committee. To the extent
that meetings are held in person, they shall alternate between the offices of the Parties unless the Parties agree otherwise. The Program Managers shall attend all meetings of the Joint Steering Committee. All decisions of the Joint Steering
Committee must be unanimous. In the event of a dispute, either Party may call a meeting of the Joint Steering Committee, which must be held within seven (7) business days from the date of receipt of written notice to the other Party.

  

	 	f)	Minutes. The Program Managers shall alternate responsibility for keeping minutes of the Joint Steering Committee Meeting, unless otherwise agreed. Within fifteen (15) days after each Joint Steering Committee
meeting, the applicable Program Manager shall prepare and distribute minutes of the meeting, which shall provide a description in reasonable detail of the discussions had at the meeting and a list of any actions, decisions or determinations approved
by the Joint Steering Committee. Minutes shall be approved or disapproved and revised, as necessary, at the next meeting. Final minutes shall be distributed to the members of the Joint Steering Committee. 

 

	 	g)	Dispute Resolution. In the event that the Joint Steering Committee cannot reach agreement with respect to any material issue, then the issue will be resolved in accordance with the dispute resolution provisions
in Section 18. 

  

	 	h)	Limitations. The Joint Steering Committee is not empowered to amend the terms of this Agreement. 

Section 25. Assignment 
 This Agreement shall
not be assigned in whole or in part by either Party without the prior written consent of the other, which consent shall not be unreasonably withheld or delayed. Any attempt to assign this Agreement without such consent shall be void and of no
effect. Notwithstanding the foregoing, either Party shall be entitled, without the prior written consent of the other Party, to assign all or any part of its rights under this Agreement to a purchaser of all or substantially all of its assets to
which this Agreement relates, or an entity with which it may merge or sell its capital stock where it is not the surviving company; provided, that, the assignee agrees in writing to assume all obligations undertaken by its assignor in this
Agreement. In addition, Sponsor may assign this Agreement in whole or in part to one of its Affiliates without Fujifilm’s prior written consent. No assignment shall relieve the assigning Party of responsibility for the performance of any of its
obligations hereunder. The terms of this Agreement shall inure to the benefit of successors and assigns. 

  

					
			CONFIDENTIAL		31

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

 Section 26. Notice 

All notices to be given as required in this Agreement shall be in writing and shall be delivered personally, sent by fax, or mailed either by a reputable
overnight carrier or first class mail, postage prepaid to the Parties at the addresses set forth below or such other addresses as the Parties may designate in writing. Such notice shall be effective on the date after the date it was sent if sent by
fax, delivered personally or delivered by overnight carrier and on the date received if mailed first class. 
 If to Sponsor: 

Synageva BioPharma Corp. 
 33 Hayden Avenue 

Lexington, MA 02421 
 P: 781-357-9900 

F: 781-357-9901 
 Attention: General Counsel 

If to Fujifilm: 
 President 

FUJIFILM Diosynth Biotechnologies U.S.A., Inc. 
 101 J. Morris
Commons Lane 
 Morrisville, NC 27560 
 P: 919-337-4404 

F: 919-337-0899 
 With copies to: 

General Counsel 
 Fujifilm Diosynth Biotechnologies 

Hexagon Tower 
 Blackley, Manchester, M9 8ES, United Kingdom 

Facsimile No.: +44 161 721 5801 
 Assistant General Counsel 

FUJIFILM Holdings America Corporation 
 200 Summit Lake Drive 

Valhalla, New York 10595-1356 
 Fax: 914-789-8514 

Section 27. Choice of Law 
 This Agreement
shall be construed and enforced in accordance with the laws of and in the venue of the State of Delaware except for its rules regarding conflict of laws. 

  

					
			CONFIDENTIAL		32

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

 Section 28. Equitable Relief 

Notwithstanding any provision of this Agreement, either Party may seek injunctive or other equitable relief to enforce or protect its rights hereunder with
respect to a breach of confidentiality or intellectual property rights in any court of competent jurisdiction. 
 Section 29. Waiver 

No failure or delay by either Party in exercising or enforcing any right, power or privilege hereunder shall operate as a waiver thereof, nor shall any single
or partial exercise thereof preclude any other or further exercise thereof. A waiver by either Party in one or more instances shall not be construed as constituting a continuing waiver or as a waiver in other instances. 

Section 30. Severability 
 If any provisions
herein are found to be invalid or unenforceable, it is the intent of the Parties that such provisions be replaced, reformed or narrowed so that their original business purpose can be accomplished to the extent permitted by law. The invalidity or
unenforceability of any provision of this Agreement shall not affect the validity or enforceability of any other provisions of this Agreement, which shall remain in full force and effect. 

Section 31. Nonsolicitation  
 For the term of
this Agreement, and for twelve (12) months following termination of this Agreement, for any reason, each Party agrees not to solicit any employee of the other Party with whom they have come in contact pursuant to the performance of services
under this Agreement. The foregoing sentence shall not prohibit a Party from hiring an employee of the other who (i) responds to a general advertisement, (ii) is found by a recruiter who was not asked to target such employee, or
(iii) has left the employment of the non-hiring Party. 
 Section 32. Entire Agreement; Modification/Counterparts 

 

	 	a)	This instrument including the attached Appendices sets forth the entire agreement between the Parties hereto with respect to the performance of the Program by Fujifilm for Sponsor as well as all of Sponsor’s
obligations with respect to the Program and the purchase of Product and as such, supersedes all prior and contemporaneous negotiations, agreements, representations, understandings, and commitments with respect thereto and shall take precedence over
all terms, conditions and provisions on any purchase order form or form of order acknowledgment or other document purporting to address the same subject matter. This Agreement shall not be waived, released, discharged, changed or modified in any
manner except by an instrument signed by the duly authorized officers of each of the Parties hereto, which instrument shall make specific reference to this Agreement and shall express the plan or intention to modify same. 

 

	 	b)	This Agreement may be executed in one or more counterparts each of which shall be deemed an original but all of which together shall constitute one and the same instrument. 

  

					
			CONFIDENTIAL		33

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

 Section 33. Foreign Corrupt Practices Act; Anti-Bribery Laws 

Fujifilm shall comply with the requirements of all applicable anti-bribery legislation both national and foreign, including but not limited to the U.S. Foreign
Corrupt Practices Act and the U.K. Bribery Act (collectively, “Anti-Bribery Laws”) and Fujifilm has not and will not make, promise or offer to make any payment or transfer anything of value (directly or indirectly) to (i) any
individual, (ii) corporation, (iii) association, (iv) partnership, or (v) public body, (including but not limited to any officer or employee of any of the foregoing) who, acting in their official capacity or of their own accord,
are in a position to influence, secure or retain any business for and/or provide any financial or other advantage to Sponsor by improperly performing a function of a public nature or a business activity with the purpose or effect of public or
commercial bribery, acceptance of or acquiescence in extortion, kickbacks or other unlawful or improper means of obtaining or retaining business. Fujifilm shall indemnify, defend and hold harmless Sponsor and its Affiliates, and its and their
directors, officers, employees and agents, from and against any and all losses resulting or arising from any third party claims, actions, proceedings, investigations or litigation relating to or arising from any violation of Anti-Bribery Laws, to
the extent such losses resulted from Fujifilm’s failure to comply with Anti-Bribery Laws. 
 [Remainder of page intentionally left
blank. Signature page to follow.] 

  

					
			CONFIDENTIAL		34

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

			
	 Fujifilm – Synageva Agreement
		EXECUTION COPY

  

 IN WITNESS WHEREOF, the duly authorized representatives of each Party have executed this Agreement effective
as of the Effective Date. 
  

									
	Synageva BioPharma Corp.				FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
					
	By:		 /s/ Thomas W. Beetham
				By:		 /s/ M. Meeson

	Name:		Thomas W. Beetham				Name:		M. Meeson
	Title:		Sr. Vice President, General Counsel				Title:		SVP Finance
				
							FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
					
							By:		 /s/ Stephen Spearman

							Name:		Stephen Spearman
							Title:		President

 [Signature page to Commercial Supply Agreement] 

  

					
			CONFIDENTIAL		35

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment
request. 
 An unredacted version of this exhibit has been filed separately with the Commission. 

 

 APPENDICES: 

1. Attachment 1. List of Countries and Territories 

2. Attachment 2: Price; Cost of Starting Material 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment
request. 
 An unredacted version of this exhibit has been filed separately with the Commission. 

 

 Attachment 1: List of Countries and Territories 

United States of America 
 All
countries in the European Union (as the European Union is constituted as of the Effective Date) 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment
request. 
 An unredacted version of this exhibit has been filed separately with the Commission. 

 

 Attachment 2: Price; Cost of Starting Material 

Cost of Starting Material: [**] 

Price 
 [**] 

Notes: 
  

	 	1.	[**]. All other [**] listed in the table are priced at the [**]. 

  

	 	2.	One time exception: [**] 

  

	 	3.	[**]. 

  

			
	 Activities for Annual Program Maintenance
	  	Cost
	 Process Surveillance

 
	  	
	 •    Collection of surveillance parameters data for all Batches
Manufactured at Fujifilm. Surveillance parameters include but are not limited to Critical Parameters and In-Process Controls
  

•    Trending of Surveillance Parameters

 
 •    Statistical
Analysis shall be performed on Critical Process and Quality Attributes at a minimum
  

•    [**]
  

•    Preparation of surveillance parameter data report after completion of each manufacturing
campaign
  
 Note: Surveillance review in compliance with regulatory requirements
outside the above listed may incur in additional costs
	  	[**]

  

			
	 Annual Product Quality Review (APR) Report

 
	  	
	 •    [**]

 
 •    [**]

 
 •    [**]

 
	  	  
 [**]

	 [**]
  
	  	
	 Annual Regulatory Support

 
	  	
	[**]	  	
		
	 •    [**]

 
 •    [**]
	  	

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment
request. 
 An unredacted version of this exhibit has been filed separately with the Commission. 

 

			
	 •    [**]

 
 •    [**]
	  	
		
	 Annual waste disposal fee
	  	[**]
		
	 •    [**]
	  	

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment
request. 
 An unredacted version of this exhibit has been filed separately with the Commission. 

 

 Itemized Process Consumables Pricing 

[**]EX-10.2

 Exhibit 10.2 

[**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

Manufacturing Services Agreement 
  

 
 Manufacturing Services Agreement

 February 4th, 2015 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 Table of Contents 

 

							
	 ARTICLE 1
		 	1	  
		
	 INTERPRETATION
		 	1	  
			
	 1.1
		 DEFINITIONS
		 	1	  
	 1.2
		 CURRENCY
		 	8	  
	 1.3
		 SECTIONS AND HEADINGS
		 	8	  
	 1.4
		 SINGULAR TERMS
		 	8	  
	 1.5
		 SCHEDULES
		 	8	  
		
	 PATHEON’S MANUFACTURING SERVICES
		 	9	  
			
	 2.1
		 MANUFACTURING SERVICES
		 	9	  
	 2.2
		 SUBCONTRACTORS
		 	11	  
			
	 ARTICLE 3
				 	12	  
		
	 CLIENT’S OBLIGATIONS
		 	12	  
			
	 3.1
		 PAYMENT
		 	12	  
	 3.2
		 ACTIVE MATERIALS AND QUALIFICATION OF
ADDITIONAL SOURCES OF SUPPLY
		 	12	  
		
	 ARTICLE 4
		 	13	  
		
	 CONVERSION FEES AND COMPONENT COSTS
		 	13	  
			
	 4.1
		 FIRST YEAR PRICING
		 	13	  
	 4.2
		 PRICE ADJUSTMENTS – SUBSEQUENT YEARS’
PRICING
		 	13	  
	 4.3
		 PRICE ADJUSTMENTS – CURRENT YEAR
PRICING
		 	14	  
	 4.4
		 ADJUSTMENTS DUE TO TECHNICAL CHANGES OR
REGULATORY AUTHORITY REQUIREMENTS
		 	14	  
	 4.5
		 PRICE ADJUSTMENTS FOR ACTIVE MATERIAL
YIELD
		 	15	  
	 4.6
		 MULTI-COUNTRY PACKAGING REQUIREMENTS
		 	16	  
		
	 ARTICLE 5
		 	16	  
		
	 ORDERS, SHIPMENT, INVOICING, PAYMENT
		 	16	  
			
	 5.1
		 ORDERS AND FORECASTS
		 	16	  
	 5.2
		 RELIANCE BY PATHEON
		 	19	  
	 5.3
		 MINIMUM ORDERS
		 	19	  
	 5.4
		 DELIVERY AND SHIPPING
		 	19	  
	 5.5
		 INVOICES AND PAYMENT
		 	19	  

  
 - i - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

							
	 ARTICLE 6
				 	20	  
		
	 PRODUCT CLAIMS AND RECALLS
		 	20	  
	 6.1
		 PRODUCT CLAIMS
		 	20	  
	 6.2
		 PRODUCT RECALLS AND RETURNS
		 	20	  
	 6.3
		 RESPONSIBILITY FOR DEFECTIVE AND RECALLED
PRODUCTS
		 	21	  
	 6.4
		 DISPOSITION OF DEFECTIVE OR RECALLED
PRODUCTS
		 	22	  
	 6.5
		 ADVERSE EVENTS; PRODUCT QUALITY, HEALTHCARE
PROVIDER OR PATIENT QUESTIONS AND COMPLAINTS
		 	22	  
		
	 ARTICLE 7
		 	23	  
		
	 CO-OPERATION
		 	23	  
			
	 7.1
		 QUARTERLY REVIEW
		 	23	  
	 7.2
		 GOVERNMENTAL AGENCIES
		 	23	  
	 7.3
		 RECORDS AND ACCOUNTING BY PATHEON
		 	23	  
	 7.4
		 INSPECTION
		 	23	  
	 7.5
		 ACCESS
		 	24	  
	 7.6
		 NOTIFICATION OF REGULATORY INSPECTIONS
		 	24	  
	 7.7
		 REPORTS
		 	24	  
	 7.8
		 REGULATORY FILINGS
		 	24	  
		
	 ARTICLE 8
		 	26	  
		
	 TERM AND TERMINATION
		 	26	  
			
	 8.1
		 INITIAL TERM
		 	26	  
	 8.2
		 TERMINATION FOR CAUSE
		 	26	  
	 8.3
		 PRODUCT DISCONTINUATION
		 	27	  
	 8.4
		 OBLIGATIONS ON TERMINATION
		 	27	  
		
	 ARTICLE 9
		 	28	  
		
	 REPRESENTATIONS, WARRANTIES AND COVENANTS
		 	28	  
			
	 9.1
		 AUTHORITY
		 	28	  
	 9.2
		 CLIENT WARRANTIES
		 	28	  
	 9.3
		 PATHEON WARRANTIES
		 	29	  
	 9.4
		 DEBARRED PERSONS
		 	29	  
	 9.5
		 PERMITS
		 	30	  
	 9.6
		 NO WARRANTY
		 	30	  
		
	 ARTICLE 10
		 	30	  
		
	 REMEDIES AND INDEMNITIES
		 	30	  
			
	 10.1
		 CONSEQUENTIAL DAMAGES
		 	30	  
	 10.2
		 LIMITATION OF LIABILITY
		 	30	  
	 10.3
		 PATHEON INDEMNITY
		 	31	  
	 10.4
		 CLIENT INDEMNITY
		 	31	  
	 10.5
		 REASONABLE ALLOCATION OF RISK
		 	32	  

  
 - ii - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

							
	 ARTICLE 11
		 	32	  
		
	 CONFIDENTIALITY
		 	32	  
			
	 11.1
		 CONFIDENTIAL INFORMATION
		 	32	  
	 11.2
		 USE OF CONFIDENTIAL INFORMATION
		 	33	  
	 11.3
		 EXCLUSIONS
		 	33	  
	 11.4
		 PHOTOGRAPHS AND RECORDINGS
		 	33	  
	 11.5
		 PERMITTED DISCLOSURE
		 	33	  
	 11.6
		 SURVIVAL OF CONFIDENTIALITY OBLIGATIONS
		 	34	  
	 11.7
		 RETURN OF CONFIDENTIAL INFORMATION
		 	34	  
	 11.8
		 REMEDIES
		 	34	  
		
	 ARTICLE 12
		 	34	  
		
	 DISPUTE RESOLUTION
		 	34	  
			
	 12.1
		 COMMERCIAL DISPUTES
		 	34	  
		
	 ARTICLE 13
		 	35	  
		
	 MISCELLANEOUS
		 	35	  
			
	 13.1
		 INVENTIONS
		 	35	  
	 13.2
		 INTELLECTUAL PROPERTY
		 	35	  
	 13.3
		 INSURANCE
		 	36	  
	 13.4
		 INDEPENDENT CONTRACTORS
		 	36	  
	 13.5
		 NO WAIVER
		 	36	  
	 13.6
		 ASSIGNMENT
		 	37	  
	 13.7
		 FORCE MAJEURE
		 	37	  
	 13.8
		 ADDITIONAL PRODUCT
		 	37	  
	 13.9
		 NOTICES
		 	37	  
	 13.10
		 SEVERABILITY
		 	38	  
	 13.11
		 ENTIRE AGREEMENT
		 	38	  
	 13.12
		 OTHER TERMS
		 	39	  
	 13.13
		 NO THIRD PARTY BENEFIT OR
RIGHT
		 	39	  
	 13.14
		 EXECUTION IN COUNTERPARTS
		 	39	  
	 13.15
		 USE OF CLIENT NAME
		 	39	  
	 13.16
		 TAXES
		 	39	  
	 13.17
		 GOVERNING LAW
		 	40	  

  
 - iii - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 MANUFACTURING SERVICES AGREEMENT 

THIS MANUFACTURING SERVICES AGREEMENT (the “Agreement”) is made as of February 4, 2015 (the “Effective
Date”) 
 B E T W E E N: 

PATHEON UK LIMITED  
 a
corporation existing under the laws of England 
 (“Patheon”), 

- and - 
 Synageva BioPharma
Corp.,  
 a corporation existing under the laws of Delaware, U.S.A. 

(“Client”). 

THIS AGREEMENT WITNESSES THAT in consideration of the rights conferred and the obligations assumed herein, and for other good and valuable
consideration (the receipt and sufficiency of which are acknowledged by each party), and intending to be legally bound the parties agree as follows: 

ARTICLE 1 

INTERPRETATION 
  

	1.1	Definitions. 

 The following terms will, unless the context otherwise
requires, have the respective meanings set out below and grammatical variations of these terms will have corresponding meanings: 

“Active Materials”, “Active Pharmaceutical Ingredients” or “API” means the materials listed in
Schedule D; 
 “Active Materials Value” means the value of the Active Materials, as set forth in Schedule D; 

“Actual Binding Period Volume” or “ABPV” means the aggregate actual volume of Product ordered by Client
during the 100% binding Calendar Quarter(s) or three month period covered by the relevant Forecast; 
 “Actual Yearly
Volume” has the meaning specified in Section 4.2.3; 
 “Adverse Event” shall mean any untoward medical
occurrence in a patient or clinical trial subject administered a human medicinal product irrespective of whether there is a causal relationship with the treatment or not. An Adverse Event can therefore be any unfavorable and unintended sign (e.g.
abnormal laboratory finding), symptom, or disease temporally associated with the use of the medicinal product in humans, whether or not considered related to the Product; 

  
 - 1 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 “Affiliate” means: 

 

	 	(a)	a business entity which owns, directly or indirectly, a controlling interest in a party to this Agreement, by stock ownership or otherwise; or 

 

	 	(b)	a business entity which is controlled by a party to this Agreement, either directly or indirectly, by stock ownership or otherwise; or 

 

	 	(c)	a business entity, the controlling interest of which is directly or indirectly common to the majority ownership of a party to this Agreement; 

For this definition, “control” means the ownership of shares carrying at least a majority of the votes for the election of the
directors of an entity or the power to otherwise direct the management and policies of an entity on a day to day basis; 

“Agreement” has the meaning provided in the introductory paragraph; 

“Annual Limit” has the meaning provided in Section 5.1(h); 

“Annual Product Review Report” means the annual product review report prepared by Patheon or an Affiliate of Patheon as
described in Title 21 of the United States Code of Federal Regulations, Section 211.180(e); 
 “Annual Report” means
the annual report to the FDA prepared by Client regarding the Product as described in Title 21 of the United States Code of Federal Regulations, Section 314.81(b)(2); 

“Annual Volume” means the minimum volume of Product set forth in Schedule B to be purchased by Client in any Year of this
Agreement that starts on or after January 1, 2017; 
 “Applicable Laws” means (i) for Patheon, cGMP, the Laws of
the jurisdiction where the Manufacturing Site is located and the Laws of any other jurisdiction where the Manufacturing Services occur (including any Manufacturing Services provided by Subcontractors or other third parties engaged by Patheon) and
the applicable guidance of each relevant Authority; and (ii) for Client and the Products, the Laws of all jurisdictions where the Products are manufactured, distributed, and marketed as these are agreed and understood by the parties in this
Agreement, including the applicable guidance of each relevant Authority; 
 “Authority” means any governmental or regulatory
authority, department, body or agency or any court, tribunal, bureau, commission or other similar body, whether federal, state, provincial, county or municipal; 

“Batch” means a specific quantity of Product comprising a number of Units mutually agreed upon by Client and Patheon and that
is intended to have uniform character and quality within specified limits and which is produced by Patheon according to a single manufacturing order during the same cycle of manufacture; 

  
 - 2 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 “Bi-Annual Forecast” has the meaning specified in Section 5.1(e); 

“Binding Forecast Volume” or “BFV” means the volume of Product for which Client provides Patheon a 100%
binding commitment to order during the applicable Calendar Quarters(s) or three month period covered by the relevant Forecast; 

“Breach Notice” has the meaning specified in Section 8.2(a); 

“Business Day” means a day other than a Saturday, Sunday or a day that is a statutory holiday in Ferentino (FR), Italy, in
Swindon, Wiltshire, England, or in Massachusetts, USA; 
 “Calendar Quarter” shall mean each 3 month period commencing the
first day of January, April, July and October of each Year during the Term; 
 “Capital Equipment Agreement” means a
separate agreement that the parties may enter into that will address responsibility for the purchase of capital equipment and facility modifications that may be required to perform the Manufacturing Services under this Agreement; 

“cGMPs” means, as applicable, current good manufacturing practices as described in: 

 

	 	(a)	Parts 210 and 211 of Title 21 of the United States’ Code of Federal Regulations; 

  

	 	(b)	EC Directive 2003/94/EC; and 

  

	 	(c)	Division 2 of Part C of the Food and Drug Regulations (Canada); 

 together with the
latest Health Canada, FDA and EMA guidance documents pertaining to manufacturing and quality control practice, all as updated, amended and revised from time to time; 

“Client” has the meaning provided in the introductory paragraph; 

“Client Intellectual Property” means Intellectual Property generated or derived by (a) Client before or after entering
into this Agreement, or (b) by Patheon while performing any Manufacturing Services or otherwise generated or derived by Patheon which Intellectual Property is specific to, or dependent upon Client’s Active Material or Product or
Confidential Information; 
 “Client Property” has the meaning specified in Section 8.4(d); 

“Client-Supplied Components” means those Components to be supplied by Client or that have been supplied by Client; 

“CMC” has the meaning specified in Section 7.8(c); 

“Commercially Reasonable Efforts” shall mean, with respect to Patheon’s efforts to supply volumes of Product in excess of
the Annual Limits or volumes set forth in Binding Forecast Volumes or binding volumes for the first year under any Bi-Annual Forecast under Section 5.1(h), that Patheon shall, at the request of Client, supply the additional volumes of Product
as requested by Client only if, and to the extent that, at the time of Client’s request, Patheon believes, acting 

  
 - 3 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 
reasonably and in good faith, that it has the relevant available capacity at the Manufacturing Sites to meet such additional Product requirements without prejudice to its contractual and/or
commercial relationship vis-à-vis other clients; 
 “Component Cost” has the meaning specified in
Section 4.1; 
 “Components” means, collectively, all packaging components, raw materials, ingredients, and other
materials (including labels, product inserts and other labelling for the Products, as well as disposable materials, e.g. tubing, bags, filters) required to manufacture the Products in accordance with the Specifications, other than the Active
Materials; 
 “Confidential Information” has the meaning specified in Section 11.1; 

“Conversion Price” has the meaning specified in Section 4.1; 

“Credit Worthy” means a legal or natural person that (i) is, and will be after giving effect to the relevant assignment
will be, solvent and (ii) is not subject at the time of such assignment to any order, decree or petition providing for the winding-up or liquidation of such person, the appointment of a receiver over the whole or part of the assets of such
person or the bankruptcy or administration of such person. For the purposes of this definition, “solvent” means with respect to such legal or natural person as on any date of determination, that as of such date, (i) the value of the
assets of such person is greater than the total amount of actual liabilities of such person and (ii) such person is able to pay all liabilities of such person as such liabilities mature;

“C-TPAT” has the meaning specified in Section 2.1(h); 

“Deficiencies” has the meaning specified in Section 7.8(d); 

“Deficiency Notice” has the meaning specified in Section 6.1(a); 

“Delivery Date” means the date scheduled for shipment of Product under a Firm Order as set forth in Section 5.1(f); 

“Disclosing Party” has the meaning specified in Section 11.1; 

“Effective Date” has the meaning specified in the introductory paragraph; 

“EMA” means the European Medicines Agency; 

“FDA” means the United States Food and Drug Administration; 

“Firm Orders” have the meaning specified in Section 5.1(f); 

“Force Majeure Event” has the meaning specified in Section 13.7; 

“Forecast” has the meaning specified in Section 5.1(e); 

“Forecasted Yearly Volume” or “FYV” has the meaning specified in Section 4.2.3; 

  
 - 4 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 “GST” has the meaning specified in Section 13.16(a)(ii); 

“Health Canada” means the section of the Canadian Government known as Health Canada and includes, among other departments, the
Therapeutic Products Directorate and the Health Products and Food Branch Inspectorate; 
 “Importer of Record” has the
meaning specified in Section 3.2(a); 
 “Index” has the meaning specified in Section 4.2(a); 

“Initial Annual Limit” has the meaning specified in Section 5.1(h); 

“Initial Term” has the meaning specified in Section 8.1; 

“Intellectual Property” includes, without limitation, rights in patents, patent applications, formulae, trademarks, trademark
applications, trade-names, Inventions, copyrights, industrial designs, trade secrets, and know how, whether or not patentable, copyrightable or trademarkable; 

“Invention” means any innovation, improvement, development, discovery, computer program, device, trade secret, method,
know-how, process, technique or the like, whether or not written or otherwise fixed in any form or medium, regardless of the media on which it is contained and whether or not patentable or copyrightable or trademarkable; 

“Inventory” means all inventories of work-in-process of the Product produced or held by Patheon pursuant to a Firm Order for
the manufacture of the Products but, for greater certainty, does not include the Active Materials or the Components; 
 “Late
Delivery Credit” shall have the meaning specified in Section 5.1(k); 
 “Laws” means all laws, statutes,
directives, ordinances, regulations, rules, by-laws, judgments, decrees or orders of any Authority; 
 “Long Term Forecast”
has the meaning specified in Section 5.1(a); 
 “Manufacturing Services” means the manufacturing, quality control,
quality assurance, stability testing, labeling, packaging, and related services, as set forth in this Agreement, required to manufacture Product or Products using the Active Materials and Components; 

“Manufacturing Site” means the facility owned and operated by Patheon’s Subcontractor (as defined below), located at
2° Trax Via Morolense 5 03013 Ferentino (FR), Italy, where the Manufacturing Services will be performed; 
 “Media Fill
Failure” has the meaning specified in Section 6.1(a); 
 “Minimum Order Quantity” means the minimum number of
batches of a Product to be produced during the same cycle of manufacturing as set forth in Schedule B; 
 “Monthly Forecast”
has the meaning specified in Section 5.1(d); 

  
 - 5 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 “Obsolete Stock” has the meaning specified in Section 5.2(b); 

“Patheon” has the meaning specified in the introductory paragraph; 

“Patheon Competitor” means a business that derives greater than 50% of its revenues from performing contract pharmaceutical
development or commercial manufacturing services for third parties (and not, for clarity, for itself), in each case of the same type as those provided by Patheon pursuant to this Agreement; 

“Patheon Factor” means failure of the Product to conform with the Specifications, the Quality Agreement, cGMPs this Agreement
or Applicable Law that arises from any of the factors set forth in Schedule F; 
 “Patheon Intellectual Property” means
Intellectual Property generated or derived by Patheon before performing any Manufacturing Services, developed by Patheon while performing the Manufacturing Services, or otherwise generated or derived by Patheon, in each case which is not Client
Intellectual Property; 
 “Price” means the price measured in the currency applicable to the country in which the
Manufacturing Site is located to be charged by Patheon for performing the Manufacturing Services, and is comprised of the Component Cost as set forth in Schedule B, the Conversion Price as set forth in Schedule B, and annual stability testing costs
as set forth in Schedule C; 
 “Product(s)” means the product(s) listed in Schedule A; 

“Quality Agreement” means the agreement between the parties that sets out the quality assurance standards for the
Manufacturing Services to be performed by Patheon for Client that the parties will endeavor to finalize and execute in good faith within 21 days of the Effective Date and, in any event, prior to the commencement of the Manufacturing Services; a copy
of the signed Quality Agreement shall be attached hereto as Schedule E; 
 “Quarterly Forecast” has the meaning specified in
Section 5.1(b); 
 “Recall” has the meaning specified in Section 6.2(a); 

“Recipient” has the meaning specified in Section 11.1; 

“Regulatory Authority” means any federal, state, local or international regulatory agency, department, bureau or other
governmental entity which is responsible for issuing approvals, licenses, registrations or authorizations necessary for the manufacture, clinical trial use, processing, packaging, use, storage, testing, sale or distribution (including transport,
import and export) of Product, including without limitation, the FDA, EMA, and Health Canada and any other foreign regulatory agencies competent to grant marketing approvals for pharmaceutical products including the Products in the Territory; 

“Remediation Period” has the meaning specified in Section 8.2(a); 

“Renewal Term” has the meaning specified in Section 8.1; 

  
 - 6 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 “Representatives” means a party’s directors, officers, employees,
advisers, agents, consultants, subcontractors, service partners, professional advisors, or representatives; 
 “Safety
Information” shall mean all information relating to known or potential risk to humans obtained or otherwise received from any source, including information derived from clinical investigations, commercial marketing experience,
post-authorization, post-authorization epidemiological/surveillance studies, reports in the scientific literature, unpublished scientific papers, animal or in vitro studies, electronic communications and reports. Safety Information may
include Adverse Events, lack of efficacy, suspected transmission of infectious agents, overdose, abuse, misuse, medication errors, pregnancy/breastfeeding exposure and off-label use; 

“Specifications” means the file, for each Product, which is given by Client to Patheon in accordance with the procedures
listed in Schedule A and which contains documents relating to each Product, including, without limitation: 
  

	 	(a)	specifications for Active Materials and Components; 

  

	 	(b)	manufacturing specifications, directions, and processes; 

  

	 	(c)	storage requirements; 

  

	 	(d)	all environmental, health and safety information for each Product including material safety data sheets; and 

  

	 	(e)	the finished Product specifications, packaging specifications and shipping requirements for each Product; 

all as updated, amended and revised from time to time by Client in accordance with the terms of this Agreement; 

“Subcontractor” has the meaning specified in Section 2.2; 

“Subsequent Annual Limit” has the meaning specified in Section 5.1(h); 

“Target Yield” has the meaning specified in Section 4.5; 

“Tax” or “Taxes” have the meaning specified in Section 13.6(a); 

“Term” has the meaning specified in Section 8.1; 

“Territory” means the entire world where Products manufactured by Patheon will be distributed by Client; 

“Third Party Rights” means the Intellectual Property of any third party other than an Affiliate of a party hereto; 

“Transition Forecast” has the meaning specified in Section 5.1(c); 

  
 - 7 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 “Unit” means an individually packaged dose of Product, including by way of
example only, a vial, as specified in the Specifications; 
 “VAT” has the meaning specified in Section 13.16(d); 

“Year” means the period from the Effective Date up to and including December 31, 2015 and thereafter will mean a calendar
year; 
 and 
 “Zero
Forecast Period” has the meaning specified in Section 5.1(j). 
  

	1.2	Currency. 

 Unless otherwise stated in this Agreement all monetary amounts
to be paid by either party pursuant hereto are to be invoiced and paid in the currency applicable to the country in which the Manufacturing Site is located, provided that such currency shall be either U.S. Dollars or Euros unless the payer otherwise
agrees in writing. 
  

	1.3	Sections and Headings.  

 The division of this Agreement into Articles,
Sections, Subsections and Schedules and the insertion of headings are for convenience of reference only and will not affect the interpretation of this Agreement. Unless otherwise indicated, any reference in this Agreement to a Section or Schedule
refers to the specified Section or Schedule to this Agreement. In this Agreement, the terms “this Agreement”, “hereof”, “herein”, “hereunder” and similar expressions refer to this
Agreement as a whole and not to any particular part, Section or Schedule of this Agreement. 
  

	1.4	Singular Terms. 

 Except as otherwise expressly stated or unless the
context otherwise requires, all references to the singular will include the plural and vice versa. 
  

	1.5	Schedules.  

 The following Schedules are attached to, incorporated in, and
form part of this Agreement: 
  

					
	Schedule A				Product List and Specifications
	Schedule B				Minimum Order Quantity, Annual Volume and Price
	Schedule C				Annual Stability Testing [and Validation Activities][if applicable]
	Schedule D				Active Materials
	Schedule E				Executed Quality agreement
	Schedule F		-  		List of Patheon Factors

  
 - 8 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 PATHEON’S MANUFACTURING SERVICES 

 

	2.1	Manufacturing Services. 

 Patheon will perform the Manufacturing Services
for the Territory for the Prices specified in Schedules B and C. Schedule B sets forth a list of cost items that are included or not included in the Price for Products; all cost items that are not included in the Price are subject to additional fees
agreed in advance by Client to be paid by the Client if Client requests in writing that Patheon perform such non-included cost items. Patheon may amend the fees set out in Schedules B and C as set forth in Article 4. Patheon may change the
Manufacturing Site for the Products only with the prior written consent of Client provided, however that party bearing the cost of any such change will be as discussed by the parties in good faith and must be agreed in advance before Patheon may
make any such change. In performing the Manufacturing Services, Patheon and Client agree that: 
  

	 	(a)	Conversion of Active Materials and Components. Patheon will convert Active Materials and Components into Products in accordance with the Specifications, the Quality Agreement, Applicable Law (including cGMP) and
this Agreement. 

  

	 	(b)	Quality Control and Quality Assurance. Patheon will perform the quality control and quality assurance testing specified in the Quality Agreement. Batch review and release to Client will be the responsibility of
Patheon’s quality assurance group. Patheon will perform its batch review and release responsibilities in accordance with Patheon’s standard operating procedures. Each time Patheon ships Products to Client, it will give Client a certificate
of analysis and certificate of compliance including a statement that the Batch has been manufactured and tested in accordance with Specifications, the Quality Agreement and Applicable Law (including cGMPs) and this Agreement. Client will have sole
responsibility for the release of Products to the market provided however that Client shall be entitled to rely upon Patheon’s certificate of analysis and certificate of compliance. The form and style of batch documents, including, but not
limited to, batch production records, lot packaging records, equipment set up control, operating parameters, and data printouts, raw material data, and laboratory notebooks are the exclusive property of Patheon. Specific Product related information
and any other information pertaining to the Manufacturing Services contained in those batch documents is Client property and shall be made available to Client upon request and as additionally agreed upon by the parties in the Quality Agreement, the
Specifications or any other related documentation. 

  

	 	(c)	Components. Patheon will purchase and test all Components (with the exception of Client-Supplied Components) at Patheon’s expense and as required by the Specifications. 

 

	 	(d)	Stability Testing. If Client elects in writing for Patheon to perform stability testing on the Product during the Term of the Agreement, Patheon will conduct stability testing on the Products in accordance with
the protocols set out in the Specifications for the separate fees and during the time periods set out in Schedule C. Patheon will not make any changes to these testing protocols without prior written approval from Client. If a confirmed
stability test failure occurs, Patheon will notify Client within one Business Day, after which Patheon and Client will jointly determine the proceedings and methods to be undertaken to investigate the cause of the failure, including which party will
bear the cost of the investigation in accordance with Section 6.3. Patheon will give Client all stability test data and results at Client’s request. 

  
 - 9 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

	 	(e)	Packaging and Artwork. At Client’s election (if requested in writing by Client), Patheon will package the Products as set out in the Specifications. Client will be responsible for the cost of artwork
development. Patheon will determine and imprint the batch numbers and expiration dates for each Product shipped. The batch numbers and expiration dates will be affixed on the Products and on the shipping carton of each Product as outlined in the
Specifications, the Quality Agreement and as required by cGMPs and any other Applicable Laws. Client may, in its sole discretion, make changes to labels, product inserts, and other packaging for the Products. Those changes will be submitted by
Client to all applicable Regulatory Authorities and other third parties responsible for the approval of the Products, to the extent required by Applicable Laws. Client will be responsible for the cost of labelling obsolescence when changes occur, as
contemplated in Section 4.4. Patheon’s name will not appear on the label or anywhere else on the Products unless: (i) required by any Laws; or (ii) Patheon consents in writing to the use of its name. At least 120 days prior to
the Delivery Date of Product for which new or modified artwork is required (unless a sooner date is required for compliance with Applicable Laws), Client will provide at no cost to Patheon, final camera ready artwork for all packaging Components to
be used in the manufacture of the Product that meet the Specifications. For the avoidance of doubt, the parties acknowledge and agree that Client will be responsible for complying with any and all regulatory requirements for the labeling of the
Product, except to the extent such requirements are embodied in the Specifications or the Quality Agreement and Patheon has failed to comply therewith. 

  

	 	(f)	 Active Materials and Client-Supplied Components. At least [**] before the scheduled production date (provided Client has received adequate
advance notice of such date), Client will deliver the Active Materials and any Client-Supplied Components to the Manufacturing Site DDP (Incoterms 2010), [**], with any VAT paid by Client, in sufficient quantity to enable Patheon to manufacture the
desired quantities of Product and to ship Product on the Delivery Date. If Client becomes aware of any potential delay in the delivery of the Active Materials or/and any Client-Supplied Components, it shall promptly notify Patheon of such potential
delay and the parties shall jointly evaluate the impact, if any, of such delay on the scheduled production date. If Patheon has provided Client adequate advance notice of the scheduled production date, the Active Materials and/or Client-Supplied
Components are not received [**] before the scheduled production date and the parties are [**]. All shipments of Active Material will be accompanied by certificate(s) of analysis from the Active Material manufacturer and the Client, confirming the
identity and purity of the Active Materials and its compliance with the Active Material specifications. Client shall retain title to all Active Materials and Client-Supplied Components. Unless so authorized by (a) Client; (b) a court
appointed administrator, receiver or other insolvency specialist; or (c) otherwise under a judicial proceeding or a court decision, Patheon shall not at any time sell or offer for sale, assign, mortgage, lease or allow any lien or other
security interest to be created upon, or permit any seizure or confiscation of, the Active Materials or the Client Supplied Components while in Patheon’s possession. Patheon will not use the Active Materials or Client-Supplied Components except
to perform the Manufacturing Services. Patheon represents, warrants and covenants that, unless otherwise agreed in writing by Client, it will (i) store the Active Materials and Client Supplied Components only at the Manufacturing Site, and
(ii) without prejudice to the provisions under Section 8.4(d), store and maintain the Active Materials and Client Supplied Components at its cost and expense only in the quantity necessary during the performance of the Manufacturing
Services pursuant to Section 5.2(a), in 

  
 - 10 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

	 	
accordance with Applicable Laws (including cGMP), the Specifications, the Quality Agreement and this Agreement, as well as Client’s reasonable prior written instructions. Each Calendar
Quarter, Patheon will provide Client with a quarterly Active Materials inventory report. 

  

	 	(g)	Validation Activities (if applicable). Patheon may assist in the development and approval of the validation protocols for analytical methods and manufacturing procedures (including packaging procedures) for the
Products. The fees for these services, if any, are not included in the Price and will be set out separately in Schedule C. 

  

	 	(h)	C-TPAT. Patheon acknowledges that Client is participating in the Customs Trade Partnership Against Terrorism program (“C-TPAT”) with the United States Bureau of Customs and Border Protection, the
requirements for which are more fully described at http://www.cbp.gov/border-security/ports-entry/cargo-security/c-tpat-customs-trade-partnership-against-terrorism. Prior to making any shipment, Patheon (i) shall develop and implement security
procedures that complement and support Client’s participation in the C-TPAT in all material respects, as previously requested in writing by Client, provided that the requested security procedures do not conflict with Patheon’s Code of
Business Conduct (http://www.Patheon.com), and (ii) shall allow Client to conduct such inspections and audits, as long as such inspections and audits are necessary to ensure compliance herewith and without prejudice to Section 7.4
and Section 7.5. Any changes to Patheon’s procedures that are recommended by Client will require mutual agreement of both parties prior to implementation. Patheon acknowledges that Client has provided Patheon with a copy of Client’s
minimum security requirements developed in connection with the C-TPAT. 

  

	 	(i)	Additional Services. If Client requests services other than those expressly set forth herein (such as qualification of a new packaging configuration or shipping studies, or validation of alternative batch sizes),
Patheon will provide a good faith and reasonable written quote of the fee for the additional services and Client will advise Patheon whether it wishes to have the additional services performed by Patheon. The scope of work and fees will be set forth
in a separate agreement signed by the parties or an amendment to this Agreement. The terms and conditions of this Agreement will apply to these services. 

  

	2.2	Subcontractors 

 Client hereby agrees that Patheon may subcontract to its
Affiliate, Patheon Italia S.p.A. (“Subcontractor”), any Manufacturing Services under this Agreement. In such case Client will have a right of access to the Subcontractor’s Manufacturing Site for auditing purposes, in
accordance with the terms and conditions set out in Section 7. The subcontracting of any Services hereunder to the Subcontractor by Patheon shall not relieve Patheon of, and Patheon shall remain solely liable for, its obligations under this
Agreement and Patheon shall remain fully liable for the performance of any obligations hereunder by the Subcontractor and for such Subcontractor’s compliance with the terms of this Agreement, the Specifications, Applicable Law and the Quality
Agreement. 

  
 - 11 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 ARTICLE 3 

CLIENT’S OBLIGATIONS 
  

	3.1	Payment. 

 Client will pay Patheon for performing the Manufacturing
Services according to the Prices specified in Schedules B and C. These Prices may be subject to adjustment under other parts of this Agreement. 
  

	3.2	Active Materials and Qualification of Additional Sources of Supply. 

  

	 	(a)	Client will at its sole cost and expense deliver the Active Materials to Patheon in accordance with Section 2.1(f). If applicable, Patheon and the Client will reasonably cooperate to permit the import of the Active
Materials to the Manufacturing Site. Client’s obligation will include obtaining the proper release of the Active Materials from the applicable Customs Agency and Regulatory Authority. Client or Client’s designated broker will be the
“Importer of Record” for Active Materials imported to the Manufacturing Site. The Active Materials will be held by Patheon on behalf of Client as set forth in this Agreement. Title to the Active Materials will at all times remain
the property of Client. Unless so authorized by (a) Client; (b) a court appointed administrator, receiver or other insolvency specialist; or (c) otherwise under a judicial proceeding or a court decision, Patheon shall not at any time
sell or offer for sale, assign, mortgage, lease or allow any lien or other security interest to be created upon, or permit any seizure or confiscation of, the Active Materials while in Patheon’s possession. Any Active Materials received by
Patheon will only be used by Patheon to perform the Manufacturing Services. Within 10 Business Days of Patheon’s receipt of any Active Materials, Patheon shall review the accompanying cGMP documentation and incoming identification testing and
perform any tests required in the Quality Agreement and the Specifications to confirm the Active Materials conform with the Specifications, the Quality Agreement, Applicable Law (including cGMP) and this Agreement and were received in the quantity
indicated in the shipment-related documentation. In the event Patheon notifies Client of non-conformity of any Active Material received by Patheon, Client shall have the right to confirm such findings of non-conformity. Client shall promptly
investigate such deficiency and provide Patheon with instructions on how to handle the deficient Active Material. 

  

	 	(b)	If Client asks Patheon to qualify an additional source for the Active Material or any Component, Patheon may agree to evaluate the Active Material or Component to be supplied by the additional source to determine if it
is suitable for use in the Product. The parties will agree on the scope of work to be performed by Patheon at Client’s cost. For an Active Material, this work at a minimum will include: (i) [**] and (ii) [**]. 

 

	 	(c)	Patheon will promptly advise Client if it encounters supply problems, including delays and/or delivery of non-conforming Active Material or Components from a Client designated additional source; and Patheon and Client
will cooperate to reduce or eliminate any supply problems from these additional sources of supply. Client will be obligated to certify all Client designated sources of supply on an annual basis at its expense and will provide Patheon with copies of
these annual certifications. If Patheon agrees to certify a Client designated additional sources of supply on behalf of Client, it will do so at Client’s expense. 

  
 - 12 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 ARTICLE 4 

CONVERSION FEES AND COMPONENT COSTS 
  

	4.1	First Year Pricing. 

 The Price for the first Year will be listed in
Schedules B and C and will be subject to the adjustments set forth in Sections 4.2 and 4.3 and any other adjustments provided elsewhere in this Agreement. The Price is made up of the Conversion Price and the Component Cost. The
“Conversion Price” is the price [**] set forth in Schedule B. The “Component Cost” is the [**] as set forth in Schedule B. Both the Conversion Price and the Component Cost are subject to adjustment from time to time
as specified in this Agreement. 
  

	4.2	Price Adjustments – Subsequent Years’ Pricing. 

 After the first
Year, [**] may adjust the Price [**] as follows: 
  

	 	(a)	Manufacturing and Stability Testing Costs. [**] 

  

	 	(b)	Component Costs. [**] But Patheon will not be required to give information to Client that is subject to obligations of confidentiality between Patheon and its suppliers, accordingly if any confidential
information is contained in such documentation, redacted documentation shall be provided to Client. 

  

	 	(c)	Pricing Basis. Client acknowledges that the Price in any Year [**] specified in Schedule B. [**]. For greater certainty, if Patheon and Client agree that the [**]. But Patheon will not be required to give
information to Client that is subject to obligations of confidentiality between Patheon and its suppliers, accordingly if any confidential information is contained in such documentation, redacted documentation shall be provided to Client.

  

	 	(d)	For all Price adjustments under this Section 4.2, Patheon will deliver to Client on or before November 30 of each Year a revised Schedule B and/or Schedule C, as applicable, to be effective for Product
delivered on or after the first day of the next Year. [**]. 

  

	4.2.1	Payment due to Volume Changes from Forecast Volumes for Sterile Products on Calendar Quarter basis – Effective Date through December 31, 2016. 

On the execution of this Agreement and on a Calendar Quarter basis thereafter through October 1, 2016 as described in Sections 5.1(b) and
5.1(c), Client will give to Patheon a Quarterly Forecast as defined in Section 5.1(b) or a Transition Forecast as defined in Section 5.1(c) reflecting the Binding Forecast Volume. For clarity, the volume forecasted for the first 2 Calendar
Quarters of any Quarterly Forecast represent the [**]: 
 Amount due to Patheon = [**] 

  
 - 13 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

	4.2.2	Payment due to Volume Changes from Forecast Volumes for Sterile Products on a Monthly Basis – January 1, 2017 Onward 

Beginning in December 2016, in lieu of the Quarterly Forecast, Client will give to Patheon a Monthly Forecast (as defined in
Section 5.1(d)) and the [**]: 
 [**] 
  

	4.2.3	Payment due to Volume Changes from Forecast Volumes for Sterile Products on an Annual Basis– January 1, 2017 Onward 

[**] (the “Actual Yearly Volume” or “AYV”) [**] (the “Forecasted Yearly Volume” or
“FYV”), [**]: 
 [**] 

[**] 
  

	4.3	Price Adjustments – Current Year Pricing. 

 During any Year, the
Prices set out in Schedule B will be adjusted as follows: 
 Extraordinary Increases in Component Costs. If, at any time, market
conditions result in Patheon’s cost of Components (other than Client Supplied Components) being materially greater than normal forecasted increases, then [**]. Changes materially greater than normal forecasted increases will have occurred if:
(i) the [**]; or (ii) [**]. If Component Costs have been previously adjusted to reflect [**]. 
 For a Price adjustment under this
Section 4.3, Patheon will deliver to Client a revised Schedule B and budgetary pricing information, documentation evidencing adjusted Component costs or other documents reasonably sufficient to demonstrate that a Price adjustment is justified.
Patheon will have no obligation to deliver any supporting documents that are subject to obligations of confidentiality between Patheon and its suppliers accordingly if any confidential information is contained in such documentation, redacted
documentation shall be provided to Client. The revised Price will be effective for any Product ordered pursuant to a Firm Order submitted on or after the first day of the month following Client’s receipt of the revised Schedule B. 

 

	4.4	Adjustments Due to Technical Changes or Regulatory Authority Requirements. 

(a) Amendments requested by Patheon. Any amendments to the Manufacturing Services, including but not limited to the Specifications, the
Quality Agreement, the Components or the Manufacturing Site requested by Patheon, for reasons other than those provided under Section 4.4(c) below, will only be implemented following the written approval of Client, such approval not to be
unreasonably withheld or delayed and shall be implemented at Patheon’s sole cost and expense, unless otherwise agreed by the parties in writing. 

(b) Amendments requested by Client. Amendments to the Specifications, or the Quality Agreement requested by Client for reasons other
than those provided under Section 4.4(c) will only be implemented following a technical and cost review that Patheon will promptly perform and are subject to Client and Patheon reaching agreement on Price changes required because of the
amendment. 

  
 - 14 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 (c) Amendments required by Applicable Laws. The cost of changes to the Manufacturing
Services required by Applicable Laws will be borne by Patheon if such changes apply to the Product as well as to other products produced by Patheon for itself or third parties. If such changes apply solely to the Product, Client shall be responsible
for the increase in direct costs resulting from such changes. 
 (d) If Client accepts a proposed Price change for such an amendment
requested by Client or required by Applicable Laws (to the extent Client is responsible for such Price change pursuant to Section 4.4(c)), the proposed change and the associated scope of work will be implemented at Client’s cost, and the
Price change will become effective, only for those orders of Products that are manufactured under the relevant amendments. In addition, Client agrees to purchase, at Patheon’s cost all Inventory used or manufactured under the “old”
Specifications or Quality Agreement which is already in process when the changes go into effect, if the Inventory can no longer be converted to Product and delivered under the relevant amendments. 

 

	4.5	Price Adjustments for Active Material Yield. 

 For each Batch, depending on the relevant Batch
size and quantity of API therein contained, a minimum number of vials to be obtained (the “Target Yield”) is agreed between the Parties and, in the event that the [**]. 

Calculation of Target Yield 
  

															
					 	[	**] 		 	[	**] 		 	[	**] 
					
	 a    
		[**]		 	[	**] 		 	[	**] 		 	[	**] 
					
	 b
		[**]		 	[	**] 		 	[	**] 		 	[	**] 
	 c
		[**]		 	[	**] 		 	[	**] 		 	[	**] 
	 d
		[**]		 	[	**] 		 	[	**] 		 	[	**] 
	 e
		[**]		 	[	**] 		 	[	**] 		 	[	**] 
	 f
		[**]		 	[	**] 		 	[	**]		 	[	**] 
					
	 g
		[**]		 	[	**] 		 	[	**] 		 	[	**] 
	 h
		[**]		 	[	**] 		 	[	**] 		 	[	**] 

 [**] 
 [**] 

Target yields and line losses assumptions will be [**] as jointly determined by the Parties 

  
 - 15 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 Calculation of reduced payment (if applicable) 

[**] 
 [**] 

[**] 
 [**] 

 

	4.6	Multi-Country Packaging Requirements.  

 If Client elects for Patheon to
perform packaging services during the Term of the Agreement, or if Client at any time decides to have Patheon perform Manufacturing Services for the Product for new countries within the Territory that have specific requirements, then Client will
inform Patheon of the packaging requirements for each new country and Patheon will prepare a quotation for consideration by Client of any additional costs for Components (other than Client-Supplied Components) and the change over fees for the
Product destined for each new country. The agreed additional packaging requirements and related packaging costs and change over fees will be set out in a written amendment to this Agreement. 

ARTICLE 5 
 ORDERS,
SHIPMENT, INVOICING, PAYMENT 
  

	5.1	Orders and Forecasts. 

  

	 	(a)	Long Term Forecast. When this Agreement is executed, Client will give Patheon a non-binding [**] forecast of Client’s volume requirements for the Product for each Year during the term of this Agreement (the
“Long Term Forecast”). The Long Term Forecast will thereafter be updated once per Year (as of December 1) during the Initial Term. If Patheon is unable to accommodate any portion of the Long Term Forecast, it will notify Client
and the parties will agree on any revisions to the forecast, provided, however, that this clause shall not be interpreted to affect Patheon’s obligation to supply forecasted quantities pursuant to this Section 5.1. 

 

	 	(b)	Rolling [**] Month Quarterly Forecast. Commencing on the Effective Date of this Agreement and [**] calendar days prior to the first day of each Calendar Quarter thereafter up to and including the Calendar Quarter
beginning January 1, 2016, Client will provide to Patheon in writing a forecast for the following [**] Calendar Quarters, broken down by month, of Client’s estimated requirements for the Product (each, a “Quarterly
Forecast”). The first 2 Calendar Quarters of each Quarterly Forecast shall be [**]. The Quarterly Forecast for the third (Q3) and fourth (Q4) Calendar Quarters shall be [**]. The Quarterly Forecasts for the Calendar Quarters thereafter
(i.e. Q5 and Q6) shall [**]. 

  
 - 16 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

	 	(c)	Transition from Quarterly Forecast to Monthly Forecast. On or before [**] prior to the Calendar Quarters beginning [**] in lieu of the Quarterly Forecast, Client will provide to Patheon in writing a forecast of
Client’s estimated Product requirements for the following [**] month (each, a “Transition Forecast”). The Transition Forecasts will be [**]: 

 

									
	 [**]
		 	[	**] 		[**]		[**]
	 [**]
		 	[	**] 		[**]		[**]
	 [**]
		 	[	**] 		[**]		[**]
	 [**]
		 	[	**] 		[**]		[**]

  

	 	(d)	Rolling [**] Month Monthly Forecast. Beginning in [**] Client will issue an updated [**] month rolling forecast that starts on the first day of the next month setting forth [**] (each, a “Monthly
Forecast”). [**]. 

  

	 	(e)	Rolling Bi-Annual Forecast. Beginning with the [**] (the “Bi-Annual Forecast” and together with the Quarterly Forecasts, the Transition Forecasts and the Monthly Forecasts, the
“Forecasts”). 

 As the second Year under a Bi-Annual Forecast becomes the first Year under the next Bi-Annual
Forecast, the [**]. 
  

	 	(f)	Firm Orders. Client will issue a new firm written order in the form of a purchase order or otherwise (“Firm Order”) by Client to purchase and for Patheon to manufacture and deliver the agreed
quantity of the Products consistent with the quantity set forth for the 100% binding portion of the most recent Forecast, subject to Section 5.1(h). Subject to Section 5.1(g) below, the Delivery Date will be the date specified in the Firm
Order, provided such date shall [**] following the date that the Firm Order is submitted for [**] Product and [**] following the date that the Firm Order is submitted for [**] Product. Firm Orders submitted to Patheon will specify Client’s [**]
information reasonably requested by Patheon. The quantities of Products ordered in those written orders will be firm and binding on Client and may not be reduced by Client. 

 

	 	(g)	Acceptance of Firm Order. Patheon will accept Firm Orders by sending an acknowledgement to Client within [**] of its receipt of the Firm Order, which acknowledgement will include the scheduled production date.
The Delivery Date may be amended by agreement of the parties or as set forth in Section 2.1(f). If Patheon fails to acknowledge receipt of a Firm Order within the [**], the Firm Order will be deemed to have been accepted by Patheon. Patheon
shall be obligated to accept a Firm Order submitted by Client in compliance with Section 5.1(f), subject to Section 5.1(h). 

  
 - 17 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

	 	(h)	Annual Limit and Obligation to Manufacture Beyond Forecasted Quantity. 

  

	 	(i)	[**] (the “Initial Annual Limit”) [**] (the “Subsequent Annual Limit” and together with the Initial Annual Limit, the “Annual Limit”), [**] Notwithstanding the
foregoing, if Client [**]. 

  

	 	(ii)	If the actual quantities ordered by Client in a Firm Order exceed the applicable Binding Forecast Volume for that same period, Patheon agrees to provide the Manufacturing Services for up to [**] the forecasted amount
subject to the Annual Limit. Patheon agrees to use Commercially Reasonable Efforts to provide the Manufacturing Services for the number of Batches exceeding [**]. 

 

	 	(i)	Cancellation of a Firm Order. If Client cancels a Firm Order for any reason not due to Patheon’s negligence (e.g. defects of API or Client-Supplied Components) or due to termination by Client pursuant to
Section 8.2(a), Client will [**]. 

  

	 	(j)	Zero Volume Forecast. Unless and until the earlier of Client’s receipt of Regulatory Authority approval to market and sell the Product in both the United States and the European Union and January 1,
2017, Client shall not have any limitations on forecasting a zero volume of Product, provided that any Firm Orders that exceed a zero volume must meet or exceed the Minimum Order Quantity. After the earlier of Client’s receipt of approval to
market and sell the Product in both the United States and the European Union and January 1, 2017, if Client forecasts zero volume for [**] period during the term of this Agreement (the “Zero Forecast Period”), then Patheon will
have the option, at its sole discretion, to provide a [**] to Client of Patheon’s intention to terminate this Agreement on a stated day within the Zero Forecast Period. Client thereafter will have [**] either (i) withdraw the zero forecast
and re-submit a reasonable volume forecast (which shall be deemed reasonable if within [**] of its prior year’s forecast), or (ii) negotiate other terms and conditions on which this Agreement will remain in effect. Otherwise, Patheon will
have the right to terminate this Agreement at the end of the [**] period. 

  

	 	(k)	Late Delivery. If Patheon fails to deliver any portion of a Firm Order within [**] of the Delivery Date and such failure is solely attributable to Patheon and/or its suppliers, contractors or consultants, Client
shall be entitled to take a credit to be applied to the Price owed for such undelivered portion of the Products in the amount set forth below (a “Late Delivery Credit”). 

 

					
	 Number of Days Late
		 	Late Delivery Credit	 
	 [**] after Delivery Date
		 	[**]	  
	 [**] after Delivery Date
		 	[**]	  

 For clarity, if the Delivery Date is modified due to a delay in Active Material or Client-Supplied Components
pursuant to Section 2.1(f), the Late Delivery Credit shall not apply to the original Delivery Date but shall be applicable to the modified Delivery Date, nor shall Late Delivery Credits apply where the parties agree to an ongoing investigation
which delays release. 
  

	 	(l)	Rounding. When applying the percentages specified in Sections 5.1(b), 5.1(c), 5.1(e) and 5.1(h), the parties will round up or down to the nearest whole Batch, as applicable. 

  
 - 18 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

	5.2	Reliance by Patheon. 

 (a) Client understands and acknowledges that Patheon
will rely on the Firm Orders and 100% binding portion of the Forecasts submitted under Sections 5.1 (b), 5.1(c), and 5.1(d) in ordering the Components (other than Client-Supplied Components) required to meet the Firm Orders. In addition, Client
understands that to ensure an orderly supply of the Components, Patheon may want to purchase the Components in sufficient volumes to meet the production requirements for Products during part or all of the forecasted periods referred to
in Section 5.1(a) or to meet the production requirements of any longer period agreed to by Patheon and Client. Accordingly, Client authorizes Patheon to purchase Components (other than Client Supplied Components) to satisfy the Manufacturing
Services requirements for Products for the 100% binding portion of any Forecast given by Client under Sections 5.1(b), 5.1(c) or 5.1(d) to the extent such purchase is reasonable in light of Patheon’s existing inventory of such Components.
Patheon may make other purchases of Components (other than Client Supplied Components) to meet Manufacturing Services requirements for longer periods if agreed to in writing by the parties. The Client will give Patheon written authorization to order
Components for any launch quantities of Product requested by Client which will be considered a Firm Order when accepted by Patheon. 
 (b)
Client will [**], provided that Patheon has placed open purchase orders for such Components that may not be cancelled and such Components are not used in products manufactured by Patheon for itself or any third party (collectively, “Obsolete
Stock”). [**] 
 (c) If Client fails to take possession or arrange for the destruction of finished Product in the case of the
delivery of conforming finished Product not accepted by Client within one month of manufacture and release, Client will pay Patheon [**]. 
  

	5.3	Minimum Orders. 

 Client may only order Manufacturing Services for batches
of Products in multiples of the Minimum Order Quantities as set out in Schedule B. 
  

	5.4	Delivery and Shipping. 

 The Product will be delivered to Client after it
has been manufactured and released to the Client by Patheon. Delivery of Products will be made [**]. Risk of loss or of damage to Products will remain [**]. Products will be transported in accordance with the Specifications. 

 

	5.5	Invoices and Payment. 

 Invoices will be sent by fax or email to the fax
number or email address given by Client to Patheon in writing. Invoices will be issued when the Product is manufactured and released by Patheon to the Client in accordance with the requirements of this Agreement, the Specifications, Applicable Laws
and the Quality Agreement. Patheon will also submit to Client, with each shipment of Products, a duplicate copy of the invoice covering the shipment. Patheon will also give Client an invoice covering any Components which are to be purchased by
Client under Section 5.2 of this Agreement. Each invoice will, to the extent applicable, identify Client’s Manufacturing Services purchase order number, Product numbers, names and quantities, unit price, freight charges, and the total
amount to be paid by Client. Client will pay all invoices [**] of the date thereof. If any portion of an invoice is disputed, the Client will pay Patheon for the undisputed amount and the parties will use good faith efforts to reconcile the disputed
amount as soon as practicable. [**] 

  
 - 19 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 ARTICLE 6 

PRODUCT CLAIMS AND RECALLS 
  

	6.1	Product Claims. 

 (a) Product Claims. Client has the right to reject
any portion of any shipment of Products that does not conform to the Specifications, this Agreement, the Quality Agreement, cGMPs, or Applicable Laws or if there has been a media fill failure at the Manufacturing Site with either an assignable cause
affecting the sterility assurance of a Batch or a lack of assignable cause resulting in a lack of sterility assurance of the Batch (“Media Fill Failure”), in each case without invalidating any remainder of the shipment. Client will
inspect the Products manufactured by Patheon upon receipt and will give Patheon written notice (a “Deficiency Notice”) of all claims for Products that do not conform to the Specifications, this Agreement, the Quality Agreement,
cGMPs, or Applicable Laws within [**] after Client’s receipt thereof (or, in the case of any defects not reasonably susceptible to discovery upon receipt of the Product, [**] after discovery by Client or with respect to a Media Fill Failure,
[**] after being notified thereof by Patheon, as applicable, but not after the expiration date of the Product). Should Client fail to give Patheon the Deficiency Notice within the applicable [**] period, then the delivery will be deemed to have been
accepted by Client on the [**] after delivery or discovery, as applicable. Patheon will have no liability for any non-conforming Product for which it has not received notice within the applicable [**] period. Responsibility for non-conforming
Product shall be in accordance with Section 6.3 below. 
 (b) Determination of Deficiency. Upon receipt of a Deficiency Notice,
Patheon will have [**] to investigate Client’s claims reflected in the Deficiency Notice and advise Client by notice in writing that it disagrees in good faith with the contents of the Deficiency Notice and the reasons therefor. If Client and
Patheon fail to agree [**] after Patheon’s notice to Client as to the existence or cause of the non-conformity, then the parties will mutually select an independent laboratory to evaluate if the Products conform to the Specifications, this
Agreement, the Quality Agreement, cGMPs, or Applicable Laws and the cause of the non-conformity. This evaluation will be binding on the parties. The cost of the evaluation will be borne by the party responsible for the cost of the non-conforming
Product pursuant to Section 6.3 below or, in the case the Product is deemed to be conforming, by Client. 
 (c) Shortages and Price
Disputes. Claims for shortages in the Units of Products shipped by Patheon or a Price dispute will be dealt with by reasonable agreement of the parties, provided, however, that Client’s good faith claims for shortages ascertained by the
carrier upon delivery to such carrier by Patheon pursuant to Section 5.4 shall be determinative as to the existence of a shortage. 
  

	6.2	Product Recalls and Returns. 

 (a) Records and Notice. Patheon and
Client will each maintain records necessary to permit a Recall of any Products delivered to Client or customers of Client. Each party will promptly notify the other by telephone (to be confirmed in writing) of any information which might affect the
marketability, safety or effectiveness of the Products or which might result in the Recall or seizure of the Products. Upon receiving this notice or upon this discovery, each party will stop making any further shipments of any Products in its
possession or control until a decision has been made whether a Recall or some other corrective action is necessary. The decision to initiate a Recall or to take some other corrective action, if 

  
 - 20 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 
any, will be made and implemented by Client. “Recall” will mean any action (i) by or at the request of Client to recover title to or possession of quantities of the Products
sold or shipped to third parties (including, without limitation, the voluntary withdrawal of Products from the market); or (ii) by any Regulatory Authorities to detain or destroy any of the Products. Recall will also include any action by
either party to refrain from selling or shipping quantities of the Products to third parties which would have been subject to a Recall if sold or shipped. 

(b) Recalls. If (i) any Regulatory Authority issues a directive, order or, following the issuance of a safety warning or alert
about a Product, a written request that any Product be Recalled, any Regulatory Authority threatens to prohibit the delivery or use of any Product or any other regulatory reportable event occurs, (ii) a court of competent jurisdiction orders a
Recall, or (iii) Client determines that any Product should be Recalled or that a “Dear Doctor” letter or its equivalent is required relating the restrictions on the use of any Product, Patheon will notify Client (to the extent it is
the party that becomes first aware of such event) and, in any case, Patheon will co-operate as reasonably required by Client, having regard to all applicable laws and regulations. 

(c) Product Returns. Client will have the responsibility for handling customer returns of the Products. Patheon will give Client any
assistance that Client may reasonably require to handle the returns. 
  

	6.3	Responsibility for Defective and Recalled Products. 

 (a) Defective Product
– Client Responsibility. If the parties mutually agree (or in the absence of mutual agreement, a third party laboratory determines pursuant to Section 6.1(b)) that Product fails to conform to the Specifications, this Agreement, the
Quality Agreement, cGMPs or Applicable Law and the non-conformity arose other than from a Patheon Factor and Client’s rejection of the Product did not result from a Media Fill Failure, Client shall be responsible for [**]. 

(b) Defective Product – Patheon Responsibility. If Client rejects Product pursuant to Section 6.1 due to a Media Fill Failure
or the parties mutually agree (or in the absence of mutual agreement, a third party laboratory determines pursuant to Section 6.1(b)) that Product fails to conform to the Specifications, this Agreement, the Quality Agreement, cGMPs or
Applicable Law and such non-conformity arose from a Patheon Factor, Patheon shall be responsible as follows: 
  

					
	 If Client previously paid for the non-conforming Product:
		 
  
  
	[**]:
         [**]

        [**]
	  
   

  

		
	 If Client has not yet paid for the non-conforming Product:
		 
  
	[**]
 [**]
	  
   

 Further, if, and provided that, the non-conformity or Media Fill Failure arose from a Patheon Factor due to Patheon’s
negligence, gross negligence or willful misconduct, at Client’s election, Patheon will either [**]. 
 (c) Recalled Product. If
a Recall or return results from a Media Fill Failure or the Products’ non-conformity with the Specifications, the Quality Agreement, this Agreement, cGMPs, or 

  
 - 21 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 
Applicable Laws and such non-conformity arose from a Patheon Factor, Patheon will be responsible for (i) the [**] (ii) the [**]. In addition, upon Client’s request, Patheon will
use its commercially reasonable efforts to replace the Recalled or returned Products with new Products, contingent upon the receipt from Client of all Active Materials and Client-Supplied Components required for the manufacture of the replacement
Products subject to payment therefore under Section 3.1. Patheon’s liability under Sections 6.3(c)(i) and (iii) shall not exceed the limitations set forth in Article10. 

(d) For clarity, this Section 6.3 shall apply to all non-conforming Product and therefore if the remedies provided in this
Section 6.3 result in further non-conforming Product, these sections shall continue to apply. 
 (e) Except as set forth in Article 6,
in Section 5.1(k) and except for the indemnification obligations of Patheon set forth in Art. 10, Patheon will not be liable to Client nor have any responsibility to Client for any non-conformity of any Product manufactured by it. 

 

	6.4	Disposition of Defective or Recalled Products. 

 Client will not dispose of
any damaged, defective, returned, or Recalled Products for which it intends to assert a claim against Patheon without Patheon’s prior written authorization to do so, which authorization shall not be unreasonably withheld. Alternatively, Patheon
may instruct Client to return the Products to Patheon. Patheon will bear the cost of disposition for any damaged, defective, returned or Recalled Products for which it bears responsibility under Section 6.3. In all other circumstances, Client
will bear the cost of disposition, including all applicable fees for Manufacturing Services, for any damaged, defective, returned, or Recalled Products. 
  

	6.5	Adverse Events; Product Quality, Healthcare Provider or Patient Questions and Complaints. 

(a) In case Patheon receives or otherwise becomes aware of an Adverse Events complaint, all Adverse Events and Safety
Information must be reported to Client within 24 hours (a) by email at Pharmacovigilance@synageva.com or (b) by fax at +1 781 240 8169 or +1 800 880 4785 (from within the US). In case Patheon receives a complaint regarding
Products which requires any investigations or tests, Patheon will notify Client 1 Business Day of receipt of such complaint. Client will have the sole responsibility for responding to questions and complaints from its customers but Patheon shall
cooperate with Client in connection with any complaint regardless of the source. 
 (b) Except as set forth in Section 6.5(a),
questions or complaints received by Patheon from Client’s customers, healthcare providers or patients will be promptly referred to Client. Patheon will co-operate as reasonably required to allow Client to determine the cause of and resolve any
questions and complaints. More specifically, Patheon shall be responsible for investigating all complaints directly associated with the Manufacturing Services. This assistance will include follow-up investigations, including testing as deemed
necessary to the investigation and reporting results of the investigation and any conclusions to Client. In addition, Patheon will give Client all agreed upon information that will enable Client to respond properly to questions or complaints about
the Products as set forth in the Quality Agreement. Subject to the limitations set forth in Art. 10, unless it is determined that the cause of the complaint resulted from one or more of the factors described in Section 6.3(b) above, all
reasonable costs incurred under this Section 6.5 will be borne by Client. 

  
 - 22 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 ARTICLE 7 

CO-OPERATION 
  

	7.1	Quarterly Review. 

 Each party will forthwith upon execution of this
Agreement appoint one of its employees to be a relationship manager responsible for liaison between the parties. The relationship managers will meet not less than quarterly to review the current status of the business relationship and manage any
issues that have arisen. 
  

	7.2	Governmental Agencies. 

 Subject to Section 7.8, each party may
communicate with any governmental agency, including but not limited to governmental agencies responsible for granting regulatory approval for the Products, regarding the Products and in the case of Patheon, if in the opinion of Patheon’s legal
counsel, the communication is necessary to comply with the terms of this Agreement or the requirements of any law, governmental order or regulation, provided, however, that in the case of Patheon, Patheon must first give reasonable prior written
notice to Client of the basis and contents of the proposed communication. Unless, in the reasonable opinion of its legal counsel, there is a legal prohibition against doing so, Patheon will permit Client to accompany and take part in any
communications with the agency, and to promptly receive copies of all communications from the agency. To the extent the communication relates directly to the Product, Client shall have the final decision about the content of all such communications
as it pertains to the Product. 
  

	7.3	Records and Accounting by Patheon. 

 Patheon will keep records of the
manufacture, testing, and shipping of the Products, and retain samples of the Products as are required by this Agreement, the Specifications and the Quality Agreement and otherwise as necessary to comply with Applicable Law, as well as to assist
with resolving Product complaints and other similar investigations. Unless otherwise agreed to in the Quality Agreement, copies of the records and samples will be retained for one year following the date of Product expiry, or longer if required by
law, following which time Client will be contacted concerning the delivery and destruction of the documents and/or samples of Products. Patheon reserves the right to destroy or return to Client, at Client’s sole option and expense, any document
or samples for which the retention period has expired provided Client has at least [**] of receipt of notice from Patheon to inform Patheon of its election. Should Patheon not receive any such written notice from Client within the next following
[**], then Patheon can arrange for the said return or destruction at its sole discretion, at Client’s reasonable expense. Client is responsible for retaining samples of the Products necessary to comply with the legal/regulatory requirements
applicable to Client. 
  

	7.4	Inspection. 

 Client may inspect Patheon reports and records relating to
this Agreement during normal business hours and with reasonable advance notice, but a Patheon representative must be present during the inspection. 

  
 - 23 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

	7.5	Access. 

 In addition to access described in Section 2.1(h) above,
Patheon will give Client reasonable access at agreed times to the areas of the Manufacturing Site and will ensure that Client has reasonable access to any other facilities in which the Products are manufactured, stored, handled, or shipped to permit
Client to (a) verify that the Manufacturing Services are being performed in accordance with the Specifications, the Quality Agreement, cGMPs, and Applicable Laws and Patheon’s obligations hereunder and/or (b) have Client personnel on
site to oversee Batch production operations. But, with the exception of “for-cause” audits , Client will be limited each Year to one cGMP-type audit, lasting no more than 3 days, and involving no more than 2 auditors (and, for clarity, the
parties agree that Batch production oversight does not constitute a cGMP-type audit). The right of access set forth in Sections 7.4 and 7.5 will not include a right to access or inspect Patheon’s financial records, provided that this shall not
limit Patheon’s obligation to provide financial documentation to the extent required by, and subject to, other provisions of this Agreement. Client shall have the right to use third party contractors or other agents, to be approved from time to
time by Patheon (such approval not to be unreasonably withheld) in connection with such audits who shall be under obligations of confidentiality. 
  

	7.6	Notification of Regulatory Inspections. 

 Patheon will notify Client in
writing within [**] of being notified of any inspections by any Regulatory Authority or other governmental agency of the Manufacturing Site. In the event such inspection specifically pertains to or involves the Products, including but not limited to
a pre-approval inspection of a governmental agency required in connection with Client’s marketing application for the Products, Patheon will allow Client and those of its Representatives approved by Patheon (such approval not to be unreasonably
withheld or delayed) under obligations of confidentiality no less stringent than those contained herein to attend the Manufacturing Site and participate in such parts of the inspection that relate directly to those details of the Product outside of
the subject of this Agreement (i.e. the fill finish activities). Patheon will also promptly notify Client in writing of receipt of any form 483’s or warning letters or any other significant regulatory action which Patheon’s quality
assurance group determines could impact the regulatory status of the Products. 
  

	7.7	Reports. 

 Patheon will supply on an annual and Calendar Quarter basis by a
date specified by Client not less than [**] in advance all Product data in its control, including release test results, complaint test results, and all investigations (in manufacturing, testing, and storage), that is required for the Annual Product
Review Report or that Client otherwise reasonably requires in order to complete any filing under any applicable regulatory regime or to respond to questions from Regulatory Authorities in response to such filings, including any Annual Report that
Client is required to file with the FDA or other Regulatory Authority. Any additional report requested by Client beyond the scope of cGMPs and customary FDA or other regulatory requirements will be subject to an additional fee to be agreed upon
between Patheon and the Client. 
  

	7.8	Regulatory Filings. 

 (a) Regulatory Authority. Client will have the
sole responsibility for filing all documents with all Regulatory Authorities and taking any other actions that may be required for the receipt and/or maintenance of Regulatory Authority approval for the commercial manufacture of the Products.
Notwithstanding the foregoing, none of the provisions of this Agreement constitute a requirement for 

  
 - 24 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 
Client to make any such filings or take any such actions, which shall be in Client’s sole discretion. Nor shall the failure of Client to receive any Regulatory Approval be deemed to
constitute a breach of Client’s obligations hereunder, subject to Section 5.1(j). Patheon will assist Client, to the extent consistent with Patheon’s obligations under this Agreement, to obtain Regulatory Authority approval for the
commercial manufacture of the Product as quickly as reasonably possible. 
 (b) Verification of Data. Prior to filing any documents
with any Regulatory Authority that incorporate data generated by Patheon, Client will give Patheon a copy of the relevant portions of the documents incorporating this data to give Patheon the opportunity to verify the accuracy and regulatory
validity of those documents as they relate to Patheon generated data, provided, however, that in the event Patheon has previously reviewed and approved the Patheon-generated data for submission, if Client wants to re-file such data with any
Regulatory Authority, it shall previously inform Patheon thereon, but it is not required to re-submit it to Patheon for review even if the data is being submitted to a different source, unless there have been subsequent changes to the Manufacturing
Services pursuant to Section 4.4. Patheon requires 10 business days to perform this review, provided that Patheon shall have 5 business days or such other agreed term to perform this review for any submissions under an accelerated assessment,
expedited review or for which Client otherwise received less than 60 days to complete its submission, but the parties may agree to a shorter time for the review as reasonably needed. 

(c) Verification of CMC. Prior to filing with any Regulatory Agency any documentation which is or is equivalent to the FDA’s
Chemistry and Manufacturing Controls (all such documentation herein referred to as “CMC”) related to any Marketing Authorization, such as a Biologic License Application, Client will give Patheon a copy of the relevant sections of
the CMC; provided, however, that once Patheon has reviewed the first CMC, Client shall previously inform Patheon thereon, but it is not required to provide Patheon the opportunity for prior review for any subsequent filings, whether to the same or
to a different Regulatory Authority, provided that the disclosure in such subsequent filing(s) regarding the work that Patheon has and will perform under this Agreement is substantially to the same as the initial disclosure and there have not been
changes to the Manufacturing Services pursuant to Section 4.4. This disclosure will permit Patheon to verify that the CMC accurately describes the work that Patheon has performed and the manufacturing processes that Patheon will perform under
this Agreement. Patheon requires [**] to perform this review, provided that Patheon shall have [**] to perform this review for any submissions under an accelerated assessment, expedited review or for which Client otherwise received less than [**] to
complete its submission, but the parties may agree to a [**]. Client will give Patheon copies of all relevant CMC sections contained in FDA filings at the time of submission which contain CMC information regarding the Product. 

(d) Deficiencies. If, in Patheon’s sole discretion, acting reasonably, Patheon determines that any of the information given by
Client under clauses (b) and (c) above is inaccurate (the “Deficiencies”), Patheon will notify Client in writing of the Deficiencies. The parties will work together to have the Deficiencies resolved prior to any
pre-approval inspection. 
 (e) Client Responsibility. For clarity, the parties agree that in reviewing the documents referred to in
clause (b) above, Patheon’s role will be limited to verifying the accuracy of the description of the work undertaken or to be undertaken by Patheon. Subject to the foregoing, Patheon will not assume any responsibility for the accuracy of
any application for receipt of an approval by a Regulatory Authority. The Client is solely responsible for the preparation and filing of the application for approval by the Regulatory Authority and the fees associated therewith. 

  
 - 25 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 ARTICLE 8 

TERM AND TERMINATION 
  

	8.1	Initial Term. 

 This Agreement will become effective as of the Effective
Date and will continue until December 31, 2019 (the “Initial Term”), unless terminated earlier by one of the parties in accordance herewith. This Agreement will automatically renew after the Initial Term for successive terms of
2 Years each, unless either party gives written notice to the other party of its intention to terminate this Agreement at least 2 Years prior to the end of the then current term (each, a “Renewal Term” and collectively with the
Initial Term and any other Renewal Term, the “Term”). 
  

	8.2	Termination for Cause. 

 (a) Either party at its sole option may terminate
this Agreement upon written notice where the other party has failed to remedy a material breach of any of its representations, warranties, or other obligations under this Agreement [**] following receipt of a written notice (the “Remediation
Period”) of the breach that expressly states that it is a notice under this Section 8.2(a) (a “Breach Notice”). The aggrieved party’s right to terminate this Agreement under this Section 8.2(a) may only be
exercised for a period of [**] following the expiry of the Remediation Period (where the breach has not been remedied) and if the termination right is not exercised during this period then the aggrieved party will be deemed to have waived the breach
of the representation, warranty, or obligation described in the Breach Notice. The non-breaching party may provide that the effective date of the termination will be at a later date ([**]), during which period Patheon will continue to perform the
Manufacturing Services hereunder until the effective date of termination. 
 (b) Either party at its sole option may immediately terminate
this Agreement upon written notice, but without prior advance notice, to the other party if: (i) the other party is declared insolvent or bankrupt by a court of competent jurisdiction; (ii) a voluntary petition of bankruptcy is filed in
any court of competent jurisdiction by the other party; or (iii) this Agreement is assigned by the other party for the benefit of creditors. 

(c) Client may terminate this Agreement upon [**] prior written notice if any Authority takes any action, or raises any objection, that
prevents Client from importing, exporting, purchasing, or selling the Product. But if this occurs, Client must still fulfill all of its obligations under Section 8.4 below and under any Capital Equipment Agreement regarding the Product. 

(d) Patheon may terminate this Agreement upon six months’ prior written notice if Client assigns under Section 13.6 any of its
rights under this Agreement to an assignee that is: (i) not Credit Worthy; or (ii) is a Patheon Competitor. Patheon may exercise this right within [**] of written notice from Client of such assignment, otherwise such right will be deemed
waived. 
 (e) Client may terminate this Agreement after providing at least [**] prior written notice to Patheon, if it is determined
hereunder that Patheon has produced at least [**] Batches which are determined to be non-conforming, rejected due to a Media Fill Failure or a Patheon Factor and/or subject to a Recall pursuant to Article 6 within [**]. Client may exercise this
right within [**] of determination of the 

  
 - 26 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 
triggering event for the sixth Batch, otherwise such right will be deemed waived. In such case, Client may provide that the effective date of the termination will be at a later date (not to
exceed 24 months from the notice date) during which period Patheon will continue to perform the Manufacturing Services hereunder until the effective date of the termination. 

(f) Client may terminate this Agreement at any time after providing at least [**] prior written notice to Patheon in the event that any of the
following events occur: (a) Product is withdrawn from the market in either Europe or the United States; or (b) Client is unable to produce Active Material meeting the relevant specifications for a period of [**]. 

 

	8.3	Product Discontinuation. 

 Client will give at least [**] advance notice if
it intends to no longer order Manufacturing Services for a Product due to this Product’s discontinuance in the market. 
  

	8.4	Obligations on Termination. 

 If this Agreement is completed, expires, or
is terminated in whole or in part for any reason, then: 
  

	 	(a)	Client will take delivery of and pay for all undelivered conforming Products that are manufactured and/or packaged under a Firm Order, at the price in effect at the time the Firm Order was placed; 

 

	 	(b)	other than a termination by Client pursuant to Sections 8.2(a), Client will satisfy the purchase price payable under Patheon’s orders with suppliers of Components, if the orders were made by Patheon in reliance on
Firm Orders or in accordance with Section 5.2, to the extent that Patheon’s open purchase orders with its suppliers for such Components cannot be cancelled provided that Patheon deliver any such Components to Client and shall not use any
such Components for itself or any third party; 

  

	 	(c)	Client acknowledges that no Patheon Competitor will be permitted access to the Manufacturing Site; and 

  

	 	(d)	Client will make commercially reasonable efforts, at its own expense, to remove from Patheon site(s), [**], all unused Active Material, Client-Supplied Components, and Components for which Client is obligated to
reimburse Patheon pursuant to Section 5.2, undelivered Product, chattels, equipment or other moveable property owned by Client, related to this Agreement and located at a Patheon site or that is otherwise under Patheon’s care and control
(“Client Property”). If Client fails to remove the Client Property within [**] following the completion, termination, or expiration of this Agreement, [**] unless otherwise approved in writing by Client. 

Except as set forth in Sections 8.4(a) and 8.4(b) above, any termination or expiration of this Agreement will not affect any outstanding obligations or
payments due prior to the termination or expiration, nor will it prejudice any other remedies that the parties may have under this Agreement or any related Capital Equipment Agreement. For greater certainty, termination of this Agreement for any
reason will not affect the obligations and responsibilities of the parties under Articles 6, 10 and 11 and Sections 3.2(a), 5.4, 5.5, 7.3, 8.4, 13.1, 13.2, 13.3, 13.9, 13.15, 13.16, 13.17 and 13.18, all of which survive any termination. 

  
 - 27 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 8.5 Technology Transfer Assistance. In the event of expiration or termination of this
Agreement, if requested by Client, Patheon will promptly provide Client with technology transfer assistance in order to enable Client to successfully manufacture Product or have Product manufactured. Client and Patheon will use good faith
efforts to agree upon a plan and schedule for such transfer. Client will be responsible for the costs and expenses associated with such transfer.

ARTICLE 9 

REPRESENTATIONS, WARRANTIES AND COVENANTS 
  

	9.1	Authority. 

 Each party covenants, represents, and warrants that it has the
full right and authority to enter into this Agreement and that it is not aware of any impediment that would inhibit its ability to perform its obligations hereunder. 
  

	9.2	Client Warranties. 

 Client covenants, represents, and warrants that: 

 

	 	(a)	Non-Infringement. 

  

	 	(i)	the Specifications for each of the Products are its or its Affiliate’s property and that Client may lawfully disclose the Specifications to Patheon; 

 

	 	(ii)	any Client Intellectual Property, used by Patheon in performing the Manufacturing Services according to the Specifications (A) is Client’s or its Affiliate’s unencumbered property or is licensed to Client
for such use, (B) may be lawfully used as directed by Client, and (C) to Client’s knowledge, does not infringe and will not infringe any Third Party Rights; 

 

	 	(iii)	to Client’s knowledge, the performance of the Manufacturing Services by Patheon under this Agreement or the use or other disposition of the Product by Patheon as may be required to perform its obligations under
this Agreement, in each case other than with respect to use of Patheon Intellectual Property, does not and will not infringe any Third Party Rights; and 

  

	 	(iv)	to Client’s knowledge, there are no actions or other legal proceedings, concerning the infringement of Third Party Rights related to any of the Specifications, or any of the Active Materials and the Components, or
the sale, use, or other disposition of any Product made in accordance with the Specifications; 

  

	 	(b)	Quality and Compliance. 

  

	 	(i)	the Products, if labelled and manufactured in accordance with the Specifications, this Agreement, the Quality Agreement and in compliance with applicable cGMPs and Applicable Laws may be lawfully sold and distributed in
every jurisdiction in which Client receives regulatory approval to market the Products. 

  
 - 28 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

	 	(ii)	the Specifications for all Products conform to all applicable cGMPs and Applicable Laws (provided that in the event of a change in cGMPs and Applicable Laws, Client shall have a reasonable period of time within which to
update the Specifications in accordance with this Agreement, during which period failure to meet this representation and warranty shall not constitute a breach of this Agreement); 

 

	 	(iii)	on the date of shipment, the API will conform to the specifications for the API that Client has given to Patheon and to the affirmations of fact on the container. 

 

	9.3	Patheon Warranties. 

 Patheon covenants, represents, and warrants that:

  

	 	(a)	it will perform the Manufacturing Services in accordance with the Specifications, the Quality Agreement, cGMPs, and Applicable Laws and all other requirements of this Agreement; 

 

	 	(b)	any Patheon Intellectual Property used by Patheon to perform the Manufacturing Services (i) is Patheon’s or its Affiliate’s unencumbered property, (ii) may be lawfully used by Patheon, and
(iii) does not infringe and will not infringe any Third Party Right; 

  

	 	(c)	any other production activities by Patheon pursuant to this Agreement that are not unique to the Product and that do not require any use of Client Intellectual Property may lawfully be used by Patheon and do not
infringe and will not infringe any Third Party Right; 

  

	 	(d)	the Components (other than Client-Supplied Components) used in the Product shall be delivered free and clear of any liens or encumbrances; and 

 

	 	(e)	all Products shall, at the time of Patheon’s release, be manufactured by Patheon in accordance with the Specifications, this Agreement, the Quality Agreement and Applicable Laws (including cGMPs) and, unless any
such adulteration or misbranding is due to Specifications and/or other instructions provided by Client, shall not be adulterated or misbranded within the meaning of the Federal Food, Drug and Cosmetic Act (United States). 

 

	9.4	Debarred Persons. 

 Patheon covenants that it will not in the performance
of its obligations under this Agreement use the services of any person debarred or suspended under 21 U.S.C. §335(a) or (b). Patheon represents that it does not currently have, and covenants that it will not hire, as an officer or an employee
any person who has been convicted of a felony under the laws of the United States for conduct relating to the regulation of any drug product under the Federal Food, Drug, and Cosmetic Act (United States). Patheon represents, warrants and
covenants that it has never been, is not currently and during the term of this Agreement will not be debarred or suspended under 21 U.S.C. §335(a) or (b). 

  
 - 29 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

	9.5	Permits. 

 As between Patheon and Client, Client will be solely responsible
for obtaining or maintaining, on a timely basis (but at its sole discretion), any permits or other regulatory approvals for the commercial sale of the Products, including, without limitation, all marketing and post-marketing approvals. 

Patheon will maintain at all relevant times all governmental permits, licenses, approval, and authorities required to enable it to lawfully
and properly perform the Manufacturing Services. 
  

	9.6	No Warranty. 

 NEITHER PARTY MAKES ANY WARRANTY OR CONDITION OF ANY
KIND, EITHER EXPRESSED OR IMPLIED, BY FACT OR LAW, OTHER THAN THOSE EXPRESSLY SET FORTH IN THIS AGREEMENT. PATHEON AND CLIENT GIVE NO WARRANTY OR CONDITION OF FITNESS FOR A PARTICULAR PURPOSE NOR ANY WARRANTY OR CONDITION OF MERCHANTABILITY FOR THE
PRODUCTS. 
 ARTICLE 10 

REMEDIES AND INDEMNITIES 
  

	10.1	Consequential Damages. 

 Under no circumstances whatsoever will either
party be liable to the other in contract, tort, breach of statutory duty, or otherwise for (i) any direct or indirect loss of profits, of production, of anticipated savings, of business, or goodwill or (ii) for any other liability, damage,
costs, or expense of any kind incurred by the other party of an indirect or consequential nature, regardless of any notice of the possibility of these damages. 
  

	10.2	Limitation of Liability. 

 (a) Active Materials. Under no
circumstances will Patheon be responsible for any loss or damage to the Active Materials, unless the loss of any Active Materials occurred through the negligence, gross negligence or willful default or misconduct of Patheon. But in no case
[**]. 
 (b) Maximum Liability. Except with respect to Section 10.3, Article 11, Patheon’s obligation to remake or repay
the cost of a Batch pursuant to Sections 6.3(b) or (c), or any infringement of Third Party Rights by Patheon or its Subcontractor, Patheon’s maximum liability to Client under this Agreement for any reason whatsoever, including, without
limitation, any liability resulting from Section 10.2(a) and any and all breaches of its representations, warranties, or any other obligations under this Agreement will [**]. 

(c) Death, Personal Injury and Fraudulent Misrepresentation. Nothing contained in this Agreement shall act to exclude or limit either
party’s liability for personal injury, death caused by the negligence or fraudulent misrepresentation of such party. 

  
 - 30 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

	10.3	Patheon Indemnity. 

 (a) Patheon agrees to defend, hold harmless and
indemnify Client, its Affiliates and its and their officers, directors, employees, and agents against all losses, damages, costs, claims, demands, judgments and liability to, from and in favour of third parties (other than Affiliates) resulting
from, or relating to (i) any claim of personal injury or property damage to the extent that the injury or damage is the result of a failure by Patheon to perform the Manufacturing Services in accordance with the Specifications, the Quality
Agreement, this Agreement, cGMPs and Applicable Laws, (ii) Patheon’s breach of Sections 9.3(b), 9.3(c), 9.3(d), 9.3(e), 9.4, 9.5 or 13.2(b) or Article 11, or (iii) Patheon’s breach of any of its obligations under this Agreement
if such breach occurred because of the gross negligence or willful misconduct of Patheon, or (iv ) Patheon Intellectual Property or any other production activities by Patheon that are not unique to the Product or that do not require the use of
Client Intellectual Property that violate or allegedly violate Third Party Rights, in each case, except to the extent that the losses, damages, costs, claims, demands, judgments, and liability are due to the negligence or wrongful act(s) of Client,
its officers, employees, agents, or Affiliates or the other bases for indemnification by Client pursuant to Section 10.4. 
 (b) If a
claim occurs, Client will: (a) promptly notify Patheon of the claim; (b) use commercially reasonable efforts to mitigate the effects of the claim; (c) reasonably cooperate with Patheon in the defense of the claim; and (d) permit
Patheon to control the defense and settlement of the claim, all at Patheon’s cost and expense. Patheon shall not enter into any settlement agreement with any third party without the prior written consent of Client, which consent will not be
unreasonably withheld or delayed, provided such settlement: (i) includes an unconditional release of Client from all liability arising out of such claim; (ii) does not contain any admission or statement suggesting any wrongdoing or
liability on behalf of Client; and (iii) does not contain any equitable order, judgment or term (other than the fact of payment or the amount of such payment) that in any manner affects, restrains or interferes with the business of Client. The
failure to deliver notice to Patheon within a reasonable time after the commencement of any action, to the extent prejudicial to its ability to defend such action, will relieve Patheon of its obligations under this Section 10.3, but the failure
to deliver notice to Patheon will not relieve Patheon of any obligation that it may have thereunder otherwise than as stated in this sentence. 
  

	10.4	Client Indemnity. 

 (a) Client agrees to defend, hold harmless and
indemnify Patheon, its Affiliates, their officers, employees, and agents against all losses, damages, costs, claims, demands, judgments and liability to, from and in favour of third parties (other than Subcontractor and Affiliates) resulting from,
or relating to (i) any claim of infringement or alleged infringement of any Third Party Rights in the Products, or any portion thereof, except to the extent arising from (a) Patheon Intellectual Property or (b) any other
production activities by Patheon that are not unique to the Product and do not require the use of Client Intellectual Property, or (ii) any claim of personal injury or property damage to the extent that the injury or damage is the result of a
material breach of this Agreement by Client, including, without limitation, any representation or warranty contained herein or (iii) the safety of any Product when used in accordance with its labeling, except in each case to the extent that the
losses, damages, costs, claims, demands, judgments, and liability are due to the negligence or wrongful act(s) of Patheon, its officers, employees, or agents or the other bases for indemnification by Patheon pursuant to Section 10.3. 

(b) If a claim occurs, Patheon will: (a) promptly notify Client of the claim; (b) use commercially reasonable efforts to mitigate
the effects of the claim; (c) reasonably cooperate with Client in the defense of the claim; and (d) permit Client to control the defense and settlement of the claim, all at Client’s cost and expense. Client shall not enter into any
settlement agreement with any third party without the prior written consent of Patheon, which consent will not be unreasonably withheld or delayed, 

  
 - 31 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 
provided such settlement: (i) includes an unconditional release of Patheon from all liability arising out of such claim;(ii) does not contain any admission or statement suggesting any
wrongdoing or liability on behalf of Patheon; and (iii) does not contain any equitable order, judgment or term (other than the fact of payment or the amount of such payment) that in any manner affects, restrains or interferes with the business
of Patheon. The failure to deliver notice to Client within a reasonable time after the commencement of any action, to the extent prejudicial to its ability to defend such action, will relieve Client of its obligations under this Section 10.4,
but the failure to deliver notice to Client will not relieve Client of any obligation that it may have thereunder otherwise than as stated in this sentence. 
  

	10.5	Reasonable Allocation of Risk. 

 This Agreement (including, without
limitation, this Article 10) is reasonable and creates a reasonable allocation of risk for the relative profits the parties each expect to derive from the Products. Patheon assumes only a limited degree of risk arising from the manufacture,
distribution, and use of the Products because Client has developed and holds the marketing approval for the Products, Client requires Patheon to manufacture and label the Products strictly in accordance with the Specifications, and Client, not
Patheon, is best positioned to inform and advise potential users about the circumstances and manner of use of the Products. 
 10.6 Mitigation of Loss
and Damages. Notwithstanding anything to the contrary in this Agreement, either Party shall be obligated to use reasonable commercial efforts to mitigate the costs, expenses, damages, losses and other forms of financial liability of the
other Party pursuant to this Agreement. 
 ARTICLE 11 

CONFIDENTIALITY 
  

	11.1	Confidential Information. 

 “Confidential
Information” means any information disclosed by the Disclosing Party to the Recipient (whether disclosed in oral, written, electronic or visual form) that is non-public, confidential or proprietary including, without limitation,
information relating to the Disclosing Party’s patent and trademark applications, process designs, process models, drawings, plans, designs, data, databases and extracts therefrom, formulae, methods, know-how and other intellectual property,
its clients or client confidential information, finances, marketing, products and processes and all price quotations, manufacturing or professional services proposals, information relating to composition, proprietary technology, and all other
information relating to manufacturing capabilities and operations. In addition, all analyses, compilations, studies, reports or other documents prepared by any party’s Representatives containing the Confidential Information will be considered
Confidential Information. Samples or materials provided hereunder as well as any and all information derived from the approved analysis of the samples or materials will also constitute Confidential Information. 

For the purposes of this ARTICLE 11, a party receiving Confidential Information under this Agreement is a “Recipient,” and a
party disclosing Confidential Information under this Agreement is the “Disclosing Party.” 

  
 - 32 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

	11.2	Use of Confidential Information.  

 The Recipient will use the Confidential
Information solely for the purpose of meeting its obligations under this Agreement. The Recipient will keep the Confidential Information strictly confidential and will not disclose the Confidential Information in any manner whatsoever, in whole or
in part, other than to those of its Representatives who (i) have a need to know the Confidential Information for the purpose of this Agreement; (ii) have been advised of the confidential nature of the Confidential Information and
(iii) have obligations of confidentiality and non-use to the Recipient no less restrictive than those of this Agreement. Recipient will protect the Confidential Information disclosed to it by using all reasonable precautions to prevent the
unauthorized disclosure, dissemination or use of the Confidential Information, which precautions will in no event be less than those exercised by Recipient with respect to its own confidential or proprietary Confidential Information of a similar
nature. 
  

	11.3	Exclusions. 

 The obligations of confidentiality will not apply to the
extent that the information: 
 (a) is or becomes publicly known through no breach of this Agreement or fault of the Recipient or its
Representatives; 
 (b) is in the Recipient’s possession at the time of disclosure by the Disclosing Party other than as a result of
the Recipient’s breach of any legal obligation; 
 (c) is or becomes known to the Recipient on a non-confidential basis through
disclosure by sources, other than the Disclosing Party, having the legal right to disclose the Confidential Information, provided that the other source is not known by the Recipient to be bound by any obligations (contractual, legal, fiduciary, or
otherwise) of confidentiality to the Disclosing Party with respect to the Confidential Information; 
 (d) is independently developed by the
Recipient without use of or reference to the Disclosing Party’s Confidential Information as evidenced by Recipient’s written records; or 

(e) is expressly authorized for release by the written authorization of the Disclosing Party. 

Any combination of information which comprises part of the Confidential Information are not exempt from the obligations of confidentiality
merely because individual parts of that Confidential Information were publicly known, in the Recipient’s possession, or received by the Recipient, unless the combination itself was publicly known, in the Recipient’s possession, or received
by the Recipient. 
  

	11.4	Photographs and Recordings. 

 Neither party will take any photographs or
videos of the other party’s facilities, equipment or processes, nor use any other audio or visual recording equipment (such as camera phones) while at the other party’s facilities, without that party’s express written consent. 

 

	11.5	Permitted Disclosure. 

 Notwithstanding any other provision of this
Agreement, the Recipient may disclose Confidential Information of the Disclosing Party to the extent required, as advised by legal counsel, in response to a 

  
 - 33 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 
valid order of a court of competent jurisdiction or other governmental body or as required by applicable law, regulation or stock exchange rule. But the Recipient will advise the Disclosing Party
in advance of the disclosure to the extent practicable and permissible by the order, law, regulation or stock exchange rule and any other applicable law, will reasonably cooperate with the Disclosing Party, if required, in seeking an appropriate
protective order or other remedy, and will otherwise continue to perform its obligations of confidentiality set out herein. If any public disclosure is required by law, the parties will consult concerning the form of announcement prior to the public
disclosure being made. Notwithstanding anything to the contrary in this Agreement, no provision of this Agreement shall be construed so as to preclude Client’s disclosure of Patheon’s Confidential Information to the competent public
authorities as may be reasonably necessary to secure from any Regulatory Authority or other governmental agency necessary approvals or licenses or to obtain patents with respect to the Product. 

 

	11.6	Survival of Confidentiality Obligations.  

 All obligations of confidentiality and non-use
imposed under this agreement shall expire ten (10) years after the expiration or earlier termination of this agreement. 
  

	11.7	Return of Confidential Information. 

 Upon the written request of the
Disclosing Party, the Recipient will promptly return the Confidential Information to the Disclosing Party or, if the Disclosing Party directs, destroy all Confidential Information disclosed in or reduced to tangible form including any copies thereof
and any summaries, compilations, analyses or other notes derived from the Confidential Information except for one copy which may be maintained by the Recipient for its records. The retained copy will remain subject to all confidentiality provisions
contained in this Agreement. 
  

	11.8	Remedies. 

 The parties acknowledge that monetary damages may not be
sufficient to remedy a breach by either party of this Agreement and agree that the non-breaching party will be entitled to seek specific performance, injunctive and/or other equitable relief to prevent breaches of this Agreement and to specifically
enforce the provisions hereof in addition to any other remedies available at law or in equity. These remedies will not be the exclusive remedies for breach of this Agreement but will be in addition to any and all other remedies available at law or
in equity. 
 ARTICLE 12 

DISPUTE RESOLUTION 
  

	12.1	Commercial Disputes. 

 If any dispute arises out of this Agreement (other
than a dispute under Section 6.1(b)), the parties will first try to resolve it amicably. In that regard, any party may send a notice of dispute to the other, and each party will appoint, within [**] from receipt of the notice of dispute, a
single representative having full power and authority to resolve the dispute. The representatives will meet as necessary in 

  
 - 34 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 
order to resolve the dispute. If the representatives fail to resolve the matter within one month from their appointment, or if a party fails to appoint a representative within the [**] period set
forth above, the dispute will immediately be referred to the Chief Operating Officer (or another officer as he/she may designate) of each party who will meet and discuss as necessary to try to resolve the dispute amicably. Should the parties fail to
reach a resolution under this Section 12.1, the dispute will be referred to a court of competent jurisdiction in accordance with Section 13.17. 

ARTICLE 13 

MISCELLANEOUS 
  

	13.1	Inventions. 

 (a) For the term of this Agreement, Client hereby grants to
Patheon a non-exclusive, paid-up, royalty-free, non-transferable license solely to Client’s Intellectual Property that is necessary for Patheon’s performance of the Manufacturing Services provided said license is limited solely to uses by
Patheon in order to fulfill its obligations under this Agreement and not for use to manufacture product or provide any other service to itself or any third party. 

(b) All Intellectual Property generated or derived by Patheon while performing the Manufacturing Services, to the extent it is specific to the
development, manufacture, use, or sale of Client’s Product that is the subject of the Manufacturing Services, will be the exclusive property of Client. Patheon shall execute and deliver any documents of assignment or conveyance that may be
reasonably requested by Client, to effectuate the ownership rights of Client in such Intellectual Property. 
 (c) All Patheon Intellectual
Property will be the exclusive property of Patheon. Patheon hereby grants to Client a perpetual, irrevocable, non-exclusive, paid-up, royalty-free, transferable license to use the Patheon Intellectual Property used or developed by Patheon in
performing the Manufacturing Services to enable Client to manufacture, distribute and sell the Product(s) manufactured by Patheon under this Agreement. 

(d) Subject to Section 13.1(f), each party will be solely responsible for the costs of filing, prosecution, and maintenance of patents
and patent applications on its own Inventions. 
 (e) Patheon will give Client written notice, as promptly as practicable, of all Inventions
conceived by Patheon during the performance of the Manufacturing Services and improvements or other modifications thereto. 
 (f) Client
shall have the worldwide right to control the preparation, prosecution and maintenance of patents covering Client Intellectual Property. Patheon shall have the worldwide right to control the preparation, prosecution and maintenance of patents
covering the Patheon Intellectual Property. Each Party agrees to cooperate with the other Party, as may be reasonably requested by the other Party and at the other Party’s sole cost, in the preparation and prosecution of patent applications for
the other Party’s Intellectual Property. 
  

	13.2	Intellectual Property. 

 (a) Subject to Section 13.1, all Client
Intellectual Property will be owned by Client and all Patheon Intellectual Property will be owned by Patheon. Patheon shall execute and deliver any 

  
 - 35 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 
documents of assignment or conveyance that may be reasonably requested by Client, to effectuate the ownership rights of Client in any Client Intellectual Property, as applicable. Other than as
provided under this Agreement, neither party has, nor will it acquire, any interest in any of the other party’s Intellectual Property unless otherwise expressly agreed to in writing. 

(b) Neither party will use any Intellectual Property of the other party, except as specifically authorized by the other party or as required
for the performance of its obligations under this Agreement. 
 (c) In the event Patheon conceives an invention related to the Active
Materials or any Client-Supplied Components in the course of activities that are in breach of Patheon’s obligations under Section 2.1(f), 3.2(a), Article 11 and Section 13.2 (b), Client shall be the sole and exclusive owner of such
invention and all intellectual property rights therein, and Patheon shall execute and deliver any documents of assignment or conveyance to effectuate the ownership rights of Client in such invention and related intellectual property rights. For the
avoidance of doubt, a material breach includes, but is not limited to, a breach of Sections 2.1(f), 3.2(a) or 13.2(b). 
  

	13.3	Insurance. 

 Each party will maintain commercial general liability
insurance, including blanket contractual liability insurance covering the obligations of that party under this Agreement through the term of this Agreement and for a period of three years thereafter. This insurance will have policy limits of not
less than (i) [**] for each occurrence for personal injury or property damage liability; and (ii) [**] in the aggregate per annum for product and completed operations liability. If requested each party will give the other a certificate of
insurance evidencing the above and showing the name of the issuing company, the policy number, the effective date, the expiration date, and the limits of liability. If a party is unable to maintain the insurance policies required under this
Agreement through no fault of its own, then the party will forthwith notify the other party in writing and the parties will in good faith negotiate appropriate amendments to the insurance provision of this Agreement in order to provide adequate
assurances. 
  

	13.4	Independent Contractors. 

 The parties are independent contractors and this
Agreement will not be construed to create between Patheon and Client any other relationship such as, by way of example only, that of employer-employee, principal agent, joint-venturer, co-partners, or any similar relationship, the existence of which
is expressly denied by the parties. 
  

	13.5	No Waiver. 

 Either party’s failure to require the other party to
comply with any provision of this Agreement will not be deemed a waiver of the provision or any other provision of this Agreement, with the exception of Sections 6.1 and 8.2 of this Agreement. 

  
 - 36 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

	13.6	Assignment. 

  

	 	(a)	Patheon may not assign this Agreement or any of its associated rights or obligations without the written consent of Client, this consent not to be unreasonably withheld. Patheon may not arrange for subcontractors to
perform specific testing services arising under this Agreement without the written consent of Client. Further it is specifically agreed that, except to the extent explicitly permitted pursuant to Section 2.3, Patheon may not subcontract or
delegate any part of the Manufacturing Services under this Agreement to any of its Affiliates or to any third party. 

  

	 	(b)	Client may not assign this Agreement or any of its associated rights or obligations without approval from Patheon, this consent not to be unreasonably withheld. But Client will give Patheon prior written notice of any
assignment, any assignee will covenant in writing with Patheon to be bound by the terms of this Agreement. 

  

	 	(c)	Despite the foregoing provisions of this Section 13.6, either party may assign this Agreement to any of its Affiliates or to a successor to or purchaser of all or substantially all of its business to which this
Agreement relates, but the assignee must execute an agreement with the non-assigning party whereby it agrees to be bound hereunder. 

  

	13.7	Force Majeure. 

 Neither party will be liable for the failure to perform
its obligations under this Agreement if the failure is caused by an event beyond that party’s reasonable control, including, but not limited to, strikes or other labor disturbances, lockouts, riots, quarantines, communicable disease outbreaks,
wars, acts of terrorism, fires, floods, storms, interruption of or delay in transportation, defective equipment, lack of or inability to obtain fuel, power or components, or compliance with any order or regulation of any government entity acting
within colour of right (a “Force Majeure Event”). A party claiming a right to excused performance under this Section 13.7 will immediately notify the other party in writing of the extent of its inability to perform, which
notice will specify the event beyond its reasonable control that prevents the performance. Neither party will be entitled to rely on a Force Majeure Event to relieve it from an obligation to pay money (including any interest for delayed payment)
which would otherwise be due and payable under this Agreement. 
  

	13.8	Additional Product. 

 Additional Products may be added to this Agreement by
amendments to this Agreement. 
  

	13.9	Notices. 

 Any notice, approval, instruction or other written communication
required or permitted hereunder will be sufficient if made or given to the other party by personal delivery, by telecopy, facsimile communication, or confirmed receipt email or by sending the same by first class mail, postage prepaid to the
respective addresses, telecopy or facsimile numbers or electronic mail addresses set forth below: 
 If to Client: 

Synageva BioPharma Corp. 
 33
Hayden Avenue 
 Lexington, MA 02421 

Attention: General Counsel 

Facsimilie No.: +1 781 357 9901 

  
 - 37 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 If to Patheon: 

Patheon UK Limited 
 Kingfisher
Drive 
 Covingham 
 Swindon
Wiltshire SN3 5BZ 
 England 

Attention: Legal Director 

Facsimile No: +44 (0) 1793 501081 

With a copy to Subcontractor: 

Patheon Italia S.p.A. 
 2°
Trax Via Morolense, 5 
 03013 Ferentino (FR) 

Italy 

	 	Attention:	Managing Director 

	 	CC:	Legal Counsel 

	 	Fax No.:	+39 0392047219 

 or to any other addresses, telecopy or facsimile numbers or electronic mail addresses given to
the other party in accordance with the terms of this Section 13.9. Notices or written communications made or given by personal delivery, telecopy, facsimile, or electronic mail will be deemed to have been sufficiently made or given when sent
(receipt acknowledged), or if mailed, five days after being deposited in the United States, Canada, or European Union mail, postage prepaid or upon receipt, whichever is sooner. 

 

	13.10	Severability. 

 If any provision of this Agreement is determined by a court
of competent jurisdiction to be invalid, illegal, or unenforceable in any respect, that determination will not impair or affect the validity, legality, or enforceability of the remaining provisions, because each provision is separate, severable, and
distinct. 
  

	13.11	Entire Agreement. 

 This Agreement, together with the Quality Agreement and
the Confidentiality Agreement, constitutes the full, complete, final and integrated agreement between the parties relating to the subject matter hereof and supersedes all previous written or oral negotiations, commitments, agreements, transactions,
or understandings concerning the subject matter hereof. Any modification, amendment, or supplement to this Agreement must be in writing and signed by authorized representatives of both parties. In case of conflict, the prevailing order of documents
will be this Agreement, the Quality Agreement, and the Confidentiality Agreement. 

  
 - 38 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

	13.12	Other Terms. 

 No terms, provisions or conditions of any purchase order or
other business form or written authorization used by Client or Patheon will have any effect on the rights, duties, or obligations of the parties under or otherwise modify this Agreement, regardless of any failure of Client or Patheon to object to
the terms, provisions, or conditions unless the document specifically refers to this Agreement and is signed by both parties. 
  

	13.13	No Third Party Benefit or Right. 

 For greater certainty, nothing in this
Agreement will confer or be construed as conferring on any third party any benefit or the right to enforce any express or implied term of this Agreement. 
  

	13.14	Execution in Counterparts. 

 This Agreement may be executed in two or more
counterparts, by original, facsimile or “pdf” signature, each of which will be deemed an original, but all of which together will constitute one and the same instrument. 

 

	13.15	Use of Client Name. 

 Patheon will not make any use of Client’s name,
trademarks or logo or any variations thereof, alone or with any other word or words, without the prior written consent of Client, which consent will not be unreasonably withheld.

 

	13.16	Taxes. 

 (a) The Client will bear all taxes, duties, levies and similar
charges (and any related interest and penalties) (“Tax” or “Taxes”), however designated, imposed as a result of the provision by the Patheon of Services under this Agreement, except: 

 

	 	(i)	any Tax based on net income or gross income that is imposed on Patheon and 

  

	 	(ii)	any Tax that is recoverable by Patheon in the ordinary course of business for purchases made by Patheon in the course of providing its Services, such as Value Added Tax (as more fully defined in subparagraph
(d) below), Goods & Services Tax (“GST”) and similar taxes. 

 (b) If the Client is required to
bear a tax, duty, levy or similar charge under this Agreement by any state, federal, provincial or foreign government, including, but not limited to, Value Added Tax, the Client will pay the tax, duty, levy or similar charge and any additional
amounts to the appropriate taxing authority as are necessary to ensure that the net amounts received by Patheon hereunder after all such payments or withholdings equal the amounts to which Patheon is otherwise entitled under this Agreement as if the
tax, duty, levy or similar charge did not exist. 
 (c) Patheon will not collect an otherwise applicable tax if the Client’s purchase
is exempt from Patheon’s collection of the tax and a valid tax exemption certificate is furnished by the Client to Patheon. 

  
 - 39 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 (d) If subparagraph 13.16 (a)(ii) does not apply, any payment due under this Agreement for
the provision of Services to the Client by Patheon is exclusive of value added taxes, turnover taxes, sales taxes or similar taxes, including any related interest and penalties (hereinafter all referred to as “VAT”). If any VAT is
payable on a Service supplied by Patheon to the Client under this Agreement, this VAT will be added to the invoice amount and will be for the account of (and reimbursable to Patheon by) the Client. If VAT on the supplies of Patheon is payable by the
Client under a reverse charge procedure (i.e., shifting of liability, accounting or payment requirement to recipient of supplies), the Client will ensure that Patheon will not effectively be held liable for this VAT by the relevant taxing
authorities or other parties. Where applicable, Patheon will use its reasonable commercial efforts to ensure that its invoices to the Client are issued in such a way that these invoices meet the requirements for deduction of input VAT by the Client,
if the Client is permitted by law to do so. 
 (e) Any Tax that Client pays, or is required to pay, but which Client believes should
properly be paid by Patheon pursuant hereto may not be offset against sums due by Client to Patheon whether due pursuant to this Agreement or otherwise. 
  

	13.17	Governing Law. 

 This Agreement will be construed and enforced in
accordance with the laws of England and the parties hereby irrevocably submit to the exclusive jurisdiction of the English courts for all matters related to this. The UN Convention on Contracts for the International Sale of Goods will not apply to
this Agreement. 
  

	13.18	Foreign Corrupt Practices Act. Anti-Bribery Laws.

 Patheon shall comply
with the requirements of all applicable anti-bribery legislation both national and foreign, including but not limited to the U.S. Foreign Corrupt Practices Act and the U.K. Bribery Act (collectively, “Anti-Bribery Laws”) and Patheon
has not and will not make, promise or offer to make any payment or transfer anything of value (directly or indirectly) to (i) any individual, (ii) corporation, (iii) association, (iv) partnership, or (v) public body,
(including but not limited to any officer or employee of any of the foregoing) who, acting in their official capacity or of their own accord, are in a position to influence, secure or retain any business for and/or provide any financial or other
advantage to Client by improperly performing a function of a public nature or a business activity with the purpose or effect of public or commercial bribery, acceptance of or acquiescence in extortion, kickbacks or other unlawful or improper means
of obtaining or retaining business. Patheon shall indemnify, defend and hold harmless Client and its Affiliates, and its and their directors, officers, employees and agents, from and against any and all losses resulting or arising from any third
party claims, actions, proceedings, investigations or litigation relating to or arising from any violation of Anti-Bribery Laws, to the extent such losses resulted from Patheon’s failure to comply with Anti-Bribery Laws. 

[Signature page to follow] 

  
 - 40 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 IN WITNESS WHEREOF, the duly authorized representatives of the parties have executed this
Agreement as of the Effective Date. 
  

			
	PATHEON UK LIMITED
		
	By:		 /s/ Michael J. Lehmann

	Name:		Michael J. Lehmann
	Title:		President, Global PDS
	
	SYNAGEVA BIOPHARMA CORP.
		
	By:		 /s/ Thomas W. Beetham

	Name:		Thomas W. Beetham
	Title:		Sr. Vice President, General Counsel

  
 - 41 - 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 SCHEDULE A 

PRODUCT LIST AND SPECIFICATIONS 

Product List 
 SBC-102 sterile [**] vials 

Specifications 
 Prior to the start of commercial
manufacturing of Product under this Agreement Client will give Patheon the originally executed copies of the Specifications as approved by the applicable Regulatory Authority. If the Specifications received are subsequently amended, then Client will
give Patheon the revised and originally executed copies of the revised Specifications. Upon acceptance of the revised Specifications, Patheon will give Client a signed and dated receipt indicating Patheon’s acceptance of the revised
Specifications. 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 SCHEDULE B 

MINIMUM ORDER QUANTITY, ANNUAL VOLUME, AND PRICE 

[**] 
 [**] 

[**] 
  

											
	 Product
	  	 Batch

Size
 (Litres)
	  	 Campaign

Length

(Batches)
	  	 Price Per Batch(Bulk)

	  	  	  		  	 [**]
	  	[**]
	 [**]
	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]
	 [**]
	  	[**]	  	[**]	  	[**]	  	[**]	  	[**]

 [**] 
 [**] 

[**] 
 [**] 

Costs Not Included in Unit Price Proposed 

[**] 
 Manufacturing Assumptions 

[**] 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 Campaign Assumptions 

[**] 
 Testing Assumptions 

[**] 
 Cleaning Assumptions 

[**] 
 Supply Chain Assumptions 

Patheon will procure components for the manufacture of SBC-102 sterile [**] vials from Patheon qualified suppliers. Should Synageva require
Patheon to source any components from specified suppliers, then these suppliers will remain under the Quality audit control of Synageva unless an agreement is reached for Patheon to take on this responsibility. 

Components will be supplied by Patheon in accordance with the Specifications. Patheon has issued formal Patheon specifications for each
component. 
 Each lot of incoming components will be sampled and tested according to the Specifications. 

If different component specifications for primary packaging are required, these will be subjected to a further evaluation and assessment by
Patheon and a mutual agreement between the Parties. 
 It is assumed the BDS would be provided free issue/released to Patheon by Synageva or
its qualified supplier, and that the API will only require ID testing. 
 The BDS used for the manufacture will be GMP grade and from TSE/BSE
certified sources. 
 Patheon will package drug product vials according to the Specifications. 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 SCHEDULE C 

ANNUAL STABILITY TESTING [and VALIDATION ACTIVITIES (if applicable)] 

Patheon and Client will agree in writing on any stability testing to be performed by Patheon on the Products. This agreement will specify the commercial and
Product stability protocols applicable to the stability testing and the fees payable by Client for this testing. 
 [**] 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 SCHEDULE D 

ACTIVE MATERIALS 
  

					
	 Active Materials
	  	Active Material Value	 	Supplier
	SBC102	  	[**]	 	Client

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 SCHEDULE E 

Executed Quality Agreement 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 

 SCHEDULE F 

List of Patheon Factors 
  

	 	1.	Patheon’s gross negligence or willful misconduct; 

  

	 	2.	Product non-conformity with the Product Specifications for the following: 

 [**] 

 

	 	3.	Patheon non-adherence to the Quality Agreement applicable to Patheon; 

  

	 	4.	Patheon non-adherence to cGMPs; and/or 

  

	 	5.	Patheon non-adherence with Applicable Law. 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
  

 
 QUALITY AGREEMENT 

Commercial Product 
 Among

 SYNAGEVA BIOPHARMA CORP. 

33 Hayden Ave. 
 Lexington, MA 02421

 a corporation existing under the laws of the State of Delaware 

(hereinafter referred to as the “Synageva”) 

-and- 
 PATHEON UK LIMITED

 a company incorporated in England & Wales (registered number 3764421) with registered office at Kingfisher Drive, Covingham,
Swindon, Wiltshire SN35BZ, United Kingdom 
 (hereinafter referred to as the “Contract Acceptor”) 

and 
 Patheon Italia S.p.A

 with operation facility at 

2aTrav. SX via Morolense 5, Ferentino (FR) – Italy 

(hereinafter referred to as the “Patheon” or “Sub-contract Acceptor” ) 

Revision #: 00 
 Effective Date:
Date of last approval signature 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
 

 
  

 TABLE OF CONTENTS 

 

									
	 GLOSSARY/DEFINITIONS
	   

			
	 SECTION 1
		 PREMISES AND AGREEMENT
		 	5	  
			
	 SECTION 2
		 RESPONSIBILITIES TABLE
		 	6	  
			
	 SECTION 3
		 GENERAL
		 	7	  
			
	 SECTION 4
		 DESCRIPTION OF RESPONSIBILITIES
		 	9	  
			
	 SECTION 5
		 APPENDICES
		 	26	  
				
			 APPENDIX A:
		 PRODUCT(S)
				
				
			 APPENDIX B:
		 QUALITY CONTACTS
				
				
			 APPENDIX C:
		 PATHEON APPROVED VENDOR LIST
				
				
			 APPENDIX D:
		 SYNAGEVA APPROVED VENDOR LIST
				
				
			 APPENDIX E:
		 PATHEON APPROVED CONTRACT LABORATORIES LIST
				
				
			 APPENDIX F:
		 BDS MATERIALS EU REQUIREMENTS
				

  

					
	 		

		Page 54 of 34

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
 

 
  

 GLOSSARY/DEFINITIONS 

Batch Record shall mean the documentation needed to trace the complete cycle of manufacture of the Product from the receipt of all materials through all
processing and subsequent packaging to dispatch for sale or supply to the Synageva. Batch record includes, but is not limited to, the following main record types: batch production record, batch packaging record and batch quality control record.
Quality control record includes quality control, quality assurance and environmental data specific to the batch. 
 Bulk Drug Substance (BDS) shall
have the meaning for the defined term “Active Materials” in the MSA. 
 Business Day(s) shall have the meaning for the defined term
“Business Day” in the MSA. 
 Change shall mean any change that might affect validated status, quality, regulatory compliance or the
Synageva’s Product Quality Standard compliance. 
 Consumables shall mean any material used during Production, coming to direct contact with the
Product, disposable, by default. 
 Deviation shall mean any departure from SOPs, methods, specifications, protocols, batch records, instructions,
processes, process specifications or normal conditions (e.g. borderline conformances) or other official documentation. 
 Facility shall mean either
the Patheon manufacturing facility located in Ferentino, 2° Trav. SX Via Morolense, 5, or any other facility approved by the Synageva for use by Contract Acceptor in the Manufacture and Supply of Product. 

GMP or cGMP shall have the meaning for the defined term “cGMPs” in the MSA. 

Manufacture, Manufacturing or Production shall mean any and all operations to process, formulate, sterilize, compound, aseptic fill, lyophilize, label,
test, handle, primary or bulk packaging, and warehousing of the Product at the Facility (including quality control, quality assurance and related services), all in accordance with the agreed Manufacturing instructions, cGMPs, Specifications and
Standard Operating Procedures (SOPs) as well as this Quality Agreement and the MSA. 
 Packaging materials shall mean all materials employed in the
packaging of a Product, excluding any outer packaging used for transportation or shipment. Packaging materials are referred to as primary or secondary packaging materials according to whether or not they are intended to be in direct contact with the
medicinal product and as bulk packaging materials. 

  

					
	 		

		Page 55 of 34

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
 

 
  

 Periodic Product Review shall mean a regular comprehensive analysis of each Product’s
Manufacturing process, which includes a review of market performance (including customer complaints), the impact of process changes, quality events (process Deviations and audit findings) and adherence to Specifications and standards. This review is
conducted with annual frequency and is in line with EU (Eudralex Vol IV Part 1 Chapter I) and US (US 21CFR Part 211.180) regulations. 
 Product
shall mean filled, finished form of the product as designated in Appendix A hereto Manufactured by Patheon. 
 Product Quality Standard shall mean
all mandatory aspects of the composition, Manufacturing process, control methods and Specifications and Packaging, which are essential to ensure safety, quality and efficacy of the Product. 

Qualified Person or “QP” shall mean the person(s) responsible for batch release, as defined in Article 48 of Directive 2003/94/EC. 

Quality Agreement shall mean this Agreement, the Appendices, and any mutually agreed amendment. 

Raw materials shall mean all materials used in the Manufacture of Product in accordance with the Specifications, except packaging materials, but
including Consumables which are not present in the finished product (e.g. water, vial headspace gas) and BDS. 
 Reference Samples shall mean samples
of BDS, Raw materials, Packaging materials, and the Product that are kept for possible re-examination. 

Reprocessing shall mean the introduction of material back into the process and repeating a step, [**] using the same equipment and techniques of the
established Manufacturing process. 
 Rework shall mean the introduction of material to one or more processing steps that are different from the
established Manufacturing process. 
 Specifications shall have the meaning for the defined term “Specification” in the MSA. 

  

					
	 		

		Page 56 of 34

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
 

 
  

 SECTION 1: PREMISES AND AGREEMENT 

PREMISES. WHEREAS, Synageva and Patheon UK are parties to that certain manufacturing services agreement executed on 3rd February
(“MSA”) whereby Synageva has engaged Patheon UK to provide certain Manufacturing services on behalf of and for the benefit of Synageva, in respect of certain pharmaceutical products (as described in Appendix A hereto) in certain
countries/region. Under the MSA, Patheon UK is obligated to meet certain requirements in the Manufacture of the Product, including but not limited to operating within the Specifications and according to cGMPs. 

WHEREAS, pursuant to the MSA, Synageva agreed that Patheon UK could provide such services by way of a sub-contract of such services to Patheon Italia at the
site located in 2° Trav. SX. Via Morolense 5, 30103 Ferentino (FR) (“Facility”); 
 WHEREAS, Synageva is required to give certain information
to Patheon in order for Patheon to perform the Manufacturing, including the Specifications. 
 WHEREAS, the parties desire to allocate the responsibility
for procedures and Specifications impacting on the identity, strength, quality and purity of the Products. 
 In the event of any conflict
between the terms of this Quality Agreement and the MSA, the MSA shall take precedence except with respect to any specific quality issue, in which case the Quality Agreement shall take precedence. 

AGREEMENT. NOW THEREFORE in consideration of the Premises and rights conferred and the obligations assumed under the MSA and
herein, and for other good and valuable consideration (the receipt and sufficiency of which are 

  

					
	 		

		Page 57 of 34

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
 

 
  

 acknowledged by each party), and intending to be legally bound, the parties agree as follows:

 SECTION 2: RESPONSIBILITIES TABLE 

Patheon will be responsible for all the operations that are marked with “X” in the column titled “Patheon” and Synageva will be responsible
for all the operations that are marked with “X” in the column titled “Synageva”. If marked with “(X)”, cooperation is required from the designated party. 

 

							
	 Section No.
	  	 Subject / Terms
	  	Synageva	 	Patheon
	 4.1 Quality Management

	4.1.1	  	GMP, Health and Safety Compliance	  	[**]	 	[**]
	4.1.2	  	Synageva Audit Rights	  	[**]	 	[**]
	4.1.3	  	Subcontracting	  	[**]	 	[**]
	4.1.4	  	Self-Inspection	  	[**]	 	[**]
	 4.2 Regulatory Requirements

	4.2.1	  	Permits (Site licences & GMP Certificates (EU), Site Master File PIC)	  	[**]	 	[**]
	4.2.2	  	Product Licences and Registration files life-cycle management	  	[**]	 	[**]
	4.2.3	  	 Product permits: supply of all necessary approved registration information (CTD quality sections) and relevant updates
(EU/US)
	  	[**]	 	[**]
	4.2.4	  	Regulatory Compliance	  	[**]	 	[**]
	4.2.5	  	Components compliance documentation ([**], GMP declaration)	  	[**]	 	[**]
	4.2.6	  	Government Agency Inspections, Communications and Requisitions	  	[**]	 	[**]
	 4.3 Material Control

	4.3.1	  	Test Methods and Specifications	  	[**]	 	[**]
	4.3.2	  	Material Destruction	  	[**]	 	[**]
	4.3.3	  	Vendor Quality Management	  	[**]	 	[**]
	4.3.4	  	Synageva Supplied Materials	  	[**]	 	[**]
	4.3.5	  	Incoming Material Release	  	[**]	 	[**]
	 4.4 Building, Facilities, Utilities and Equipment

	4.4.1	  	General	  	[**]	 	[**]
	4.4.2	  	Equipment, Calibration and Preventative Maintenance	  	[**]	 	[**]
	4.4.3	  	Environmental Monitoring Program	  	[**]	 	[**]
	 4.5 Production Controls

	4.5.1	  	Test Methods and Specifications	  	[**]	 	[**]
	4.5.2	  	Master Batch Record	  	[**]	 	[**]
	4.5.3	  	Reprocessing and Rework	  	[**]	 	[**]
	4.5.4	  	Personnel and Training	  	[**]	 	[**]
	4.5.5	  	Container closure integrity test	  	[**]	 	[**]
	 4.6 Exception Reports (Deviations / Investigations)

	4.6.1	  	Manufacturing Instruction Deviations	  	[**]	 	[**]
	4.7.2	  	Packaging Instructions Deviations	  	[**]	 	[**]

  

					
	 	  	

	  	Page 58 of 34

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

 
  

							
	 4.6.2
		 Notification of Deviations
		[**]		[**]
	 4.7 Release of Product
				
	 4.7.1
		 Batch Certification for Shipment (QP confirmation)
		[**]		[**]
	 4.7.2
		 Product Release to the market
		[**]		[**]
	 4.7.3
		 Certificate of Compliance and Certificate of Analysis
		[**]		[**]
	 4.8 Validation

	 4.8.1
		 Master Validation Plan
		[**]		[**]
	 4.8.2
		 Cleaning Validation Program
		[**]		[**]
	 4.8.3
		 Analytical Method and Procedure Validation
		[**]		[**]
	 4.8.4
		 Manufacturing Process Validation
		[**]		[**]
	 4.8.5
		 Shipment Validation
		[**]		[**]
	 4.8.6
		 Media Fill
		[**]		[**]
	 4.9 Change Control

	 4.9.1
		 General
		[**]		[**]
	 4.10 Documentation

	 4.10.1
		 Record Retention
		[**]		[**]
	 4.10.2
		 Batch Document Requisition
		[**]		[**]
	 4.11 Laboratory Controls

	 4.11.1
		 Specifications and Test Methods
		[**]		[**]
	 4.11.2
		 Out of Specifications (OOS) / Out of Trend (OOT)
		[**]		[**]
	 4.11.3
		 Confirmed OOS notification to authorities
		[**]		[**]
	 4.12 Stability

	 4.12.1
		 Sample Storage
		[**]		[**]
	 4.12.2
		 Stability Protocol, and Studies
		[**]		[**]
	 4.12.3
		 Stability Failures
		[**]		[**]
	 4.13 Annual Product Review / Product Quality Review

	 4.13.1
		 General
		[**]		[**]
	 4.14 Storage and Distribution

	 4.14.1
		 General
		[**]		[**]
	 4.14.2
		 Product Storage and Shipment (Ex Works)
		[**]		[**]
	 4.14.3
		 Product Quarantine
		[**]		[**]
	 4.15 Product Complaints

	 4.15.1
		 Complaint Investigation
		[**]		[**]
	 4.16 Product Recall / Biological Product Deviations (US)

	 4.16.1/2
		 Product Recall Notification/Investigation
		[**]		[**]
	 4.16.3
		 Government Agency Notification
		[**]		[**]
	 4.16.4
		 Suspected Falsified Medicine/suspected re-packaging failure within parallel importation
		[**]		[**]
	 4.17 Reference and Retention Samples

	 4.17.1
		 Excipient and Active Ingredient Reference Sample
		[**]		[**]
	 4.17.2
		 Finished Product Retention Sample
		[**]		[**]

 SECTION 3: GENERAL 
  

	3.1	Any communications about the subject matter of this Quality Agreement will be directed, in the first instance, to the person(s) identified in Appendix B. 

  

					
	 		

		Page 59 of 34

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

	

  

	3.2	Capitalized terms not otherwise defined herein will have the meaning specified in the MSA. 

  

	3.3	If any provision of this Quality Agreement should be or found invalid, or unenforceable by law, the rest of the Quality Agreement will remain valid and binding and the parties will negotiate a valid provision which
meets as close as possible the objective of the invalid provision. 

  

	3.4	Any amendment of this Quality Agreement will be made in writing and signed by both parties. 

  

	3.5	This Quality Agreement will start on the Effective Date that is set forth on the cover page of this Quality Agreement and will remain valid until the later of (i) expiration or earlier termination of the MSA and
(ii) all Quality obligations under the MSA have been fulfilled. 

  

					
	 		

		Page 60 of 34

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
 

 
  

 SECTION 4: DESCRIPTION OF RESPONSIBILITIES 

 

	4.1	QUALITY MANAGEMENT 

  

	4.1.1	GMP, Health and Safety Compliance 

 Patheon will conduct operations in compliance with
applicable environmental, occupational health and safety laws, and cGMP regulations. 
  

	4.1.2	Synageva Audit Rights 

 Patheon will permit audits on reasonable prior written notice, of
all relevant premises, procedures and documentation by Synageva; to the extent such audits are related to Synageva’s Product. Synageva audits [**] Patheon will provide access to the manufacturing facility, on reasonable prior written notice, to
Synageva personnel as well as third party contractors or other agents approved from time to time by Patheon (such approval not to be unreasonably withheld) during the Manufacturing of Synageva Product(s) or, if longer, the Term, as defined in the
MSA. 
 Synageva shall provide Patheon with the audit report within [**] of the audit date. Patheon shall respond to Synageva audit report
within [**] of Synageva audit report receipt. If a response is not provided to Synageva [**] then a request for an extension, including justification for the extension and a new target date for completion, is to be provided in writing to Synageva.

 Patheon will allow Synageva to observe operations related to the Product, to be considered separate from the annual audit. Synageva will
make every effort to coordinate such efforts to minimize impact to the Facility resources. 
  

	4.1.3	Subcontracting 

 Patheon will not subcontract tasks to a third party without
Synageva’s written consent. Patheon may subcontract Raw material testing to other Patheon facilities and to other qualified third party laboratories (as defined in Appendix E). 

 

	4.1.4	Self-Inspection  

 Patheon will perform self-inspections of its premises, facilities, and
processes used to manufacture the Product, including manufacture, package, test, and store Synageva’s starting, intermediate, and/or finished products in accordance with Patheon’s written standard operating procedures
(“SOP’s”) to ensure compliance with cGMP, the Specifications, the MSA and this Quality Agreement. 

  

					
	 		

		Page 61 of 34

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
 

 
  

	4.2	REGULATORY REQUIREMENTS 

  

	4.2.1	Permits (Site licences & GMP certificates (EU), Site Master File PIC) Patheon will obtain and maintain the appropriate Manufacturing License(s), GMP certificates and Sites Master File PIC to allow for the
Manufacturing services. Patheon shall provide the Manufacturing License(s), GMP Certificate(s), and the Site Master File to Synageva for submission of any regulatory dossier. 

 

	4.2.2	Product Licences and Registration files life-cycle management 

 Synageva will determine
whether changes to the Product or related to the Product will impact a regulatory filing and will apply for and receive approval for any required Manufacturing amendment, change or addition to their Product marketing authorization. 

Upon request, Patheon may provide regulatory support in the preparation and overall regulatory consistency review of pertinent sections of new
or supplemental regulatory applications. Such services shall be subjected to a specific regulatory services agreement. 
 Prior to filing any
documents with any Regulatory Authority that incorporate data generated by Patheon, Client will give Patheon a copy of the relevant portions of the documents incorporating this data, in accordance with the terms and conditions of section 7.8 of the
MSA. 
 As between the two parties, Synageva is responsible for all communications with Regulatory Authorities as well as for the approval,
maintenance, and updating of marketing approval. 
 In particular, in the event of a substantial change to cGMPs or regional governances
directly impacting Product Quality compliance, it shall be mutually agreed prior to its implementation. 
  

	4.2.3	Product Permits: supply of all necessary approved registration information (CTD quality sections) and relevant updates (EU/US) 

As between the two parties, Synageva will be solely responsible for obtaining or maintaining any permits or other regulatory approvals for the
Products or the Specifications, including, without limitation, all marketing and post-marketing approvals. 
 It is the responsibility of
Synageva to provide Patheon EU sites with the accurate Product registration information as per European legislations (cGMPs guide part I - chapters 1,4,6,7 and annex 16 / directives 2001/83/EC – title IV, articles 46,48,51 and 2003/94/EC
article 5). 

  

					
	 		

		Page 62 of 34

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
 

 
  

	4.2.4	Regulatory Compliance  

 Patheon will ensure that Product(s) are Manufactured and tested
in strict compliance with current US Federal and EC regulatory and statutory requirements relating to Good Manufacturing Practices (GMP) (US 21 CFR parts 210 and 211 and EU Directives 2003/94/EC – 2004/27/EC – 2011/62/EC for the
manufacture of finished medicinal product) as applicable, regulatory approvals and local laws and regulations applicable at the site(s) of Manufacture and/or testing. 

Patheon shall notify Synageva of any quality related inspections of the Manufacturing process of the Products or the Facility by Regulatory
Authorities or other governmental agency within one (1) Business Day of being notified thereof. As soon as practicable and after the inspection by the relevant Regulatory Authorities, Patheon shall provide the results and appropriate reports
received from the Regulatory Authorities to Synageva. Synageva shall be allowed to attend and participate in inspections in accordance with Section 7.6 of the MSA. 
  

	4.2.5	Components compliance documentation [**] 

 Patheon will ensure that the procured
materials are in compliance with [**], Residues of Metal Catalyst or Metal Reagents, risk of Melamine contamination guidelines, as per internal procedure. 

Synageva will assure the compliance to the above mentioned guidelines for Synageva-supplied materials, as per paragraph 4.3.4. 

 

	4.2.6	Government Agency Inspections, Communication and Requisitions 

 Subject to the terms and
conditions set forth in the MSA, Patheon will permit all relevant inspections by regulatory authorities of premises, procedures, and documentation. 

Patheon will notify Synageva within [**] of receipt of any notice of inspection from a regulatory authority. Patheon will permit Synageva to be
present at Patheon’s facility during the inspections involving the Product and to participate in such inspections in accordance with Section 7.6 of the MSA. 

Patheon will notify Synageva [**] of any regulatory authority request for Product samples, batch documentation, or other information related to
the Product. Patheon will not make any commitments affecting the Product to any regulatory authority without first obtaining Synageva’s written agreement. In such cases, Synageva will provide Patheon with some feedback on the requested
information within [**] from the date of request. 

  

					
	 		

		Page 63 of 34

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
 

 
  

 Patheon will notify Synageva [**] of receipt of any Form 483’s, warning letter, or the
like from any regulatory agency that relates to the Product; or if the supply of Product will be affected, or if the facilities used to produce, test or package the Product will be affected. 

The responses from Patheon related to the Product are subject to review and approval by Synageva prior to submission to the regulatory agency.
Notwithstanding, Patheon reserves the right to respond to the regulatory agency without approval, if, in the reasonable opinion of Patheon’s Legal counsel, the communication is necessary to comply with the terms of this Quality Agreement, the
MSA or the requirements of any law, governmental order or regulation, subject to the prior notice obligations in Section 7.2 of the MSA. 
  

	4.3	MATERIAL CONTROL 

  

	4.3.1	Test Methods and Specifications 

 Synageva will give Patheon a copy of the Specifications
and test methods used if Synageva issues Raw material Specifications as well as any relevant updates. Per each Raw material delivered to Patheon a MSDS document will be provided by Synageva to detail the manipulation procedures. 

 

	4.3.2	Material Destruction 

 Patheon has the right to either return to Synageva or dispose of
any outdated or appropriately-rejected Synageva-supplied material. If the material is disposed of, disposal will be consistent with the nature of the material and sent to a permitted waste disposal facility. Prior to such disposal: 

 

	 	(i.)	Patheon will send notice to Synageva about Patheon’s intent to dispose of the material. If no direction is received from Synageva, Patheon will dispose of the material no sooner than [**] after the date of the
notice. 

  

	 	(ii.)	The materials will be disposed and destroyed in compliance with local environmental regulations and performed in a secure and legal manner that prevents unauthorized use or diversion. 

Patheon will maintain destruction records in accordance with Patheon SOP’s. A copy of the certificate of destruction will be sent to
Synageva. 

  

					
	 		

		Page 64 of 34

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
 

 
  

	4.3.3	Vendor Quality Management 

  

	4.3.3.1	Excipient and BDS Vendors: 

  

	 	(i.)	If Synageva is responsible for the supplying an excipient or BDS, Synageva will audit and approve the manufacturers and ensure cGMP compliance. Synageva stipulated vendor(s) will be included on Synageva’s approved
vendor list (attached hereto as Appendix D).Synageva will provide to Patheon all documentation related to BDS identified in Appendix F. 

  

	 	(ii.)	If Patheon is responsible for procuring the excipient, Patheon will audit and approve the manufacturers and ensure cGMP compliance in accordance with Patheon’s SOP. The Patheon stipulated vendor(s) will be included
on Patheon’s approved vendor list (attached hereto as Appendix C). 

  

	4.3.3.2	Packaging Component Vendors: 

  

	 	(iii.)	If Synageva is responsible for the supplying a packaging component vendor, Synageva will audit and approve the manufacturer and ensure cGMP compliance. Synageva stipulated vendor(s) will be included on the approved
vendor list (attached hereto as Appendix D). 

  

	 	(iv.)	If Patheon is responsible for procuring the packaging component vendor, Patheon will audit and approve the manufacturer and ensure cGMP compliance in accordance with Patheon’s SOP. The Patheon stipulated vendor(s)
will be included on the approved supplier list (Appendix C). 

  

	4.3.4	Synageva Supplied Materials  

 Synageva is responsible for vendor qualification of
Synageva furnished materials and for providing a certificate of compliance confirming the following: 
  

	 	a.	[**] 

  

	 	b.	[**] 

  

	 	c.	Information on genotoxic Impurities, Residues of Metal Catalyst information. (iv) a GMP compliance declaration to the EU directive 2004/27/EC (when sourced from an EU country) or to ICH Q7 (when sourced from a non
EU country) and (vi) certificate of compliance confirming that such Materials are compliant with the provisions outlined in the US FDA Guideline “Pharmaceutical Components at risk for Melamine contamination” 

  

					
	 		

		Page 65 of 34

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
 

 
  

	 	d.	Synageva is responsible for providing Patheon with documents on supplied BDS, as defined in Appendix F. 

[**] 
 Once complete and before
the batch Manufacture is released the final CoA will be delivered to Patheon by Synageva. 
  

	4.3.5	Incoming Material Release 

 Prior to its use in the Manufacture of any Product all
material(s) will be inspected, tested and released by Patheon against the Specification approved by Synageva. 
  

	4.4	BUILDING, FACILITIES, UTILITIES AND EQUIPMENT 

 

	4.4.1	General 

 All buildings and facilities used in the Manufacture of the Product, including
but not limited to manufacturing, packaging, testing and storage of any materials and/or Product will be of suitable size, construction and location to facilitate cleaning, and will be maintained in a good state of repair. Maintenance and cleaning
records will be kept in accordance with Patheon’s SOP’s. Any facility modifications that may impact the Product, qualified state of operations, or Production schedule must be communicated and agreed upon by Synageva in writing. 

 

	4.4.2	Equipment, Calibration and Preventative Maintenance 

 All equipment used in the
Manufacture of the Product, including but not limited to manufacturing, packaging, testing and storage of any materials and/or Product will be suitable for its intended use and appropriately located to allow for cleaning and maintenance. Calibration
and maintenance records will be kept according to Patheon SOP’s for all equipment. Patheon will calibrate instrumentation and qualify and/or validate computer systems used in the Manufacture and testing of the Product in accordance with
Patheon’s SOP’s. Patheon shall have appropriate procedures in place to ensure appropriate handling, segregation, and storage of Product dedicated equipment and spare parts. 

  

					
	 		

		Page 66 of 34

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
 

 
  

	4.4.3	Environmental Monitoring Program 

 Patheon will perform and maintain an environmental
monitoring program. The collected data will be reviewed and interpreted by the responsible person within Patheon’s quality unit. Any out of limit results will be managed appropriately in accordance with Patheon SOP’s. If any of the out of
limit results have an impact on the Product then Synageva will be notified within one (1) Business Day. 
  

	4.5	PRODUCTION CONTROLS 

  

	4.5.1	Test Methods and Specifications 

 Synageva will provide to Patheon the finished Product
Specifications and will develop and supply validated analytical test methods or results to Patheon for the finished Product at release (and shelf-life if requested). Patheon is responsible to verify the performance of test methods in the actual
condition of use for any assays run within Patheon’s control. 
  

	4.5.2	Master Batch Record 

 Synageva will provide the Specifications to Patheon and Patheon
will Manufacture Product in accordance with the Specifications. 
 Patheon is responsible for preparing the master batch records for the
Product, however, Synageva is responsible to review and approve such master batch records prior to the Manufacture of the Product. 
 Patheon
will not make changes to master batch records except through the established Patheon change control system, and all master document revisions are subject to approval by Synageva’s quality unit. Any changes made to issued batch records (prior to
master revisions) must be reviewed and approved by Synageva’s quality unit prior to implementation unless otherwise agreed to in writing. 
  

	4.5.3	Reprocessing and Rework 

 [**] 

 

	4.5.4	Personnel and Training  

 Patheon will provide appropriate training for all
employees. Each person engaged in the Manufacture of the Product, including any manufacture, packaging, testing, storage, and shipping of the Product will have the education, training, and experience necessary, consistent with current GMP and safety
training requirements. 

  

					
	 		

		Page 67 of 34

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

	

  

	4.5.5	Container Closure Integrity Test 

 Patheon will perform Container Closure Integrity Test
during Manufacturing of the Product as defined per EU GMP Annex 1. 
  

	4.5.6	Date of Manufacture and Retest Dating/Expiration 

 Patheon will assign the date of
Manufacture as the date of the start of sterile filtration. The drug product expiration date is assigned by Synageva based on stability data. 
  

	4.6	EXCEPTION REPORTS (DEVIATIONS / INVESTIGATIONS) 

  

	4.6.1	Manufacturing Instruction Deviations 

 Patheon will document, investigate and resolve
deviations from approved Manufacturing instructions or Specifications in accordance with Patheon’s SOP’s. Patheon will report and obtain approval from Synageva’s quality unit for deviation report (“DR”) type deviations where
there is a potential to affect Product quality (major and critical deviations). Such Synageva approval will not be unreasonably withheld. Patheon will provide copies of all DR’s to Synageva as part of the executed batch record. 

 

	4.6.2	Notification of Deviations 

 Patheon will notify Synageva’s quality unit [**] if any
significant deviation occurs during Manufacture of the Product, where such deviation affects the quality, efficacy or availability of the Product. 

If the deviation affects, or could affect, batches already released and distributed, Patheon will notify Synageva [**] after detecting the
deviation. 
 Synageva will provide with a feedback to Patheon on the investigation report within [**]. 

 

	4.7	RELEASE OF PRODUCT 

  

	4.7.1	Batch Certification for Shipment (QP Confirmation) 

 Batch review and certification for
shipment to Synageva will be the responsibility of Patheon’s Quality Assurance department (who will act in accordance with Patheon’s SOP’s after reception of Synageva QP certificate of batch release. 

  

					
	 		

		Page 68 of 34

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
 

 
  

 Patheon will provide Synageva with copies of executed QA reviewed batch records and
associated documentation [**]. Upon review of the batch record by Synageva, if Synageva notices errors, missing information, documentation errors, or deviations, Synageva will notify Patheon within [**]. Patheon will respond in writing within
[**] from Synageva’s notification date to resolve all issues/conflicts. 
  

	4.7.2	Product Release to the market 

 Synageva will have sole responsibility
for release of the Product to the market. 
 When Patheon EU Qualified Person (“QP”) services are employed, Patheon QP may release
the Product to the market according to internal SOP and on behalf of Synageva 
  

	4.7.3	Certificate of Compliance and Certificate of Analysis 

 For each batch certified by
Patheon prior to release for shipment to Synageva, Patheon will deliver to Synageva a Certificate of Analysis, CoA (signed by QC Manager) which contains a statement of compliance of batch to Specifications and Certificate of Compliance, CoC (signed
by Qualified Person) which will include a statement that the batch has been Manufactured in accordance with cGMPs and complies to the Specifications. 
  

	4.8	VALIDATION 

  

	4.8.1	Master Validation Plan 

 Patheon will establish applicable master validation plans and
maintain a validation program for the Product. Synageva will review and approve the master validation plan, performance qualification and process validation protocols and reports for the Product. 

 

	4.8.2	Cleaning Validation Program 

 Synageva will provide to Patheon toxicological information
to be used in the development of a cleaning program. Patheon will maintain an appropriate cleaning and cleaning validation program. Synageva will be notified of any changes in the cleaning validation program that might affect the Product. 

 

	4.8.3	Analytical Method Validation 

 Synageva must ensure that its analytical methods are
validated. If the methods are not validated by Synageva, then Patheon may assist in validation development with the costs being borne by Synageva subject to Synageva’s prior written approval. 

  

					
	 		

		Page 69 of 34

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
 

 
  

	4.8.4	Manufacturing Process Validation 

 Patheon will establish together with Synageva a
process validation strategy for the Product. Synageva will review and approve the process validation protocol and process validation report for the Product. 
  

	4.8.5	Shipment Validation 

 Synageva shall establish a qualified shipping method, including
controls for temperature and humidity, if necessary. Placement locations for temperature monitors will be provided by Synageva to Patheon. 
  

	4.8.6	Media Fill 

 Media Fills will be performed periodically and they are Patheon’s
responsibility. Synageva will be notified within [**] of failure of a media fill associated with or which may affect Synageva’s Product. Upon request by Synageva, results of media fills, applicable to the Product, will be made available within
a reasonable timeframe. 
  

	4.9	CHANGE CONTROL 

 For clarity, nothing in this
Section 4.9 will limit or modify Patheon UK/Patheon’s obligations pursuant to Section 4.4(a) of the MSA. 
  

	4.9.1	General 

 Patheon will notify and obtain approval from Synageva before implementing any
proposed changes to (i) the process, materials, testing, equipment or premises, where such changes may directly affect the Manufacturing or the Product or (ii) the Specifications. This Synageva approval will not to be unreasonably
withheld. Client approval is expected to be completed in [**] from the receiving of the Patheon notification. 
 Patheon shall refrain from
any activity which could intentionally adversely affect the quality of the Products. Patheon shall inform Synageva prior to the implementation of any product categories according to cGMP and categories listed below which are introduced to the same
compounding or clean rooms where the Product is Manufactured: 
 [**] 

Such product introduction would be assessed using change control and requires Synageva approval prior to implementation. 

  

					
	 		

		Page 70 of 34

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
 

 
  

 Synageva will be responsible for determining whether or not to initiate registration
variation (EU)/post-approval change (US) procedures and for maintaining adequate control over the quality commitments of the marketing authorization made to the regulatory authorities by Synageva for the Products. 

Patheon will evaluate any change proposal initiated by Synageva with opening an internal change and delivering it to Synageva. 

Following validation of a process change, Patheon will deliver a copy of the related validation report to Synageva and the associated stability
data, if applicable, as it becomes available. 
 In the event of a substantial change to cGMPs or regional governances directly impacting
Product Quality compliance, it shall be shared between both parties prior to its implementation 
  

	4.10	DOCUMENTATION 

  

	4.10.1	Record Retention 

 Patheon will maintain all batch records for a minimum of [**] and
supply all these records to Synageva upon request. 
 Patheon will maintain records and evidence on the testing of Raw materials and
packaging/labeling materials for [**] after the materials were last used in the Manufacture or packaging/labeling of the Product. 
 At the
end of the above noted retention period, Synageva will be contacted concerning the future storage or destruction of the documents. 
  

	4.10.2	Batch Document Requisition 

 At the request of Synageva, Patheon will provide a copy of
any of the executed batch documents relating to Products to Synageva [**] of such request. 
 Patheon will share with Synageva a defined
Batch numbering rule which will be adopted to identify each Product batch. 
  

	4.11	LABORATORY CONTROLS 

  

	4.11.1	Specifications and Test Methods 

 Patheon will test and approve starting material,
intermediate, and the finished Product in accordance with the approved Specifications, analytical methods, and Patheon’s SOP’s. 

  

					
	 		

		Page 71 of 34

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
 

 
  

 Upon receipt, the materials are generally fully tested. Nevertheless, these may be reduced
only after approval from Synageva. 
 Synageva will provide to Patheon the BDS Specifications including a certificate of analysis. 

Synageva will provide to Patheon test methods for BDS [**]. Synageva is responsible for validating non-compendial testing methods. If these
methods are not validated by Synageva, then Patheon may assist in validation development with the costs being borne by Synageva, subject to Synageva’s prior written approval. 

 

	4.11.2	Out of Specifications (OOS) / Out of Trend (OOT) 

 Patheon will notify Synageva’s
quality unit of out-of-Specification (“OOS”) or out-of-trend (“OOT”), if applicable (data trending has been examined and significant out of trend conditions have been agreed for selected parameters between the two parties),
results within [**]. Patheon will notify Synageva if an OOS result requires retesting. Written approval must be obtained by Synageva’s quality unit prior to any retests. Being confirmed OOS treated as Deviations, Patheon will generate a DR type
deviation as per Patheon SOP’s and obtain approval of the DR from Synageva’s responsible person within their quality unit. This Synageva approval will not be unreasonably withheld. 

Patheon will notify Synageva’s quality unit of confirmed OOS results within [**] since result confirmation. 

 

	4.11.3	Confirmed OOS notifications to authorities 

 For confirmed OOSs on batches Manufactured
by Patheon identified after a batch has been distributed Synageva will notify to authorities about the confirmed out-of-specification (“OOS”) and communicate to Patheon any communication to Regulatory authorities within [**]. 

 

	4.12	STABILITY 

  

	4.12.1	Sample Storage 

 [**] 

 

	4.12.2	Stability Protocol and Studies 

 [**] 

  

					
	 		

		Page 72 of 34

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
 

 
  

	4.12.3	Stability Failures 

 [**] 

 

	4.13	ANNUAL PRODUCT REVIEW / PRODUCT QUALITY REVIEW 

 

	4.13.1	General 

 Patheon will complete the annual / product quality review (PQR) in accordance
with regulatory requirements of the Product marketed authorization. Patheon will provide copies of all information and correspondence necessary to support the annual product reviews when requested by Synageva. Copy of the final document will be send
to Synageva It will be finalised by Patheon and provided to Synageva, for revision and approval, within 90 calendar day of the reporting period. This review shall include, as a minimum, the number and disposition of Batches Manufactured, changes to
the Product and processes, customer complaints, recalls and returns, and a summary of relevant Manufacturing Deviations and rejects. The report will be conducted in accordance with relevant cGMP reference US 21CFR Part 211.180 and Eudralex Vol 4
Chapter 1 and according to Patheon’s SOP and shall be sent to Synageva. The report will also include a summary of visual examination of QC retain samples of Product batches as requested by US 21CFR Part 211.170.This document will support
the “Customer Annual Product Review/ Product Quality Review”. 
  

	4.14	STORAGE AND DISTRIBUTION 

  

	4.14.1	General 

 Patheon will ship Product Ex-Works in accordance with the provided
specifications and agreed qualified transportation requirements provided by Synageva to Patheon. 
 Synageva is responsible for the transport
according to local governances (such as EU cGDP and directive 2011/62/EC). 
  

	4.14.2	Product Storage and Shipment (Ex Works) 

 Patheon will communicate any proposed changes
in storage or shipping to Synageva for review and approval. Synageva approval will not be unreasonably withheld. 
 Patheon will notify
Synageva of any temperature excursions that affect the Product during the storage at Patheon within [**] of the event 

  

					
	 		

		Page 21 of 34

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
 

 
  

	4.14.3	Product Quarantine 

 Patheon will have a system in place for assuring that unreleased
Product is not shipped unless authorized by Synageva’s quality unit. Shipment of batches under quarantine will be an exceptional practice which will require proper allowance from Quality board of both sides. 

 

	4.15	PRODUCT COMPLAINTS 

  

	4.15.1	Complaint Investigation  

 Synageva will investigate and resolve all medical and
non-medical Product complaints, Patheon will acknowledge receipt of the complaint and will investigate all Product quality complaints related to the Manufacturing Services provided. If a complaint sample(s) is available and if the type of complaint
is potentially related to Patheon’s manufacture, the complaint sample will be forwarded to Patheon by Synageva in a timely manner to facilitate a complete and comprehensive investigation 

 

	4.16	PRODUCT RECALL/BIOLOGICAL PRODUCT DEVIATIONS (US) 

For clarity, nothing in this Section 4.16 will limit or modify Patheon UK/Patheon’s obligations pursuant to Articles 6 or 7 of the
MSA. 
  

	4.16.1/2	Product Recall Notification/Investigation  

 Synageva will notify Patheon about any
Product recall or other regulatory type Product notification if determined to be related to the quality of the Product or the Manufacturing process (e.g., US biological product deviation) as soon as possible. Synageva will be responsible for the
decision to initiate a Recall or to take some other corrective action. If Patheon discovers, after release and distribution of a batch(es), any finding which impacts, or could impact, on the quality and safety attributes of the batch(es), Patheon
will notify Synageva within [**]. Patheon will provide its best effort for the recall of the affected batch(es). 
 Patheon shall proceed
with a comprehensive investigation in a timely manner and feedback to Synageva to enable regulatory actions. 
  

	4.16.3	Government Agency Notification 

 Synageva will perform the Product recall and will inform
the appropriate regulatory authorities. Where legislated, Patheon reserves the right to notify regulatory authorities of Product quality issues. Patheon will inform Synageva, in writing, prior to any notification to the regulatory authorities. 

  

					
	 		

		 Page 22 of 34

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 

	

  

	4.16.4	Suspected Falsified Medicine/suspected re-packaging failure within parallel importation 

Synageva shall notify immediately Patheon of any suspected falsified Product to enable the investigation in a timely fashion. In the event of
the confirmed falsified Product, all appropriate measure to physically and securely segregate it from the legitimate Products supply chain shall be taken and Synageva shall inform the competent authorities. 

In the same way, if brought to the attention of Synageva, Synageva shall notify immediately Patheon of any suspected repacking failure which
has occurred within a parallel importation procedure. 
  

	4.17	REFERENCE AND RETENTION SAMPLES 

  

	4.17.1	Excipient and Active Ingredient Reference Sample 

 Patheon will keep a reference sample
of each material supplied to Patheon and used to Manufacture the Product (including but not limited to active pharmaceutical ingredients, excipients and packaging materials with the exception of water and compressed gases). The reference sample size
will be in agreement with relevant cGMPs, i.e. 21 CFR211.170 and Eudralex Vol.4 Annex 19 or local regulations. The reference sample will consist of at least two (2) times the necessary quantity for all Quality Control tests required to
determine whether the materials meet required Specifications. For Raw Materials including BDS to be used for batches to be marketed in Italy, according to the Italian regulation, additional quantity shall be sampled as retain and size of sampling
should be agreed with Synageva. 
 The reference samples will be stored by Patheon under controlled conditions in accordance with GMP storage
requirements for [**]. The reference samples will be made available by Patheon to Synageva, if requested. 
  

	4.17.3	Finished Product Retention Sample 

 Retention samples of finished Product will be
retained by Patheon for [**]. Patheon will also be responsible for maintaining the retention samples necessary for Synageva testing. Where applicable, the legal sample(s) of finished Product must be retained by Synageva. 

Patheon will perform regular annual assessments of all retention samples of commercial batches according to 21CFR 211.170 for any signs of

  

					
	 		

		Page 23 of 34

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
 

 
  

 
deterioration. Synageva will be notified within [**] if evidence of deterioration is noted. Patheon will investigate all evidence of deterioration. Results of this inspection will be included in
Annual Product Review / Product Quality Review. 
 5.0 Revision History 
  

					
	 REVISION
	  	 DATE
	  	 SUMMARY

	00	  	Date of last signature	  	New

  

					
	 	  	

	  	 Page 24 of 34

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
 

 
  

 *    *    * 

IN WITNESS WHEREOF, the parties have caused their duly authorized officer to execute and deliver this Quality Agreement as of the Effective Date identified on
the first page: 
  

									
	Synageva BioPharma Corp.						
					
	By:		 /s/ Caitlin Dazzano
				Date:		February 4, 2015
			Caitlin Dazzano, Director Quality						
			Assurance						
					
	By:		 /s/ Thomas W. Beetham
				Date:		February 4, 2015
			Thomas W. Beetham, Sr. Vice						
			President, General Counsel						
				
	PATHEON UK LTD.						
					
	By:		 /s/ Orazio Cultrera
				Date:		February 9, 2015
			Orazio Cultrera, Vice President						
			Quality Europe						
				
	PATHEON ITALIA S.P.A.						
					
	By:		 /s/ Tiziana Archilletti
				Date		: February 9, 2015
			Tiziana Archilletti, QA/QC Director,						
			Qualified Person						
					
	By:		 /s/ Alessia D’Ettole
				Date:		February 9, 2015
			Alessia D’Ettole, QA Manager						

  

					
	 		

		Page 25 of 34

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
 

 
  

 SECTION 5: APPENDES 

 

	 	•	 	Appendix A: Product(s) & Markets 

  

	 	•	 	Appendix B: Key Contacts 

  

	 	•	 	Appendix C: Patheon Approved Supplier List 

  

	 	•	 	Appendix D: Synageva Approved Supplier List 

  

	 	•	 	Appendix E: Patheon Approved Contract Laboratories List 

  

	 	•	 	Appendix F: BDS Materials EU Requirements 

  

					
	 		

		Page 78 of 34

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
 

 
  

 APPENDIX A: PRODUCT(S) 

 

							
	 Products (s)
	  	Dosage
(Strength)	 	BDS name	  	Market (s)
	 Kanuma (Sebelipase alfa)
	  	[**]	 	Sebelipase alfa	  	Pending

  
 

 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
 

 
  

 APPENDIX B: KEY CONTACTS 

 

					
	 	  	 Patheon
	  	 Synageva

	Responsibility	  	Quality Assurance	  	General
			
	Name	  	Tiziana Archilletti	  	 Caitlin Pazzano

Director, QA
 [**]

	Title	  	QA/QC Director, Qualified Person	  	
	Phone	  	+39 0775 399 226	  	
	Fax	  	+39 0775 399 271	  	
	E-mail	  	tiziana.archilletti@patheon.com	  	
	Address	  	 Patheon Italia S.p.A.

2° Trav. SX Via Morolense, 5

03013 Ferentino (FR)
	  	
			
	Name	  	Alessia D’Ettole	  	
	Title	  	QA Manager	  	
	Phone	  	+39 0775 399 351	  	
	Fax	  	+39 0775 399 271	  	
	E-mail	  	 alessia.d’ettole@patheon.com
	  	
	Address	  	 2° Trav. SX Via Morolense, 5

03013 Ferentino (FR)
	  	
			
	Responsibility	  	Regulatory Affairs	  	Regulatory Affairs
			
	Name	  	Silvia Piacentini	  	 Mark Hayes

Vice President of Regulatory Affairs

[**]

	Title	  	Regulatory Affair Supervisor	  
	Phone	  	+39 0775 399 379	  
	Fax	  	+39 0775 399 271	  
	E-mail	  	silvia.piacentini@patheon.com	  
	Address	  	 2° Trav. SX Via Morolense, 5

03013 Ferentino
	  
			
	Responsibility	  	Product Complaints	  	Audits
			
	Name	  	Giuliano Izzizzari	  	
	Title	  	QA Compliance Head	  	 Caitlin Pazzano

Director, QA
 [**]

	Phone	  	+39 0775 399 282	  	
	Fax	  	+39 0775 399 271	  	
	 E-mail
	  	giuliano.izzizzari@patheon.com	  	
	Address	  	 2° Trav. SX Via Morolense, 5

03013 Ferentino (FR)
	  	

  
 

 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
 

 
  

					
	 Responsibility
		Product Release		Product Release
			
	 Name
		Tiziana Archilletti		
	 Title
		QA/QC Director, Qualified Person		 Caitlin Pazzano

Director, QA
 [**]

	 Phone
		+39 0775 399 226		
	 Fax
		+39 0775 399 271		
	 E-mail
		tiziana.archilletti@patheon.com		
	 Address
		 Patheon Italia S.p.A.

2° Trav. SX Via Morolense, 5

03013 Ferentino (FR)
		
			
	 Responsibility
		Business/Account Manager		
			
	 Name
		Simona Corsetti		Tom Lauzon
	 Title
		Associate Technical Business Manager		Vice President, Manufacturing
	 Phone
		+39 0775 399 339		[**]
	 Fax
		+39 0775 399 259		
	 E-mail
		simona.corsetti@patheon.com		
	 Address
		 Patheon Italia S.p.A.

2° Trav. SX Via Morolense, 5

03013 Ferentino (FR)
		
			
	 Responsibility
		Quality Control		Quality Control
			
	 Name
		Alessandro Barbato		 Mike Bauer

Vice President of Quality

[**]

	 Title
		QC Manager	
	 Phone
		 +39 0775 399225

(m) +39 335 7775971
	
	 Fax
		+39 0775 399259	
	 E-mail
		alessandro.barbato@patheon.com	
	 Address
		 2° Trav SX Via Morolense 87

03013 Ferentino (FR)
	

  
 

 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
 

 
  

 APPENDIX C: PATHEON APPROVED VENDOR LIST 

 

									
	 Patheon Italia Code
		 	Description	  		 	Patheon Italia Supplier	  
	 241038
		 	Vials	  		 	[**]	  
			
	 271735
		 	Stopper	  		 	[**]	  
			
	 275223*
		 	Caps [**]	  		 	[**]	  
			
	 275726
		 	Caps [**]	  		 	[**]	  

  

	*	[**] 

  
 

 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
 

 
  

 APPENDIX D: SYNAGEVA APPROVED VENDOR LIST 

 

					
	 Patheon Italia Code
		Description		Supplier
	 101568
		SBC-102 [**]		[**]
			
	 101695
		SBC-102 DIOSYNTH		Fujifilm Diosynth
Biotechnologies on behalf of
Synageva BioPharma Corp.

  
 

 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
 

 
  

 APPENDIX E: PATHEON APPROVED CONTRACT LABORATORIES LIST 

N.A. 

  
 

 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
 

 
  

 CMO EU QA TEMPLATE 

APPENDIX F: BDS STARTING MATERIALS EU REQUIREMENTS 

Synageva is responsible for providing Patheon with the following on any supplied BDS: 

Registration information 
  

	 	•	 	all registered BDS manufacturing sites including addresses & functions; 

  

	 	•	 	approved registered file (CTD module 3.2.S) and any relevant update; 

 Regulatory compliance
information 
  

	 	•	 	for BDS sourced from a non listed Third country (waiver for listed ones) or country with an EU Mutual Recognition Agreement (MRA): 

  

	 	•	 	EU Member State or foreign authority GMP certificate or GMP declaration of the manufacturer. 

  

	 	•	 	for all: [**] where applicable), [**] information. 

 Quality compliance information 

 

	 	•	 	Proof of the BDS manufacturer GMP/GDP compliance via audit certificates ; 

  

	 	•	 	Well identified and documented BDS supply chain (including BDS manufacturers, brokers, traders, repackers, relabellers, micronisers and importers). 

Current EU regulation references 
  

	 	•	 	Compilation of the Community Procedures on Inspections and Exchanges of Information:  

  

	 	•	 	Union format for registration of Manufacturer, Importer or Distributor of Active Substance (MAY/2012) 

  

	 	•	 	Union format for a GMP certificate [including active substances] (JUN/ 2012) 

  

	 	•	 	Union format for a GDP certificate for active substances to be used as starting materials (MAY/2012) 

  

	 	•	 	GMP Guide Part I / Chapter 5: Production (draft revision JAN/2013) 

  

	 	•	 	GMP Guide Part I / Chapter 7: Outsourced activities (revised JAN/2013) 

  

	 	•	 	GMP Guide Part II: Basic requirements for Active Substances used as Starting Materials 

  

	 	•	 	GDP for active substances: [SANCO/D/6/SF/mg/ddg1.d.6(2013)179367] draft (FEB/2013) 

  

	 	•	 	Directive 2011/62/EU (JUL/2011) articles 46, 46 b (2), 47, 111b and derivative texts: 

  

	 	•	 	Implementing decision on the assessment of a third country’s regulatory framework applicable to active substances of medicinal products for human use [2013/51/EU] (JAN/2013); 

 

	 	•	 	Template for written confirmation [SANCO SFS/SF/mg/ddg1.d.6(2013)118630] (V2 - JAN/2013) & Q&As 

  
 

 

 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. 

An unredacted version of this exhibit has been filed separately with the Commission. 
 

 
  

 [SANCO/D/SF/mg/ddg1.d.6(2013)629544] (V4 – APR/2013) (except for Bulk
Drug Substance); 
  

	 	•	 	Concept paper for delegated act on the principles and guidelines of GMP for active substances [Sanco.ddg1.d.6(2012)73176] (JAN/2012). 

 

	 	•	 	EMA/CHMP/CVMP/QWP/696270/2010: Draft template for Qualified Person’s declaration concerning GMP compliance of the active substance used as starting material and verification of its supply chain - “The
QP declaration template” & Draft Q&As EMA/CHMP/CVMP/QWP/696305/2010 (DEC/2010) 

  

	 	•	 	EMA/410/01 Rev3: Note for guidance on guidance on minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal product (MAR/2011) 

 

	 	•	 	Ph. Eur. 5.2.8: Minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products 

 

	 	•	 	EU EMA/CHMP/ICH/82260/2006: (ICH topic Q3C R5) Impurities - guideline for residual solvents (MAR/2011) + annexes I & II CPMP/QWP/450/03 (version in force) 

 

	 	•	 	Ph. Eur. Chapter 5.4: Residual Solvents 

  

	 	•	 	EMEA/CHMP/ SWP/4446/2000: Guideline on the specification limits for residues of metal catalysts or metal reagents (FEV/2008) 

 

	 	•	 	Ph Eur Chapter 5.20: Metal catalyst and metal reagents residues (OCT/2012) 

  

	 	•	 	CPMP/SWP/5199/02: Guideline on the limits of genotoxic impurities (JUN/2006) + Q&As EMA/CHMP/SWP/431994/2007 (version in force)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00244-of-00352.parquet"}]]